Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number 001-38898
Applied Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of Incorporation or Organization)
81-3405262
(I.R.S. Employer Identification No.)
545 Fifth Avenue, Suite 1400, New York, NY
(Address of Principal Executive Offices)
10017
(Zip Code)
Registrant’s telephone number, including area code (212)-220-9226
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock $0.0001 par value
APLT
The Nasdaq Global Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the
correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The approximate aggregate market value of voting stock held by non-affiliates of the registrant, based upon the last sale price of the registrant’s common stock on the last
business day of the registrant’s most recently completed second fiscal quarter, June 30, 2023, as reported on The Nasdaq Global Market, was approximately $63,926,605. This
calculation excludes approximately 12,176,806 shares held by directors, executive officers and 10% or greater shareholders of the registrant. Exclusion of these shares does not
constitute a determination that each such person is an affiliate of the registrant.
As of March 5, 2024, the total number of shares outstanding of the registrant’s Common Stock was 105,886,831 shares, net of treasury shares.
Documents Incorporated by Reference: Portions of the registrant’s definitive proxy statement for the registrant’s 2024 annual meeting, to be filed within 120 days after
the close of the registrant’s fiscal year, are incorporated by reference into Part III of this Annual Report on Form 10-K.
APPLIED THERAPEUTICS, INC.
2023 FORM 10-K ANNUAL REPORT
TABLE OF CONTENTS
PART I
Table of Contents
Item 1. Business
Item 1A. Risk Factors
Item 1B. Unresolved Staff Comments
Item 1C. Cybersecurity
Item 2. Properties
Item 3. Legal Proceedings
Item 4. Mine Safety Disclosures
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities
Item 6. Reserved
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Item 8. Financial Statements and Supplementary Data
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Item 9A. Controls and Procedures
Item 9B. Other Information
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Item 10. Directors, Executive Officers and Corporate Governance
Item 11. Executive Compensation
PART III
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Item 13. Certain Relationships and Related Transactions, and Director Independence
Item 14. Principal Accountant Fees and Services
Item 15. Exhibits and Financial Statement Schedules
Item 16. Form 10-K Summary
PART IV
i
Page
2
40
80
80
81
81
81
81
82
82
96
97
94
94
95
95
96
96
96
96
96
97
102
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K (this “Annual Report”) may contain “forward-looking statements” within the
meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than
statements of historical fact contained in this Annual Report, including statements regarding our strategy, future financial
condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,”
“anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “forecast,”
“goal,” “intend,” “may,” “objective,” “opportunity,” “plan,” “predict,” “project,” “positioned,” “potential,” “seek,”
“should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future
trends, or the negative of these terms or other comparable terminology.
We have based these forward-looking statements largely on our current expectations and projections about future
events and financial trends that we believe may affect our financial condition, results of operations, business strategy and
financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and
assumptions, including risks described in the section titled “Risk Factors” in this Annual Report:
● our plans to develop, market and commercialize our product candidates;
● the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and
our research and development programs;
● our ability to take advantage of expedited regulatory pathways for any of our product candidates;
● our estimates regarding expenses, future revenue, capital requirements, team, growth and needs for additional
financing;
● our ability to successfully acquire or license additional product candidates on reasonable terms and advance
product candidates into, and successfully complete, clinical studies;
● our ability to maintain and establish collaborations or obtain additional funding;
● our ability to obtain and timing of regulatory approval of our current and future product candidates;
● the anticipated indications for our product candidates, if approved;
● our expectations regarding the potential market size and the rate and degree of market acceptance of such
product candidates;
● our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital
resources;
● the implementation of our business model and strategic plans for our business and product candidates;
● our intellectual property position and the duration of our patent rights;
● developments or disputes concerning our intellectual property or other proprietary rights;
● our expectations regarding government and third-party payor coverage and reimbursement;
● our ability to compete in the markets we serve;
● the impact of government laws and regulations and liabilities thereunder;
● developments relating to our competitors and our industry; and
● other factors that may impact our financial results.
1
Table of Contents
The foregoing list of risks is not exhaustive. Other sections of this Annual Report include additional factors that
could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing
environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk
factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking
statements.
In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-
looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-
looking statement contained in this Annual Report, we cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You
should refer to the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” for a discussion of important factors that may cause our actual results to differ materially from those
expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be
inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or otherwise.
Unless the context otherwise requires, the terms “Applied,” “Applied Therapeutics,” “the Company,” “we,” “us,”
“our”, “the registrant” and similar references in this Annual Report on Form 10-K refer to Applied Therapeutics, Inc.
ITEM 1. BUSINESS.
Overview
PART I
We are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against
validated molecular targets in indications of high unmet medical need. We focus on molecules and pathways whose role in
the disease process is well known based on prior research, but have previously failed to yield successful products due to
poor efficacy and tolerability. Our unique approach to drug development leverages recent technological advances to design
improved drugs, employs early use of biomarkers to confirm biological activity and focuses on abbreviated regulatory
pathways. Our first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative
stress conditions, and is implicated in multiple diseases. Prior attempts to inhibit this enzyme were hindered by
nonselective, nonspecific inhibition, which resulted in limited efficacy and significant off-target safety effects. The
detrimental consequences of AR activation have been well established by decades of prior research. Our AR program
currently includes three small molecules, which are all potent and selective inhibitors of AR, but are engineered to have
unique tissue permeability profiles to target different disease states, including diabetic complications, heart disease and rare
metabolic diseases. The result of this unique multifaceted approach to drug development is a portfolio of highly specific
and selective product candidates that we believe are significantly de-risked and can move quickly through the development
process.
2
Table of Contents
AT-007(also called govorestat) is a novel central nervous system, or CNS, penetrant ARI that we are developing
for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency.
Galactosemia is a devastating rare pediatric metabolic disease that affects how the body processes a simple sugar called
galactose, and for which there is no known cure or approved treatment available. The U.S. Food and Drug Administration,
or FDA, has granted both orphan drug designation and rare pediatric disease designation to AT-007 for the treatment of
Galactosemia and in June 2021, the FDA granted Fast Track Designation to AT-007 for the treatment of Galactosemia.
In clinical studies, AT-007 significantly reduced plasma galactitol levels in both adults and children with
Galactosemia. Galactitol is a toxic metabolite of galactose, which is formed in Galactosemia patients by aberrant activity of
AR when galactose is present at high levels. In a study in children with Galactosemia aged 2-17, we demonstrated that the
galactitol reduction induced by AT-007 treatment resulted in clinical benefit on activities of daily living, behavioral
symptoms, cognition, fine motor skills and tremor over 18 months of treatment. Change in clinical outcome measures
correlated with galactitol level.
We submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the
fourth quarter of 2023, which was subsequently validated and accepted for review in December 2023. A New Drug
Application (NDA) was submitted in December 2023 to the US FDA, and the FDA accepted the filing of the NDA for
govorestat (AT-007) for the treatment of Classic Galactosemia in February of 2024. The NDA was granted Priority Review
status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA
also noted that it is planning to hold an advisory committee meeting to discuss the application. The NDA and MAA
submission packages include clinical outcomes data from the Phase 3 registrational ACTION-Galactosemia Kids study in
children ages 2-17 with Galactosemia, the Phase 1/2 ACTION-Galactosemia study in adult patients with Galactosemia, and
preclinical data.
AT-007 is also being studied in a rare disease caused by deficiency in the enzyme Sorbitol Dehydrogenase, called
SORD Deficiency. AR is the first enzyme in the polyol pathway, converting glucose to sorbitol. AR is then followed by
Sorbitol Dehydrogenase, which converts sorbitol to fructose. Patients with SORD Deficiency accumulate very high levels
of sorbitol in their cells and tissues as a result of the enzyme deficiency, which results in tissue toxicities such as peripheral
neuropathy and motor neuron disease. Recent research in drosophila and cell models of SORD Deficiency demonstrated
that treatment with an ARI that blocks sorbitol production may provide benefit in this disease. Preclinical studies on AT-
007 have demonstrated significant reduction in sorbitol levels in fibroblasts from SORD deficient patients. Treatment with
AT-007 in the drosophila model of SORD prevented the disease phenotype and protected from neuronal degeneration. On
October 25, 2021, we reported data from a pilot open-label study in 8 SORD Deficiency patients. AT-007 reduced blood
sorbitol levels by approximately 66% from baseline through 30 days of treatment. AT-007 was safe and well tolerated in all
treated patients. In December 2021, we initiated a Phase 2/3 registrational study in patients with SORD Deficiency, which
is ongoing at multiple clinical sites in the US and Europe. On February 16, 2023, we announced that in a pre-specified
interim analysis of the ongoing Phase 3 INSPIRE trial, AT-007 reduced sorbitol levels by a mean of approximately 52% (or
approximately 16,000ng/ml) over 90 days of treatment (p<0.001 vs. placebo) in patients with SORD Deficiency. At
baseline, the mean blood sorbitol level of SORD patients included in this interim analysis was approximately 29,000ng/ml,
with a range of approximately 22,000ng/ml-38,000ng/ml. On February 15, 2024, we announced positive interim 12-month
results from the ongoing Phase 3 INSPIRE trial, in which the primary endpoints and several key secondary endpoints were
achieved. The interim 12-month analysis demonstrated statistically significant correlation between sorbitol level and the
prespecified CMT-FOM composite clinical endpoint (10-meter walk-run test, 4 stair climb, sit to stand test,6-minute walk
test and dorsiflexion) (p=0.05). AT-007 treatment also provided sustained reduction in sorbitol level in patients with SORD
Deficiency over 12 months of treatment, which was statistically significant compared to placebo (p<0.001). Lastly, AT-007
treatment also resulted in a highly statistically significant effect (p=0.01) on the CMT Health Index (CMT-HI), an
important patient-reported outcome measure of disease severity and well-being, which was a secondary endpoint in the
study. Aspects of the CMT-HI that demonstrated a treatment effect included lower limb function, mobility, fatigue, pain,
sensory function, and upper limb function. AT-007 was safe and well tolerated, with similar incidence of adverse events
between active and placebo-treated groups. We plan to meet with regulatory agencies to discuss the interim analysis to
determine whether an NDA and MAA could be submitted based on the current data to date.
3
Table of Contents
We also plan to initiate a clinical development program on AT-007 in another pediatric rare disease, called PMM2-
CDG. PMM2-CDG is a glycosylation disorder caused by deficiencies in the enzyme phosphomannomutase 2, which leads
to CNS symptoms similar to Galactosemia, including low IQ, tremor, and speech and motor problems. AR is over-
activated in this disease as a compensatory consequence of PMM2 deficiency, and a CNS penetrant ARI may be a
compelling clinical option. Initial data in fibroblast cell lines derived from PMM2-CDG patients demonstrates that AT-007
treatment increases phosphomannomutase 2 activity. A young child with PMM2-CDG is being treated in a single-patient
investigator initiated trial with AT-007 at the University of North Carolina School of Medicine. Data has been presented at
medical conferences in 2022 supporting a favorable treatment effect of AT-007 on biomarkers and organ function in this
patient. The FDA has granted pediatric rare disease designation and orphan designation for AT-007 in PMM2-CDG.
In January 2023 we announced a partnership with Advanz Pharma for commercialization of AT-007 (govorestat)
in Europe, and entered into an Exclusive License and Supply Agreement with Advanz Pharma (the Advanz Agreement).
Advanz Pharma is a pharmaceutical company with a strategic focus on commercialization of specialty, hospital, and rare
disease medicines in Europe. Under the terms of the Advanz Agreement, Advanz Pharma receives exclusive commercial
rights in the European Economic Area, Switzerland, and the UK for AT-007 in Galactosemia and SORD Deficiency, with
certain rights to future indications for AT-007 in Europe. We will receive certain near-term development milestone
payments upon clinical trial completion and marketing authorization in Europe as well as commercial sales milestones,
which in the aggregate amount to over €130 million, including €10 million upfront, which was paid upon signing. We will
also receive royalties on any future net sales of AT-007 in Europe of 20%. We will continue to be responsible for the
development, manufacturing and supply of AT-007, and Advanz Pharma will be responsible for packaging, distribution and
commercialization in Europe.
AT-001(also called caficrestat) is a novel ARI with broad systemic exposure and peripheral nerve permeability
that we are developing for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart, for which no
treatments are available. We completed a Phase 1/2 clinical trial evaluating AT-001 in approximately 120 patients with
type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. In September 2019, we
announced the initiation of a Phase 3 registrational trial of AT-001 in DbCM. The study, called ARISE-HF, was designed to
evaluate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of
progression to overt heart failure. Although we did experience enrollment delays in 2020 associated with the Covid-19
pandemic, modifications were made to the trial to include additional sites and geographies to address Covid-19-related
issues. On January 4, 2024, we reported topline results from the ARISE-HF study. AT-001 (caficrestat) demonstrated a
strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months. The placebo-
treated group declined by a mean of -0.31 ml/kg/min over 15 months of treatment, while the AT-001 1500mg twice daily
treated group remained primarily stable, with a mean change of -0.01 ml/kg/min over 15 months. While a trend favored
active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant
(p=0.210). Approximately 38% of study subjects were on SGLT2 or GLP-1 therapies for treatment of diabetes, while 62%
were not. In a pre-specified subgroup analysis of the primary endpoint in patients not concomitantly treated with SGLT2 or
GLP-1 therapies, the placebo group declined by a mean of -0.54 ml/kg/min, while the 1500mg BID AT-001 treated group
improved by a mean of 0.08 ml/kg/min over 15 months of treatment, with a difference between groups of 0.62 ml/kg/min
(p=0.040). Additionally, in this subgroup analysis, the number of patients who experienced a clinically significant
worsening in cardiac functional capacity of 6% or more was substantially higher in the placebo group (46%) as compared
to the 1500mg BID AT-001 treated group (32.7%), odds ratio 0.56 (p=0.035). A 6% change in cardiac functional capacity
has been shown to predict long-term survival and hospitalization for heart failure. The effect of AT-001 was dose
dependent, with the low dose (1000mg BID) demonstrating an intermediate effect between the high dose and placebo. AT-
001 was generally safe and well tolerated, with no substantial differences in serious adverse events between AT-001 treated
groups as compared to placebo.
AT-003 is a novel ARI designed to cross through the back of the eye when dosed orally, and has demonstrated
strong retinal penetrance, for the treatment of diabetic retinopathy, or DR. DR is an ophthalmic disease that occurs in
diabetic patients and for which treatments are currently limited to high-cost biologics requiring intravitreal administration.
DR has been linked to AR activity, including elevations in sorbitol and subsequent changes in retinal blood vessels, which
distorts vision and leads to permanent blindness.
4
Table of Contents
AT-104 is a preclinical dual selective PI3K inhibitor. Due to recent regulatory changes impacting development of
the PI3K inhibitor class of compounds, the Company has discontinued its early stage preclinical PI3K program and further
development of AT-104. The compound and all rights associated with the technology were returned to Columbia
University.
Since inception in 2016, our operations have focused on developing our product candidates, organizing and
staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting
clinical trials. We do not have any product candidates approved for sale and have not generated any revenue.
We have incurred significant operating losses since inception in 2016. Our ability to generate product revenue
sufficient to achieve profitability will depend on the successful development and commercialization of one or more of our
product candidates. Our net loss was $119.8 million for the year ended December 31, 2023. As of December 31, 2023, we
had an accumulated deficit of $468.6 million. We expect to continue to incur significant expenses and increasing operating
losses for the foreseeable future in connection with our ongoing activities. Furthermore, we expect to incur additional costs
associated with operating as a public company, including significant legal, accounting, investor relations and other
expenses. As of December 31, 2023, we had cash and cash equivalents of $49.9 million.
Our management team and scientific advisory board are composed of accomplished scientists and clinicians with
decades of experience developing drugs for a wide range of diseases. Our view is that drug development does not always
need to follow the standard approach, which often requires long and costly development programs before drugs become
available to patients. By taking a unique and focused approach to drug development, we believe we can significantly
shorten development programs and bring lifesaving drugs to patients in urgent need. In May 2019, we completed our initial
public offering (the “IPO”) whereby we sold 4,000,000 shares of common stock at a public offering price of $10.00 per
share, resulting in aggregate net proceeds of $34.6 million, after deducting underwriting discounts and commissions and
offering expenses. In November 2019, we completed a private placement of 1,380,344 shares of our common stock (the
“Private Placement”), which resulted in net proceeds of approximately $18.4 million. In January 2020, we completed a
secondary public offering of 2,471,489 shares of our common stock, including 411,223 shares sold pursuant to the
underwriters’ full exercise of their option to purchase additional shares (the “Secondary Public Offering”), pursuant to
which we received $134.1 million of proceeds, net of underwriting discounts and commissions and offering expenses. In
February 2021, we issued and sold 3,000,000 shares of common stock (the
“February Offering”) at a public offering price of $23.00 per share, with an additional 450,000 shares sold pursuant to the
underwriters’ full exercise of their option to purchase additional shares in the February Offering. We received aggregate net
proceeds, net of underwriting discounts and commissions and offering costs of $74.4 million. In June 2022, we completed
an underwritten public offering of 20,000,000 shares of our common stock, 10,000,000 pre-funded warrants to purchase
shares of common stock (the “Pre-Funded Warrants”), and 30,000,000 accompanying warrants to purchase shares of our
common stock (“Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the
public of $1.00 per share, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the
public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting
discounts and commissions and offering expenses. In April 2023, we completed a sale of a total of 9,735,731 shares of
common stock and 22,000,000 pre-funded warrants to purchase common stock in a private placement. The shares were
offered to a select group of accredited investors at a price of $0.946 per share and the pre-funded warrants were offered to
select group of accredited investors at a price of $0.945 per pre-funded warrant, resulting in aggregate net proceeds of
approximately $27.5 million, after deducting underwriting discounts and commissions and offering expenses. In August
2023, we entered into a sales agreement (the “Leerink ATM Agreement”) with Leerink Partners LLC, pursuant to which
we may offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $75.0 million
through Leerink Partners LLC as sales agent. As of December 31, 2023, we sold an aggregate of 17,615,976 shares of our
common stock, pursuant to the Leerink ATM Agreement with an average sale price of $2.04 per share, resulting in net
proceeds of $36.9 million, after deducting underwriting discounts, commissions and offering expenses. In October 2023,
we entered into an exchange agreement (the “Exchange Agreement”) with entities affiliated with Venrock Healthcare
Capital Partners (the “Exchanging Stockholders”), pursuant to which we exchanged an aggregate of 5,658,034 shares of
common stock, owned by the Exchanging Stockholders for Pre-Funded warrants to purchase an aggregate of 5,658,034
shares of common stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events
affecting common stock), with an exercise price of $0.001 per share. On January 31, 2024, the Company sold an additional
1,000,000 shares of the
5
Table of Contents
company’s common stock pursuant to the Leerink ATM Agreement with an average sale price of $3.13 per share, resulting
in net proceeds of $3.0 million, after deducting underwriting discounts, commissions and offering expenses. On February
16, 2024, the Company sold an additional 2,000,000 shares of the company’s common stock pursuant to the Leerink ATM
Agreement with an average sale price of $4.90 per share, resulting in net proceeds of $9.5 million, after deducting
underwriting discounts, commissions and offering expenses. In March 2024, we completed a sale of a total of 12,285,714
shares of common stock and 2,000,000 Pre-Funded Warrants to purchase common stock in a private placement. The shares
were offered to a select group of accredited investors at a price of $7.00 per share and Pre-Funded Warrants were offered to
select group of accredited investors at a price of $6.999 per Pre-Funded Warrant, resulting in aggregate gross proceeds of
approximately $100.0 million, after deducting underwriting discounts and commissions and offering expenses.
We are actively pursuing several potential financing options. Other options for structured finance which we
continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in
particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and
pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near
term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities
related to one or more of our programs. There can be no assurances that our discussions with any of the current
counterparties will be successful, and the Company expects to continue to pursue additional opportunities.
Our Strategy
Our goal is to bring potentially transformative therapies to market across a range of fatal or debilitating diseases
for which no treatments are available. The critical components of our strategy include:
● Leveraging our unique approach to develop our pipeline of novel ARIs. We target molecules and pathways
that have a proven role in disease, but have previously failed to yield successful products due to poor efficacy
and tolerability. Our unique approach to drug development utilizes recent technological advances to design
improved drugs, employs early use of biomarkers to confirm biological activity and focuses on abbreviated
regulatory pathways. We develop product candidates with increased potency and selectivity by leveraging
recent technological advances in high throughput crystallography and in silico structural design. Our strategy
is also informed by early use of biomarkers to confirm biological activity and target engagement. Early proof
of biological activity through biomarkers in clinical trials combined with data from prior clinical
development programs on first generation drugs significantly de-risks clinical development in our target
indications. AR is our first molecular target that has been implicated in multiple diseases and for which
sorbitol levels can be assessed as a biomarker of enzyme activity. Prior AR-targeting compounds produced
nonselective inhibitors and failed to demonstrate adequate safety and efficacy. We intend to apply our
strategy to a wide range of validated targets across multiple disease indications, which we believe will result
in additional pipeline programs.
● Rapidly advancing the development of our ARI product candidates, AT-007, AT-001 and AT-003.
Registrational studies have been completed for AT-007 in Galactosemia and for AT-001 for the treatment of
DbCM. A registrational study for AT-007 for SORD Deficiency is ongoing.
● Taking advantage of regulatory pathways designed for accelerated drug development in indications with
high unmet need and seeking strategic partnerships in other indications. We plan to leverage abbreviated
development programs and biomarker-based approaches for rapid drug development and regulatory approval
where possible. For indications that require standard development programs, we plan to seek strategic
partnerships.
● Expanding our pipeline to products targeting other validated molecules and pathways outside of AR. We
will continue leveraging our relationships with academic institutions and universities to acquire or license
additional technologies that are consistent with our strategy of applying new technologies to validated
molecular pathways.
6
Table of Contents
Our Pipeline
The following table shows the status of our current ARI programs:
We seek to protect our proprietary and intellectual property position for our product candidates, our core
technology, and other know-how through U.S. and foreign patent protection. To the extent that our platform is not
patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. For more information,
see the section titled “Business — Intellectual Property.”
Our Product Candidates
Our Aldose Reductase Program
AR is the first enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway.
AR is a redox-regulated enzyme that is activated by an altered redox state within the cell, which occurs during
hyperglycemia and ischemia. AR activation is associated with downstream consequences of hyperglycemia, such as
diabetic complications, as well as consequences of ischemia in the heart, such as acute myocardial infarction and chronic
heart failure. As shown in the figure below, AR activity produces excess sorbitol, which causes osmotic dysregulation
within cells and tissues, such as nerve and retina, and is toxic to many cell types, including cardiomyocytes. Sorbitol is also
further metabolized to fructose, which initiates a cascade of metabolic dysregulation and inflammatory damage to cells,
such as: reactive oxygen species, or ROS, generation; advanced glycation end products, or AGE; protein kinase C, or PKC,
activation; and methylglyoxal overproduction. Under non-oxidative, or healthy patient conditions, AR remains largely
inactive and less than 3% of a healthy person’s glucose is processed by the polyol pathway. However, when the oxidative
environment of the cell changes due to hyperglycemia or ischemia, AR is both activated and upregulated, and greater than
30% of the patient’s glucose is then shunted through the polyol pathway, resulting in significant downstream damage to
cells and tissues. The detrimental consequences of AR activation have been well established by decades of prior research.
These include broad effects, such as mitochondrial dysfunction and cell death, as well as tissue-specific changes, such as
neuronal degeneration in peripheral nerves, collagen crosslinking and fibrosis in cardiac tissue, and damage to blood
vessels in the lens of the eye.
7
Table of Contents
AR Causes Damage to Tissues Under Conditions of Oxidative Stress
* NF-kB is a protein complex that controls transcription of DNA, cytokine production and cell survival.
Additionally, as shown in the figure below, abnormal AR activity is associated with conversion of galactose to
galactitol in patients with Galactosemia. Galactitol, like sorbitol, does not cross the cell membrane and causes damage to
cells across a wide range of tissues, including neurons in the brain, retinal cells in the eye and peripheral nerve tissue.
Galactitol Accumulation Results in Tissue Specific Damage
8
Table of Contents
* GALK, or galactokinase, and GALT, or galactose-1-phosphate uridyl transferase, are enzymes that metabolize
galactose.
** Galactose-1-phosphate is referred to as Gal-1P.
During the 1980s and 1990s, AR was a significant target of drug development due to its established role in a wide
range of debilitating indications. Although these programs failed to produce effective drugs with a favorable risk/benefit
profile, the prior ARI clinical development programs validated the role of AR in the pathogenesis of several diabetic
complications and provided useful information on optimal patient criteria and trial design.
By applying new techniques in crystallography to better understand how the enzyme works, and applying in silico
design and medicinal chemistry approaches, we have developed compounds with logarithmically improved potency and
increased selectivity. Our technology includes specific compounds that are in various stages of preclinical and clinical
development, and is coupled with an understanding of how the enzyme works and a knowledge base of structural
approaches to drug the target while controlling drug characteristics, such as PK, solubility and tissue permeability.
The following table summarizes the current status of our AR program and compound differentiation:
(1) IC50 is the amount of a compound required to inhibit 50% of enzyme activity.
(2) LogD is a log of partition of a chemical compound between the lipid and aqueous phases. LogD often predicts retinal
permeability, with compounds with negative LogD passing through the back of the eye.
AT-007 for the Treatment of Rare Metabolic Disease (Galactosemia, SORD Deficiency, PMM2-CDG)
Overview
AT-007 is a novel CNS penetrant ARI for the treatment of CNS rare diseases, including Galactosemia, SORD
deficiency and PMM2-CDG.
9
Table of Contents
Galactosemia
Galactosemia is a devastating rare pediatric metabolic disease that affects how the body processes a simple sugar
called galactose, and for which there is no known cure or approved treatment available. High levels of galactose circulating
in the blood and tissues of Galactosemia patients enable AR to convert galactose to a toxic metabolite, galactitol, which
results in long-term complications ranging from CNS dysfunction to cataracts. AT-007 was specifically designed to be
CNS penetrant to address AR activity in the brain and potentially prevent CNS consequences of the disease. We have
demonstrated that treatment with AT-007 in an animal model of Galactosemia reduces toxic galactitol levels and prevents
disease complications. We have also demonstrated that in patients with Galactosemia, plasma galactitol level statistically
correlates with disease severity (p=0.004), further supporting the role of toxic galactitol in causing long-term disease
complications. In adult and pediatric Galactosemia patients, we have demonstrated that AT 007 treatment resulted in a
statistically significant reduction in plasma galactitol versus placebo. In a study in children with Galactosemia aged 2-17,
we demonstrated that the galactitol reduction induced by AT-007 treatment resulted in clinical benefit on activities of daily
living, behavioral symptoms, cognition, fine motor skills and tremor over 18 months of treatment. Change in clinical
outcome measures correlated with galactitol level.
Diagnosis and Standard of Care
Galactosemia is caused by severe deficiency in the GALK or GALT enzymes that metabolize galactose. Galactose
is a sugar produced endogenously by the body, and is also a metabolite of lactose. Galactosemia is often fatal in infants
within the first weeks of life if they are exposed to dietary lactose in the form of breast milk or dairy-based formula. As
such, there is mandatory newborn screening for Galactosemia in the United States and many countries in Europe. While
prompt identification of infants with Galactosemia and immediate implementation of a lactose-restricted diet prevents
many fatalities, long-term consequences of disease persist due to endogenous generation of galactose within the body. We
are specifically developing AT-007 for patients with severe enzyme deficiencies in GALK, which is referred to as type 2
Galactosemia, and GALT, which is referred to as Classic Galactosemia. In these patients, despite dietary restriction,
Galactosemia manifests as a combination of CNS and systemic toxicities in tissues, including cognitive dysfunction and
intellectual deficiencies, speech and motor pathologies, pre-senile cataracts and tremor, as well as ovarian insufficiency in
females.
There are no treatments available for Galactosemia. Due to endogenous production of galactose within the body,
infants with Galactosemia develop significant complications even with immediate implementation of, and strict adherence
to, a dairy-free diet. CNS complications include cognitive impairment, low IQ, speech and motor deficiencies, and
seizures. In addition, nearly all females develop ovarian insufficiency. Further to the damage that occurs in
10
Table of Contents
childhood, many adults also develop persistent cataracts, seizures, and experience progressive worsening of tremor,
cognitive, behavioral and psychiatric issues due to ongoing tissue deposition of galactitol.
AR Activity Causes Toxic Accumulation of Galactitol in Galactosemia
We have demonstrated that inhibiting AR activity shifts galactose metabolism to an alternative enzyme called
galactose dehydrogenase, which allows galactose to be metabolized to galactonate, a benign substance that is removed in
the urine.
Market Opportunity
The global incidence of Galactosemia is estimated to be 1 in 50,000 to 1 in 90,000, depending on ethnicity. The
U.S. Galactosemia population is approximately 3,200 patients, based on newborn screening data identifying 2,500 infants
through 2014, and the estimated birth rate of 80 patients per year. Prior studies estimated that the U.S. Galactosemia
population was higher based on the incidence rates, because they did not take into account that, prior to newborn screening,
most infants with Galactosemia died within a few weeks of birth. As a result, the disease prevalence is significantly lower,
and the live population with Galactosemia is largely age 40 and younger. The EU population (including the UK) is slightly
larger than the US population, estimated at approximately 4,000 patients, leading to a combined US + EU market
opportunity of approximately 7,000 patients. When additional markets, such as Japan and Canada are considered, we
believe the overall Market opportunity for Galactosemia is approximately 7,600 patients worldwide.
Preclinical Studies
A rat model of classic Galactosemia displays similar biochemical and functional abnormalities to those associated
with Galactosemia in humans.
Treatment with AT-007 significantly reduced galactitol levels in target tissues, including blood, brain and liver,
without increasing galactose or Gal-1P levels, and prevented complications associated with galactitol accumulation in
11
Table of Contents
tissues, including cataract formation and CNS dysfunction. The effects of AT-007 were dose dependent and corresponded
with galactitol reduction.
Clinical Development
ACTION-Galactosemia Phase 1/2 Study
We have evaluated AT-007 in a pivotal Phase 1/2 clinical trial in healthy volunteers and adults with Galactosemia.
The Phase 1 portion of the study in healthy volunteers evaluated safety, tolerability, CNS penetrance and PK of AT-007 at
doses of 5mg/kg to 40mg/kg for up to seven days of consecutive treatment. The Phase 2 portion in adults with
Galactosemia evaluated safety, tolerability, PK and pharmacodynamic reduction in the biomarker galactitol. Patients
received AT-007 5mg/kg, 20mg/kg, 40mg/kg or placebo, for 28 days.
AT-007 treatment resulted in a statistically significant and robust reduction in plasma galactitol versus placebo in
adult Galactosemia patients. Reductions in galactitol were dose dependent, with higher concentrations of AT-007 resulting
in a greater magnitude of reduction in galactitol. At the higher doses tested (20mg/kg and 40mg/kg), AT-007 significantly
reduced plasma galactitol by approximately 50% from baseline. Results were statistically significant (p value of less than
0.01) vs. placebo. Galactitol reduction was rapid and sustained over time. No substantial change from baseline was
observed in placebo treated patients. AT-007 was well tolerated in both Galactosemia patients and healthy volunteers.
ACTION-Galactosemia Kids
In June 2020, we initiated the ACTION-Galactosemia Kids pediatric Galactosemia study. The study was placed
on partial clinical hold in August 2020 while we worked with the FDA to redesign and operationally modify the study to
seamless design to ensure continuous treatment and the opportunity to receive clinical benefit. The study re-started in
February 2021 and was unblinded in April 2023, and patients who were randomized to active treatment transitioned to an
expanded access program. The open-label extension for patients that were initially randomized to placebo is ongoing. The
pediatric clinical trial was a 2-part study to evaluate safety, pharmacokinetics, and reduction in the toxic biomarker,
galactitol (Part A), as well as impact on functional outcomes in children with Galactosemia over time (Part B). Three age
cohorts were studied in parallel: age 2-6, age 7-12, and age 13-17. The biomarker portion of the study, demonstrated a 40%
reduction in plasma galactitol (p<0.001 vs. placebo). The clinical outcomes portion of the study measured several aspects
of the Galactosemia phenotype on how patients feel and function. AT-007 treatment demonstrated consistent long-term
clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, and improved
activities of daily living, behavior, cognition, fine motor skills, adaptive skills and tremor vs. placebo. The primary
endpoint, the Global Statistical Test, was a composite sum of change comprised of four endpoints: OWLS-2 Oral
Expression (OE), OWLS-2 Listening Comprehension (LC), BASC-3 Behavior Symptoms Index (BSI) and the BASC-3
Activities of Daily Living (ADL). An additional pre-specified sensitivity analysis included cognition in the primary
endpoint (NIH-Toolbox Cognition Battery). Additional clinical outcomes were assessed as secondary endpoints, including
adaptive skills and tremor. Clinical outcomes were assessed every 6 months by a firewalled independent Data Monitoring
Committee (DMC). While statistical significance defined as a p value of <0.05 was not met on the primary endpoint,
systematic improvement over time was demonstrated for the overall primary endpoint (p=0.1030) and for a pre-specified
sensitivity analyses including cognition (p=0.0698). Speech and language components of the primary endpoint were not
impacted, which is suspected to be due to lack of progression in the placebo group and concomitant speech therapy
received in the trial. Of note, patients with severe speech deficits showed a favorable trend towards improvement with AT-
007 treatment vs. placebo. AT-007 (govorestat) provided a statistically significant benefit on tremor at 18 months
(p=0.0428), as measured by the Archimedes Spiral Drawing Test, and adaptive skills as assessed by the BASC-3 Adaptive
Skills Index (p=0.0265). Consistent with prior reported data, improvement in galactitol levels was sustained throughout
the trial with no impact on Gal-1p or galactose, further establishing the causal role of galactitol in disease pathogenesis.
AT-007 continued to be safe and well-tolerated in all age groups; there were no treatment-related serious adverse events
(SAEs) reported.
We submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the
fourth quarter of 2023, which was subsequently validated and accepted for review in December 2023. A New Drug
12
Table of Contents
Application (NDA) was submitted in December 2023 to the US FDA, and the FDA accepted the filing of the NDA for
govorestat (AT-007) for the treatment of Classic Galactosemia in February of 2024. The NDA was granted Priority Review
status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA
also noted that it is planning to hold an advisory committee meeting to discuss the application.
SORD Deficiency
SORD Deficiency is a newly characterized genetic cause of Charcot-Marie-Tooth Type 2 Disease (“CMT2”) and
distal hereditary neuropathy, in which patients are deficient in the enzyme Sorbitol Dehydrogenase (“SORD”). SORD is
the enzyme which follows AR in the polyol pathway and converts sorbitol to fructose. Patients who are deficient in SORD
can’t metabolize sorbitol normally, and sorbitol levels accumulate to unnaturally high levels. Sorbitol, like galactitol, has
been shown to be toxic to cells, especially neurons, resulting in progressive neuronal degeneration. Patients with SORD
Deficiency develop progressive neuropathy, which greatly impacts mobility and motility, and significantly affects quality
of life.
Diagnosis and Standard of Care
Currently, patients with SORD Deficiency are diagnosed based on neurological symptoms and confirmatory
genetic testing, which is available through several commercial labs and hospital systems. There are currently no drugs
approved to treat SORD Deficiency.
Market Opportunity
Genetic studies indicate that approximately 7-9% of CMT2 cases are caused by SORD Deficiency, estimating the
US population around 3,300 patients. The EU population (including the UK) is estimated to be approximately 4,400
patients. When additional markets, such as Japan and Canada are considered, we believe the overall Market opportunity for
Galactosemia is approximately 8,400 patients worldwide.
Preclinical Studies
Substrate reduction through AR inhibition in patient fibroblasts and a drosophila model of disease have
demonstrated preclinical proof of concept in SORD Deficiency, significantly reducing sorbitol levels and normalizing the
drosophila disease phenotype. Preclinical studies in fibroblasts derived from SORD Deficiency patients have demonstrated
significant reduction in sorbitol levels with AT-007 treatment. Preclinical studies in the drosophila model of disease have
demonstrated a positive impact on the disease phenotype with AT-007 treatment, including mobility (climbing) and
prevention of neuronal degeneration.
Clinical Development
In 2021 we conducted an open-label pilot study in 8 patients with SORD Deficiency. AT-007 treatment
significantly reduced sorbitol levels by approximately 66% from baseline, and was safe and well tolerated. In December
2021 we initiated a Phase 2/3 registrational study in patients with SORD Deficiency. The registrational study, called the
INSPIRE trial, is designed to demonstrate biomarker efficacy at 3 months through reduction in sorbitol, and long-term
clinical efficacy over 2 years of treatment, with an interim clinical outcomes assessment at 12 months. The study is a
multicenter placebo controlled trial conducted in the US and Europe in approximately 50 SORD patients age 16 and older.
In February 2023, we announced that in a pre-specified interim analysis of the ongoing Phase 3 INSPIRE trial, AT-007
reduced sorbitol levels by a mean of approximately 52% (or approximately 16,000ng/ml) over 90 days of treatment
(p<0.001 vs. placebo) in patients with SORD Deficiency. At baseline, the mean blood sorbitol level of SORD patients
included in this interim analysis was approximately 29,000ng/ml, with a range of approximately 22,000ng/ml-38,000ng/ml.
In the INSPIRE trial, a baseline cross-sectional analysis of the relationship between sorbitol level, age (or duration of
disease) and clinical outcome measures demonstrated a statistically significant correlation between sorbitol level and key
clinical outcome measures, including 10-meter-walk/run speed, 4-stair climb speed, and sit-to-stand test (p<0.05). In
February 2024 we announced positive interim 12-month results from the ongoing Phase 3 INSPIRE trial, in which the
primary endpoints and several key secondary endpoints were achieved. The interim 12-month analysis
13
Table of Contents
demonstrated statistically significant correlation between sorbitol level and the prespecified CMT-FOM composite clinical
endpoint (10-meter walk-run test, 4 stair climb, sit to stand test,6-minute walk test and dorsiflexion) (p=0.05). AT-007
treatment also provided sustained reduction in sorbitol level in patients with SORD Deficiency over 12 months of
treatment, which was statistically significant compared to placebo (p<0.001). Lastly, AT-007 treatment also resulted in a
highly statistically significant effect (p=0.01) on the CMT Health Index (CMT-HI), an important patient-reported outcome
measure of disease severity and well-being, which was a secondary endpoint in the study. Aspects of the CMT-HI that
demonstrated a treatment effect included lower limb function, mobility, fatigue, pain, sensory function, and upper limb
function. AT-007 was safe and well tolerated, with similar incidence of adverse events between active and placebo-treated
groups. We plan to meet with regulatory agencies to discuss the interim analysis to determine whether an NDA and MAA
could be submitted based on the current data to date. The study is continuing in blinded format to 24 months of treatment.
PMM2-CDG
PMM2-CDG is a glycosylation disorder in which patients have only partial function of the phosphomannomutase
enzyme (“PMM2”). As a result, patients do not process sugars properly to support protein glycosylation, which results in
systemic problems and multi-organ failure. PMM2-CDG is a severe disease, resulting in and high mortality in children,
with no FDA approved treatments. PMM2-CDG is an ultra-rare disease, with only approximately 1,000 patients identified
worldwide.
Recently, AR inhibition was demonstrated to positively impact protein glycosylation in PMM2-CDG patient
fibroblasts and a C. elegans model of disease. It is believed that AR inhibition results in increased protein glycosylation by
shifting the balance of sugar production to support PMM2 activity. In preclinical studies in PMM2-CDG patient
fibroblasts, AT-007 significantly improved PMM2 activity. Based on this data, we have received both Orphan Designation
and Pediatric Rare Disease designation from the FDA.
AT-001 for the Treatment of Diabetic Cardiomyopathy
Overview
We are developing AT-001, a novel ARI with broad systemic exposure and peripheral nerve permeability being
developed for the treatment of DbCM, a fatal fibrosis of the heart, for which no treatments are available. We completed a
Phase 1/2 clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related
adverse effects or tolerability issues were observed. This trial also demonstrated target engagement and proof of biological
activity, as measured by reduction in sorbitol, a biomarker of AR activity and NTproBNP. A registrational Phase 2/3 study
in DbCM patients at high risk of progression to overt heart failure (ARISE-HF) was recently completed.
Diagnosis and Standard of Care
DbCM is a fatal fibrosis of the heart that occurs in both type 1 and type 2 diabetic patients, which leads to
decreased contractility and decreased heart function, eventually resulting in fulminant heart failure. DbCM is caused by
metabolic derangements in cardiomyocytes that result in cell death and fibrosis. AR activity has been shown to be a large
contributor to these metabolic derangements, and the downstream effect of AR activation is responsible for the
cardiomyocyte cell death and fibrosis. DbCM is diagnosed by increased weight of the heart and decreased contractility,
which are identified by echocardiographic screening, as well as by exclusion of other forms of heart disease.
Epidemiological studies have shown that approximately 17% to 24% of diabetic patients display DbCM in the absence of
any other forms of heart disease. These patients do not have hypertension, atherosclerosis, valvular heart disease or
ischemia, and the only cause of the cardiomyopathy is the underlying diabetes. Stages of DbCM range from asymptomatic,
or stage 1, to acute heart failure, or stage 4. Most patients are not diagnosed until stage 2, where symptoms manifest as
extreme shortness of breath during exercise, referred to as decreased exercise tolerance. Exercise tolerance in these patients
(as measured by maximum amount of oxygen a person can utilize during intense exercise known as peak VO2) is
approximately 25% lower than diabetic patients without DbCM, and decreases by an additional 30% as the patients
progress to overt heart failure in later stages of diseases. Patients quickly progress at a steady state of decline to stage 3,
which includes marked cavity dilation and severe limitations in daily activities. The final stage of
14
Table of Contents
DbCM, stage 4, is represented by acute heart failure resulting in death. The current standard of care is to target glucose
control in these patients, as well as hemodynamic modulation of blood flow, through use of beta blockers and diuretics.
Both approaches are largely ineffective, and DbCM often results in death within five to ten years of diagnosis.
Approximately 24% of DbCM patients progress to overt heart failure or death within 1.5 years of diagnosis, and 37%
within five years of diagnosis.
Market Opportunity
According to a retrospective epidemiological study, approximately 17% of patients suffering from diabetes
develop DbCM. A study completed in France that utilized echocardiographic screening estimates the proportion of diabetic
patients to develop DbCM at approximately 24%. The International Diabetes Foundation estimated that there were
approximately 451 million patients globally with diabetes in 2017, which is expected to increase to 693 million by 2045.
This includes 58.0 million diabetes patients in Europe in 2017, which is expected to increase to 67.0 million in 2045, and
46.0 million in North America, which is expected to increase to 62.0 million in 2045. Based on an estimated prevalence of
17% of diabetic patients who develop DbCM, we estimate that currently there are approximately 77.0 million patients with
DbCM globally, with approximately 8.0 million in North America and 10.0 million in Europe. Initially, our development
program will target patients at high risk of progression to overt heart failure, which we estimate constitute approximately
50% of all DbCM patients. We believe these patients represent a symptomatic population that is more likely to be
responsive to treatment.
Prior AR-Based Approaches to Treat DbCM
AR activity has been implicated as a strong contributing factor to pathogenesis in DbCM. Pfizer Inc. was
developing an ARI, Alond (zopolrestat), for the treatment of DPN and DbCM in a Phase 2 clinical trial that demonstrated
favorable outcomes on heart function in DbCM patients, but the clinical trial was discontinued due to an unfavorable
risk/benefit profile, with several patients experiencing liver toxicity and significant elevations in both aspartate
aminotransferase and alanine aminotransferase, which are enzymes central to identification of liver toxicity and damage. In
this trial, patients with early-stage DbCM were identified by echocardiographic screening and were randomized to three
treatment groups, which consisted of placebo, 500 mg zopolrestat per day or 1,000 mg zopolrestat per day dosed for one
year. Due to liver toxicity seen in another trial with zopolrestat, the 1,000 mg treatment arm was reduced to 500 mg, and
the two doses were collapsed into one treatment arm. While patients on placebo displayed decreased heart function over
the year of the trial as their disease progressed, patients on zopolrestat displayed a stabilization of heart function and even
improvement in heart function in some patients based on hemodynamic endpoints. We believe this data validates the
approach of using an ARI to improve outcomes for patients with DbCM and using our compounds, which demonstrate
improved potency and have been well tolerated, may lead to greater clinical utility.
We have demonstrated that when compared to zopolrestat, AT-001 has significantly higher in vitro enzymatic
inhibitory activity and greater specificity for AR. Liver toxicity associated with “old” ARIs such as zopolrestat has been
shown to be due to off-target inhibition of a structurally related enzyme, Aldehyde Reductase, which is required for normal
liver function. AT-001 demonstrates increased selectivity for AR, and does not inhibit Aldehyde Reductase at any
concentration tested. This increased selectivity led to lack of toxicity in cultured hepatocytes, or liver cells, whereas
zopolrestat demonstrated significant toxicity in hepatocytes. Thus, we believe that not only is AT-001 a more potent AR
15
Table of Contents
inhibitor than prior drugs, but that we have overcome the safety and toxicity limitations from prior compounds, which were
due to lack of selectivity and off-target inhibition of Aldehyde Reductase.
Preclinical Efficacy Studies
In a preclinical model of DbCM AT-001 prevented cardiac damage and dysfunction and normalized cardiac
energetics. In a diabetic rat model, AT-001 prevented cardiac damage induced by ischemia/repurfusion.
Clinical Development
Until recently, development in cardiovascular disease indications often required large outcome-based trials that
examined survival and re-hospitalization as primary endpoints. These trials were extremely large, expensive and time-
consuming, and were often confounded by comorbidities in the patient population. As a result, very few cardiovascular
programs resulted in approved drugs. There has been a recent effort from the Division of Cardiovascular and Renal
Products at the FDA, as well as at the European Medicines Agency, or EMA, to streamline drug development for
cardiovascular disease to increase the probability of demonstrating a meaningful clinical effect in patients. Specifically, in
cardiomyopathies, where there is a direct functional link between hemodynamic endpoints, heart contractility and quality
of life, there is a unique opportunity to demonstrate benefit of therapy in a smaller number of patients and shorter treatment
period than was previously required. Recent clinical development programs in hereditary cardiomyopathies have pioneered
smaller trials examining exercise tolerance and/or heart functional capacity as a primary endpoint.
Consistent with these developments, at our pre-IND meeting, the FDA indicated that we would not be required to
examine survival and re-hospitalization endpoints, and confirmed that exercise tolerance would qualify as an appropriate
primary endpoint in our DbCM trial. This was also recently publicly confirmed by the FDA in a whitepaper entitled “Draft
Guidance for Industry: Treatment for Heart Failure: Endpoints for Drug Development.” Accordingly, we designed our
pivotal Phase 2/3 clinical trial to target functional capacity, or exercise tolerance, as measured by Peak VO2 on
Cardiopulmonary Exercise Testing (CPET) in DbCM patients at high risk of progression to overt heart failure.
Phase 1/2 Trial in Adult Type 2 Diabetic Patients
We have evaluated AT-001 in a placebo-controlled Phase 1/2 clinical trial in approximately 120 type 2 diabetes
patients. The primary objectives of this trial were to explore the safety, tolerability and PK profile of AT-001. Because AR
converts glucose to sorbitol, and AR activity is elevated in diabetic patients, sorbitol normalization was also examined as a
pharmacodynamic, or PD, biomarker of target engagement, which provided proof of biological activity in patients.
The Phase 1/2 clinical trial allowed use of concomitant treatments for glucose control, as well as other standard of
care treatments for diabetes, such as statins and ACE inhibitors. The FDA permitted us to directly evaluate diabetic patients
due to positive data from the preclinical studies, as well as the urgency to develop drugs quickly due to high unmet need.
AT-001 was dosed as an active pharmaceutical ingredient, or API, powder in a rapid release capsule and the trial examined
both once-daily and twice-daily, or BID, dosing regimens.
AT-001 was safe and well tolerated at all doses tested. Additionally, there were no observed adverse interactions
with any concomitant diabetes medications used by patients during the trial. Because AR converts glucose to sorbitol, and
AR activity is elevated in diabetic patients, sorbitol normalization to healthy subject levels can be used as a PD biomarker
of target engagement and proof of biological activity. Treatment with AT-001 normalized sorbitol levels in diabetic patients
to those of healthy volunteers, and prevented post-prandial elevations in sorbitol. Decrease in sorbitol levels was dose-
dependent, with higher doses of AT-001 resulting in greater reduction in sorbitol levels. Reduction in sorbitol levels lasted
for approximately 10-12 hours post dose, suggesting that twice-daily oral dosing produced optimal pharmacodynamic
impact. Placebo-treated patients did not demonstrate any reduction in sorbitol levels, and conversely demonstrated post-
prandial increase in sorbitol levels.
16
Table of Contents
Within the Phase 1/2 study, approximately 30 patients with early stage DbCM, assessed by echocardiographic
abnormalities and elevations in the cardiac stress biomarker, NTproBNP, were treated with AT-001 or placebo for 28 days.
Treatment with AT-001 (twice daily or three times daily) resulted in sustained reduction in sorbitol, and significant
reduction in NTproBNP, demonstrating that inhibition of AR decreases cardiac stress. This data supported dose selection
and advancement into a Phase 2/3 registrational trial for DbCM.
In September 2019, we initiated a Phase 3 registrational trial for AT-001 in DbCM called ARISE-HF. ARISE-HF
was a global registrational study in approximately 675 patients with DbCM at high risk of progression to overt heart
failure. The study evaluated the treatment effect of AT-001 high dose (1500 mg twice daily) and low dose (1,000mg twice
daily) compared to placebo on cardiac functional capacity over 15 months of treatment. On January 4, 2024, we announced
topline results from the ARISE-HF study. AT-001 (caficrestat) demonstrated a strong trend in stabilizing cardiac functional
capacity, while the placebo group declined over 15 months. The placebo-treated group declined by a mean of -0.31
ml/kg/min over 15 months of treatment, while the AT-001 1500mg twice daily treated group remained primarily stable,
with a mean change of -0.01 ml/kg/min over 15 months. While a trend favored active treatment, the difference between
active and placebo treated groups (0.30 ml/kg/min) was not statistically significant (p=0.210). Approximately 38% of
study subjects were on SGLT2 or GLP-1 therapies for treatment of diabetes, while 62% were not. In a pre-specified
subgroup analysis of the primary endpoint in patients not concomitantly treated with SGLT2 or GLP-1 therapies, the
placebo group declined by a mean of -0.54 ml/kg/min, while the 1500mg BID AT-001 treated group improved by a mean
of 0.08 ml/kg/min over 15 months of treatment, with a difference between groups of 0.62 ml/kg/min (p=0.040).
Additionally, in this subgroup analysis, the number of patients who experienced a clinically significant worsening in
cardiac functional capacity of 6% or more was substantially higher in the placebo group (46%) as compared to the 1500mg
BID AT-001 treated group (32.7%), odds ratio 0.56 (p=0.035). A 6% change in cardiac functional capacity has been shown
to predict long-term survival and hospitalization for heart failure. The effect of AT-001 was dose dependent, with the low
dose (1000mg BID) demonstrating an intermediate effect between the high dose and placebo. AT-001 was generally safe
and well tolerated, with no substantial differences in serious adverse events between AT-001 treated groups as compared to
placebo.
AT-001 for the Treatment of Diabetic Peripheral Neuropathy
Overview
We also intend to develop AT-001 for DPN, a debilitating neurodegenerative disease that significantly reduces
patients’ quality of life, and for which there are currently no FDA-approved treatments. We expect this indication will
require a standard clinical development path, and as such we plan to pursue a strategic partnership in order to expand into
this indication. Since many patients with DbCM also have DPN, we are collecting proof-of-concept data through our
DbCM program to support our efforts in our DPN program. We have included a DPN sub-study in our pivotal DbCM
study.
Diagnosis and Current Standard of Care
DPN is diagnosed by a simple neurological assessment, usually the Toronto Neuropathy Scoring System, which is
administered in the physician’s office and examines a patient’s ability to feel various types of neurological stimuli on the
hands and feet. AR activity has been shown to cause DPN. Epalrestat, an ARI, is approved in Japan, China and India to
prevent further neuronal degeneration in DPN patients. However, there are no disease modifying therapies approved in the
United States and Europe, and only symptomatic medications, such as Lyrica, are approved for pain associated with DPN.
Although epalrestat was approved in Japan in 1992 based on very limited clinical data that would not have been sufficient
for other markets, more recent academic studies have demonstrated an effect on MNCV and symptomatic pain endpoints in
a wide range of diabetic patients. For example, a multicenter, three-year Phase 3 clinical trial conducted in Japan on
epalrestat 150 mg versus placebo demonstrated that epalrestat prevented progression of DPN in diabetic patients versus
placebo. Epalrestat prevented degeneration of nerve function, as measured by MNCV, and prevented worsening of
symptomatic pain. A statistically significant effect was demonstrated in all patients regardless of low or high levels of
glucose attached to their hemoglobin, as tested by a hemoglobin A1C (HbA1C) test.
17
Table of Contents
Epalrestat, which is now generic in Japan, reached peak sales of approximately $226 million in 2001. This is
indicative of its widespread use in the Japanese diabetic population, which was approximately five million patients at the
time of launch despite significant tolerability issues associated with use and five times daily dosing due to a very short half-
life. We do not believe, however, that it is likely to be a candidate for further commercialization. Nevertheless, prior
research on epalrestat evinces the role of AR in DPN and provides a clinical trial design to demonstrate efficacy in this
indication.
Market Opportunity
Approximately 50% of the global diabetic population, or 226 million diabetic patients, suffer from DPN, with
23.0 million patients in North America and 29.0 million patients in Europe. Due to availability of generic epalrestat in
China and India, we view the opportunity in these two markets to be limited as a result of pricing pressures and
differentiation requirements with regard to epalrestat. However, we believe a significant market opportunity for a more
effective ARI with a favorable dosing regimen still exists in Japan, a less price sensitive market where there is familiarity
with the mechanism of action in the disease and use of epalrestat is high. As such, although we are currently focused on the
U.S. market, we may expand our efforts into Japan opportunistically.
Preclinical Studies
In preclinical studies, AT-001 prevented neuronal degeneration in animal models of DPN, as measured by MNCV
in sciatic and tail nerves of diabetic rats. AT-001 treatment prevented peripheral neuronal damage, as measured by MNCV
after six weeks of treatment. A dose-dependent reduction in neuronal dysfunction was observed in rats treated with AT-001,
and treatment at 30 mg/kg of AT-001 completely prevented neuronal degeneration, with no statistical difference from non-
diabetic WT rats.
Clinical Development
Since many DbCM patients often also suffer from DPN, we have incorporated DPN endpoints, such as MNCV, as
a sub-study into our DbCM ARISE-HF pivotal study to provide additional proof-of-concept for AT-001 in DPN. Results of
the DPN substudy of ARISE-HF are being evaluated.
AT-003 for the Treatment of Diabetic Retinopathy
Overview
We are developing AT-003, an ARI designed to cross through the back of the eye when dosed orally, which has
demonstrated strong retinal penetrance, for the treatment of DR. DR is an ophthalmic disease that occurs in diabetic
patients, and for which treatments are currently limited to intravitreal administration. DR has been linked to AR activity,
including elevations in sorbitol and subsequent changes in retinal blood vessels, which distorts vision and leads to
permanent blindness. We are currently in late stages of preclinical development and intend to advance AT-003 into a
Phase 1 clinical trial for the treatment of DR.
Diagnosis and Current Standard of Care
DR is diagnosed by routine dilated eye exam by an ophthalmologist. Annual or biennial ophthalmic exams to
screen for DR are a recommended standard of care for diabetic patients under current treatment guidelines. Vascular
endothelial growth factor, or VEGF, inhibitors, Lucentis (ranibizumab) and Eylea (aflibercept), are approved to treat severe
or late-stage DR, but are limited by high cost, the need for intravitreal injection into the eye and the lack of therapeutic
benefit in many patients. A need exists for safe, effective and tolerable treatments for DR early in the disease process that
provide a benefit to a wide range of patients. AR is an attractive target for DR drug development since AR activity is
upstream of VEGF activity in DR pathogenesis. AR has been shown to cause DR by inducing hyperosmolarity in retinal
cells due to elevated sorbitol, as well as through fructose-mediated detrimental downstream effects, such as AGE
generation and PKC activation. AR knock-out rats are protected from DR development, and several prior ARIs
demonstrated efficacy on DR endpoints in clinical trials, but were not approved due to dose-limiting safety concerns.
18
Table of Contents
Market Opportunity
A recent retrospective epidemiological analysis of diabetic patients globally confirmed that DR affects
approximately 35% of diabetics, and is a leading cause of blindness worldwide. Based on the 2017 diabetes numbers, the
global market for DR is approximately 158 million patients, with anticipated increase to 243 million by 2045. The current
market is approximately 16.0 million in North America and 20.0 million in Europe.
Preclinical Studies
AT-003 displayed significant retinal penetration when dosed orally in diabetic rats. AT-003 was observed to be
well tolerated over a seven-day dosing period in all doses tested, up to 1,000 mg/kg daily, with no adverse effects observed.
Efficacy of AT-003 is currently being explored in two animal models of DR — an ischemic injury model (acute damage)
and chronic diabetic treatment model.
Clinical Development Plan
Similar to AT-001, we plan to explore the safety, tolerability, PK profile and biomarker effects of AT-003 in a
Phase 1a/1b clinical trial in diabetic patients. Assuming positive data in this trial, we plan to initiate a pivotal Phase 2/3
clinical trial of AT-003 in patients with DR to prevent disease progression versus placebo, as measured by subjective
metrics, including fluoroscein angiography and optical coherence tomography, which are scans used in the examination and
management of retinal diseases.
Exclusive License Agreement with Columbia University
On October 26, 2016, we entered into a license agreement with Columbia University (the “2016 Columbia
Agreement”). Pursuant to the 2016 Columbia Agreement, Columbia University granted us a royalty-bearing, sublicensable
license that is exclusive with respect to certain patents, and non-exclusive with respect to certain know-how, in each case to
develop, manufacture, and commercialize ARI products, including AT-001, AT-003 and AT-007. The license grant is
worldwide with the exception of a single patent family covering AT-001 and AT-003 for which the license grant excludes
China, Taiwan, Hong Kong and Macao. Under the 2016 Columbia Agreement, we are obligated to use commercially
reasonable efforts to research, discover, develop and market licensed products for commercial sale in the licensed territory,
and to comply with certain obligations to meet specified development and funding milestones within defined time periods.
Columbia University retains the right to conduct, and grant third parties the right to conduct, non-clinical academic
research using the licensed technology; provided that such research is not funded by a commercial entity or for-profit entity
or results in rights granted to a commercial or for-profit entity. As the technology licensed to us under the 2016 Columbia
Agreement was developed as a result of a U.S. government grant, the licenses granted to us under the agreement are
subject to the terms of such grant, and to standard rights of the U.S. government under the Bayh-Dole Act, including the
grant to the government of a non-exclusive, worldwide, freedom to operate license under any patents, and the requirement,
absent a waiver, to manufacture products substantially in the United States.
As consideration for entering into the 2016 Columbia Agreement, we made a nominal upfront payment to
Columbia University and, following the occurrence of certain trigger events, issued to Columbia University shares equal to
5% of our outstanding common stock on a fully diluted basis at the time of issuance. We will be required to make further
payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and
regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual
net sales, in each case in connection with products covered by the 2016 Columbia Agreement. We will also be required to
pay tiered royalties to Columbia University in the low- to mid-single digit percentages on our, our affiliates’ and our
sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, we are required to
make specified annual minimum royalty payments to Columbia University in the mid six figures beginning on the
10th anniversary of the effective date of the agreement. When we grant sublicenses under the 2016 Columbia Agreement
we are required to pay to Columbia University a portion of the net sublicensing revenue received from such third parties, at
percentages between 10% and 20%, depending on the stage of development at the
19
Table of Contents
time such revenue is received from such third parties. The Advanz Agreement includes a sublicense under the 2016
Columbia Agreement.
Columbia University is responsible for the prosecution and maintenance of the licensed patents, in consultation
with us, and subject to a requirement to give due consideration to our comments, at our expense. We have the first right,
but not the obligation, to control the enforcement of licensed patents exclusively licensed to us against third parties. We are
required to indemnify Columbia University for any third-party claims that arise from or relate to the 2016 Columbia
Agreement.
The 2016 Columbia Agreement will terminate upon the expiration of all our royalty payment obligations in all
countries. We may terminate the 2016 Columbia Agreement for convenience upon 90 days’ written notice to Columbia
University. At its election, Columbia University may terminate the 2016 Columbia Agreement, or convert the licenses
granted to us into non-exclusive, non-sublicensable licenses, in the case of (a) our uncured material breach upon 30 days’
written notice (which shall be extended to 90 days if we are diligently attempting to cure such material breach), (b) our
failure to achieve the specified development and funding milestone events, or (c) our insolvency. The 2016 Columbia
Agreement may not be assigned by us without Columbia University’s consent, except to any successor to all or
substantially all of our business to which the 2016 Columbia Agreement relates and upon notice to Columbia University.
In January 2019, we entered into a second license agreement with Columbia University (the “2019 Columbia
Agreement”). Pursuant to the 2019 Columbia Agreement, Columbia University granted us a royalty-bearing, sublicensable
license that is exclusive with respect to certain patents, and non-exclusive with respect to certain know-how, in each case to
develop, manufacture and commercialize PI3k inhibitor products. The license grant is worldwide. Under the 2019
Columbia Agreement, we are obligated to use commercially reasonable efforts to research, discover, develop and market
licensed products for commercial sale in the licensed territory, and to comply with certain obligations to meet specified
development and funding milestones within defined time periods. Columbia University retains the right to conduct, and
grant third parties the right to conduct, non-clinical academic research using the licensed technology; provided that such
research is not funded by a commercial entity or for-profit entity or results in rights granted to a commercial or for-profit
entity. As consideration for entering into the 2019 Columbia Agreement, we made a nominal upfront payment to Columbia
University. We will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for
the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the
achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the
2019 Columbia Agreement. We will also be required to pay tiered royalties to Columbia University in the low- to mid-
single digit percentages on our, our affiliates’ and our sublicensees’ net sales of licensed products, subject to specified
offsets and reductions. In addition, we are required to make specified annual minimum royalty payments to Columbia
University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the tenth
anniversary of the effective date of the 2019 Columbia Agreement.
In July 2022, following regulatory changes impacting development of the class of PI3k inhibitors and the
Company’s decision to discontinue its early stage preclinical PI3k program, the Company and Columbia entered into an
agreement terminating the 2019 Columbia Agreement (the “2022 Columbia Termination Agreement”) as of July 25, 2022.
Under the terms of the 2022 Columbia Termination Agreement, the Company assigned certain regulatory documents
regarding the preclinical PI3k inhibitor AT-104 to Columbia and granted Columbia a non-exclusive royalty free license
(with rights to sublicense any future Columbia licensee) under certain know-how, technical information and data relating to
AT-104 that was developed by the Company during the term of the 2019 Columbia Agreement.
In March 2019, and in connection with the 2016 Columbia Agreement, the Company entered into a research
services agreement (the “2019 Columbia Research Agreement”) with Columbia University with the purpose of analyzing
structural and functional changes in brain tissue in an animal model of Galactosemia, and the effects of certain compounds
whose intellectual property rights were licensed to the Company as part of the 2016 Columbia Agreement on any such
structural and functional changes. The 2019 Columbia Research Agreement had a term of 12 months from its effective date
and expired in accordance with its terms.
20
Table of Contents
On October 3, 2019, and in connection with the 2019 Columbia Agreement, the Company entered into a research
services agreement (the “PI3k Columbia Research Agreement” and collectively with the 2016 Columbia Agreement, 2019
Columbia Agreement and 2019 Columbia Research Agreement, the “Columbia Agreements”) with Columbia University
with the purpose of analyzing PI3k inhibitors for the treatment of lymphoid malignancies. The PI3k Columbia Research
Agreement had a term of 18 months from its effective date and expired in accordance with its terms.
License Agreement with University of Miami
On October 28, 2020, we entered into a license agreement (the “2020 Miami License Agreement”) with the
University of Miami relating to certain technology that is co-owned by the University of Miami (UM), the University of
Rochester (UR) and University College London (UCL Business Ltd. (UCL)). UM was granted an exclusive agency from
UR and UCL to license each of their rights in the technology. Pursuant to the 2020 Miami License Agreement, UM, on
behalf of itself and UR and UCL, granted us a royalty-bearing, sublicensable license that is exclusive with respect to
certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain
know-how, in each case to research, develop, make, have made, use, sell and import products for use in treating and/or
detecting certain inherited neuropathies, in particular those caused by mutation in the sorbitol dehydrogenase (SORD)
gene. The license grant is worldwide. Under the 2020 Miami License Agreement, we are obligated to use commercially
reasonable efforts to develop, manufacture, market and sell licensed products in the licensed territory, and to comply with
certain obligations to meet specified development milestones within defined time periods. UM retains for itself UR and
UCL the right to use the licensed patent rights and licensed technology for their internal non-commercial educational,
research and clinical patient care purposes, including in sponsored research and collaboration with commercial entities. As
the technology licensed to us under the 2020 Miami License Agreement was developed as a result of a U.S. government
grant, the licenses granted to us under the agreement are subject to the terms of such grant, and to standard rights of the
U.S. government under the Bayh-Dole Act, including the grant to the government of a non-exclusive, worldwide, freedom
to operate license under any patents, and the requirement, absent a waiver, to manufacture products substantially in the
United States.
Under the terms of the 2020 Miami License Agreement, we are obligated to pay the University an up-front non-
refundable license fee of $1.1 million, and a second non-refundable license fee of $0.5 million due on the first anniversary
of the date of the license. We will be required to make further payments to UM of up to an aggregate $2.2 million for the
achievement of specified patenting and development milestones, and up to an aggregate of $4.1 million for achievement of
late stage regulatory milestones. We will also be required to pay royalties ranging from 0.88% - 5% on ours, our affiliates’
and our sublicensees’ net sales of licensed products. When we sublicense the rights granted under the 2020 Miami License
Agreement to one or more third parties, we are required to pay to UM a portion of the non-royalty sublicensing revenue
received from such third parties ranging from 15% – 25%. The Advanz Agreement includes a sublicense under the 2020
Miami License Agreement.
The 2020 Miami License Agreement terminates upon the expiration of all issued patents and filed patent
applications or 10 years after the first commercial sale of the last product or process for which a royalty is due, unless
earlier terminated. In addition, the 2020 Miami License Agreement may be terminated by us at any time upon 60 days prior
written notice to UM, and may be terminated by either us or UM upon material breach of an obligation if action to cure the
breach is not initiated within 60 days of receipt of written notice.
On October 28, 2020, we entered into an option agreement with the University of Miami (the “2020 Miami
Option Agreement”) concerning certain research activities and technology relating to SORD neuropathy that may be
pursued and developed by UM. Under the 2020 Miami Option Agreement, if UM conducts such research activities, then
UM is obligated to grant us certain option rights to access and use the research results and to obtain licenses to any
associated patent rights upon us making specified payments to UM within specified time limits. If we elect to obtain option
rights, we will be required to make payments to UM in the low-six figures to the low-seven figures, depending upon the
rights we elect to obtain, and we will be obligated to make certain milestone payments in the high-six figures to mid-seven
figures if UM conducts and completes certain research activities within specified time periods and we elect to receive
rights to use the results of that research.
21
Table of Contents
On December 14, 2020, we entered into a research agreement with the University of Miami (the “2020 Miami
Research Agreement”), pursuant to which the University of Miami agreed to conduct a research study relating to SORD
neuropathy and deliver a final report on the study to us. The term of the research agreement was from December 14, 2020
through December 30, 2021. The consideration for the 2020 Miami Research Agreement was $0.3 million. Due to COVID-
19 pandemic disruptions certain research under the 2020 Miami Research Agreement was not completed. In January 2022,
we amended the 2020 Miami Research Agreement to extend the term of the agreement to August 31, 2022, whereby the
research study was completed.
License Agreement with Advanz Pharma
On January 3, 2023, we entered into an Exclusive License and Supply Agreement (the “ Advanz Agreement”)
with Mercury Pharma Group Limited (trading as Advanz Pharma Holdings). Pursuant to the Agreement, we granted
Advanz Pharma the exclusive right and license to commercialize drug products containing AT-007 (also known as
govorestat), our proprietary Aldose Reductase Inhibitor (ARI) (the “Licensed Product”), for use in treatment of Sorbitol
Dehydrogenase Deficiency (“SORD”) and Galactosemia (each a “Licensed Indication”) in the European Economic Area,
Switzerland and the United Kingdom (the “Territory”). We also granted Advanz Pharma a right of negotiation and “most-
favored nation” rights with respect to acquiring the European commercialization rights for any additional indications for
which the Licensed Product may be developed in the future (or any other products we may develop solely to the extent
used for the Licensed Indications).
Advanz Pharma is required to use commercially reasonable efforts to launch and commercialize the Licensed
Products in the major markets in the Territory in each Licensed Indication following, and subject to, receipt of marketing
authorization therein. Under the Advanz Agreement, Advanz Pharma agreed to pay us (i) an upfront payment of EUR 10
million (approx. USD $10.7 million), and certain development milestone payments upon clinical trial completions and
receipt of marketing authorization in the territory, as well as certain commercial milestone payments, totaling EUR 134
million (approx. USD $142.2 million) in the aggregate, and (ii) royalties of 20% of net sales of the Licensed Product. Such
royalty rate will be payable on a country-by-country basis until the later of (i) the expiration of the licensed patents
covering the composition of matter of AT-007, or (ii) 10 years after the European Medicines Agency’s grant of marketing
authorization for the Licensed Product. The royalties are subject to certain deductions, including certain secondary
finishing costs, certain step-in establishment costs and a portion of fees for any potential third-party patent licenses if
applicable in the future. Following the initial term of the license, as described above, the royalty rate shall be reduced to
10% and shall continue in perpetuity unless the Agreement is terminated in various circumstances in accordance with its
terms.
Certain of the patents licensed to Advanz Pharma under the Advanz Agreement are sub-licensed from the
University of Miami and Columbia University, and thus remain subject to certain obligations of the Company (including
royalty obligations) to such institutions. For more information on these arrangements see “—Exclusive License Agreement
with Columbia University” and “—License Agreements with the University of Miami.”
Sales and Marketing
Due to the delay in the anticipated Galactosemia commercial launch, external non-essential commercial
expenditures have been suspended, including sales and marketing, and we have recognized significant reductions in our
commercial spending during the year ended December 31, 2023.
Manufacturing
We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We depend on
third-party contract manufacturing organizations, or CMOs, for all of our requirements of raw materials, drug substance
and drug product for our preclinical research and our clinical trials for AT-007, AT-001 and AT-003. We have not entered
into long-term agreements with our current CMOs. We intend to continue to rely on CMOs for later-stage development and
commercialization of our current products, as well as the development and commercialization of any
22
Table of Contents
other product candidates that we may identify. Although we rely on CMOs, we have personnel and third-party consultants
with extensive manufacturing experience to oversee the relationships with our contract manufacturers.
We believe the synthesis of the drug substance for AT-007 and AT-001 are reliable and reproducible from readily
available starting materials, and the synthetic routes are amenable to large-scale production and do not require unusual
equipment or handling in the manufacturing process. We have obtained adequate supplies of the drug substance for AT-007
and AT-001 to satisfy our immediate clinical and preclinical demands.
Drug product formulation development for AT-007 and AT-001 are in progress. We have contracted with a third-
party manufacturer capable of both formulation development and drug product manufacturing through commercialization.
We may identify a second drug product manufacturer in the future to add additional capacity and redundancy to our supply
chain.
Competition
The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team,
research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages,
we face potential competition from many different sources, including pharmaceutical and biotechnology companies,
academic institutions and governmental agencies and public and private research institutions. Product candidates that we
successfully develop and commercialize may compete with existing therapies and new therapies that may become available
in the future.
Our competitors may have significantly greater financial resources, established presence in the market, expertise
in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and
reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and
retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.
There are currently no therapies approved to treat Galactosemia. Two companies have announced plans for
preclinical or conceptual programs to develop gene therapies in Galactosemia. We believe these potential AAV gene
therapies are several years away from entering the clinic, and there is no data to date in preclinical or clinical studies
demonstrating efficacy or safety. Additionally, due to safety issues associated with AAV gene therapy in general, and the
fact that Galactosemia is a debilitating but not life-threatening disease, we do not believe that the risk appetite of parents or
physicians will support substantial competition from gene therapies.
There are currently no therapies approved for SORD Deficiency. There are no drugs in development to our
knowledge outside of AT-007, and we believe that the IP licensed from University of Miami is sufficiently broad to
encompass the entire class of aldose reductase inhibitors for treatment of SORD Deficiency.
There are currently no therapies approved to treat DbCM. Sponsors of sodium-glucose cotransporter-2, or SGLT2,
inhibitors are pursuing broad cardiovascular labels in type 2 diabetes patients, which may include a subset of DbCM
patients as part of the larger diabetic population at risk for heart failure. Many of these programs are sponsored by large
pharmaceutical companies with a strong presence in cardiology and metabolic disease. There have been prior studies
demonstrating effectiveness in DbCM of off-label use of sildenafil, although we do not believe this represents a
commercially viable competitive threat.
There are no disease modifying therapies approved to treat DPN outside of Japan, India and China. In these
limited markets, epalrestat, another ARI, is approved to prevent worsening of DPN, and despite challenges in compliance
due to frequent dosing three to five times daily, the drugs are generic and offer a low cost alternative. A more effective
therapy with improved tolerability and dosing may offer an advantage. A re-formulation of proprietary
23
Table of Contents
crystalline epalrestat, BNV-222, is in development for DPN in Russia in a 12-month Phase 2/3 clinical trial, which
completed enrollment in 2016, but has not yet reported any results.
There are several therapies approved to treat severe or late-stage forms of DR, or proliferative DR, such as
diabetic macular edema and proliferative DR, including anti-VEGF therapies, Lucentis and Eylea, which represents
approximately 20% of the larger DR population. There are currently no therapies approved to treat non-proliferative DR,
an earlier stage of the disease upstream of vessel or capillary proliferation. However, there are significant additional
clinical development efforts for other mechanistic interventions in early-stage or for non-proliferative DR.
Intellectual Property
Our intellectual property is critical to our business and we strive to protect it, including by obtaining and
maintaining patent protection in the United States and internationally for our product candidates, new therapeutic
approaches and potential indications, and other inventions that are important to our business. Our policy is to seek to
protect our proprietary and intellectual property position by, among other methods, filing U.S. and foreign patent
applications related to our proprietary technology, inventions and improvements that are important for the development and
implementation of our business. We also rely on the skills, knowledge and experience of our scientific and technical
personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that
is not patentable, we rely on confidentiality agreements to protect our interests. We require our employees, consultants and
advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring
disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.
Our patent portfolio includes patents and patent applications that are exclusively licensed from Columbia
University, exclusively licensed from University of Miami, and patent applications that are owned by us. Our patent
portfolio includes patents and patent applications that cover our product candidates AT-007, AT-001, and AT-003, and the
use of these candidates for therapeutic purposes in certain territories. Our proprietary technology has been developed
primarily through relationships with academic research centers and contract research organizations.
For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter
and methods of use. Throughout the development of our product candidates, we seek to identify additional means of
obtaining patent protection that would potentially enhance commercial success, including through additional methods of
use, process of making, formulation and dosing regimen-related claims.
In total, our patent portfolio, including patents licensed from Columbia University and patents owned by us,
comprises nine different patent families, filed in various jurisdictions worldwide, including families directed to
composition of matter for AR inhibitors, and families directed to methods of treating Galactosemia and complications
associated with Galactosemia, SORD Deficiency and PMM2-CDG using AR inhibitors. Our patent portfolio includes
issued patents in the United States, Europe, Japan, Australia, Canada, and other jurisdictions. Our patent portfolio is
outlined below:
Composition of Matter Patents
AT-007. We have exclusively licensed a patent family from Columbia University that includes two issued
composition of matter patents and two issued method use of patents in the United States, and 78 issued patents in Europe,
Japan, Australia, India, Israel, China, Mexico and South Africa, that claim the composition of matter of and certain
methods of use with respect to AT 007. In addition, we have pending patent applications in the United States, Europe,
Japan, China, Canada, Australia, Russia, Brazil, Israel, Mexico, New Zealand, Singapore, South Africa, and Hong Kong.
The 20-year term of patents in this family runs through June 2037, absent any available patent term adjustments or
extensions.
AT-001 and AT-003. We have exclusively licensed from Columbia University a patent family that includes six
issued patents in the United States, 82 issued patents in Europe, Japan, Canada, and Australia, a pending application in the
United States and a pending application in Europe that claim the composition of matter of and certain methods of use
24
Table of Contents
with respect to AT-001 and AT-003. The 20-year term of the patents in this family runs through July 2031, absent any
available patent term adjustments or extensions.
Methods for Treating Galactosemia
We own a family of patent applications that claims methods for treating Galactosemia and preventing
complications associated with Galactosemia using AT-007 and other inhibitors of AR. This family currently includes
granted patents in the United States, Mexico, Japan and pending patent application in the United States, Europe, Japan,
Australia, Brazil, Canada, China, Israel, Mexico, New Zealand, Russia, Singapore, South Africa, and Hong Kong. The 20-
year term of patents in this family run through July 2038, absent any available patent term adjustments or extensions.
Methods for Treating SORD Deficiencies
We own a family of patent applications that claims methods for treating SORD Deficiency using AT-007 and other
inhibitors of AR. This family currently includes pending patent applications in the United States, Europe, Japan, Australia,
Brazil, Canada, China, Israel, Mexico, New Zealand, Russia, Singapore, South Africa and South Korea. No patents have
issued to date, but we expect that the 20-year term of any patents that do issue in this family will run through 2041, absent
any available patent term adjustments or extensions.
We have exclusively licensed a patent family from University of Miami that includes pending applications in the
United States, Europe, Japan, Australia, Brazil, Canada, China, Israel, Mexico, New Zealand, India, Russia, Singapore,
South Africa, South Korea and Hong Kong, that claims methods for treating inherited neuropathy using a variety of
therapeutic modalities including inhibitors of AR. This patent family is owned by University of Miami, University of
Rochester and UCL Business Ltd. and licensed to us by University of Miami pursuant to an exclusive agency granted to
University of Miami, by University of Rochester and UCL Business Ltd. No patents have issued to date, but we expect that
the 20-year term of any patents that do grant in this family will run through 2040, absent any available patent term
adjustments or extensions.
Methods for Treating PMM2-CDG
We own a family of patent applications that claim methods for treating PMM2-CDG using AT-007 and other
inhibitors of AR. This family currently includes pending patent application in the United States, Europe, Japan, Australia,
Brazil, Canada, China, Israel, Mexico, New Zealand, Singapore, South Africa and Hong Kong. No patents have issued to
date, but we expect that the 20-year term of any patents that do grant in this family will run through 2040, absent any
available patent term adjustments or extensions.
We expect to file future patent applications on innovations that are developed in the course of advancing our
pipeline through preclinical and clinical development.
Patent Term and Term Extensions
Individual patents have terms for varying periods depending on the date of filing of the patent application or the
date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents
issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a
non-provisional patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a
portion of the United States Patent and Trademark Office, or the USPTO, delay in issuing the patent as well as a portion of
the term effectively lost as a result of the FDA regulatory review period. However, as to the FDA component, the
restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond
14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension, and
only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. The
duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from
the earliest effective filing date. All taxes, annuities or maintenance fees for a patent, as required by
25
Table of Contents
the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this
period of time.
The actual protection afforded by a patent may vary on a product by product basis, from country to country, and
can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related
extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.
Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable
to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to
claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our
business. For more information, see the section titled “Risk Factors — Risks Related to Our Intellectual Property.”
Trademarks and Know-How
In connection with the ongoing development and advancement of our products and services in the United States
and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing
trademarks and service marks where available and when appropriate. In addition to patent and trademark protection, we
rely upon know-how and continuing technological innovation to develop and maintain our competitive position. We seek to
protect our proprietary information, in part, by using confidentiality agreements with our commercial partners,
collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These
agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to
grant us ownership of technologies that are developed by our employees and through relationships with third parties. These
agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may
otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial
partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes
may arise as to the rights in related or resulting know-how and inventions. For more information, see the section titled
“Risk Factors — Risks Related to Our Intellectual Property.”
Government Regulation and Product Approval
Government authorities in the United States, at the federal, state and local levels, and in other countries,
extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control,
packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of
pharmaceutical products, such as those we are developing. The processes for obtaining regulatory approvals in the United
States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the
expenditure of substantial time and financial resources.
United States Government Regulation
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its
implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable United States requirements at any time during the drug development process,
approval process or after approval, may subject an applicant to delays and a variety of administrative or judicial sanctions,
such as the FDA’s refusal to approve a pending New Drug Application, or NDA, withdrawal of an approval, imposition of
a clinical hold, issuance of warning or untitled letters, product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal
penalties.
The process required by the FDA before a drug may be marketed in the United States generally involves:
26
Table of Contents
● completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the
FDA’s good laboratory practice, or GLP, regulations;
● submission to the FDA of an IND, which must become effective before human clinical trials may begin;
● approval by an independent institutional review board, or IRB, at each clinical site before each trial may be
initiated;
● performance of adequate and well-controlled clinical trials, in accordance with good clinical practice, or
GCP, requirements to establish the safety and efficacy of the proposed drug for each indication;
● submission to the FDA of an NDA for marketing approval, which must include data from preclinical testing
and clinical trials;
● satisfactory completion of an FDA advisory committee review, if applicable;
● satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which
the product is produced to assess compliance with cGMP requirements, and to assure that the facilities,
methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;
● satisfactory completion of an FDA inspection of selected clinical sites to assure compliance with GCPs and
the integrity of the clinical data;
● payment of user fees; and
● FDA review and approval of the NDA.
Preclinical Studies
Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal
studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with
manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as
part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes
effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or
more proposed clinical trials and places the clinical trial on a clinical hold or a partial clinical hold.
In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can
begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.
Clinical Trials
Clinical trials involve the administration of the investigational new drug to human subjects under the supervision
of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects
provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under
protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the
effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be
submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must
review and approve the plan for any clinical trial before it commences at that institution, and the IRB must continue to
oversee the clinical trial while it is being conducted and reapprove the study at least annually. Information about certain
clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public
dissemination on their ClinicalTrials.gov website. The Food and Drug Omnibus Reform Act, or FDORA, which was
signed into law on December 29, 2022, made numerous amendments to the FDCA
27
Table of Contents
including provisions intended to, among other things, decentralize and modernize clinical trials and enhance diversity in
clinical trial populations.
Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined. In
Phase 1, the drug is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an initial
indication of its effectiveness. In Phase 2, the drug typically is administered to a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases
and to determine dosage tolerance and optimal dosage. In Phase 3, the drug is administered to an expanded patient
population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough
data to statistically evaluate the safety and efficacy of the product for approval, to establish the overall risk-benefit profile
of the product and to provide adequate information for the labeling of the product.
Progress reports detailing the results of the clinical trials must be submitted, at least annually, to the FDA, and
more frequently if serious adverse events occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical
trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable
health risk. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected
suspected adverse reactions, findings from other studies or animal or in vitro testing that suggest a significant risk in
humans exposed to the product, and any clinically important increase in the case of a serious suspected adverse reaction
over that listed in the protocol or investigator brochure. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements, or if the drug has
been associated with unexpected serious harm to patients.
Marketing Approval
Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies,
together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among
other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more
indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription
Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of
“filing” of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes
12 months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a
“filing” decision. The FDA may further extend the review process for three additional months to consider new information
provided by the applicant to address any outstanding deficiency identified by the FDA following the original submission.
In addition, under the Pediatric Research Equity Act, certain NDAs or supplements to an NDA must contain data
that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric
subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or
all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data
requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with
orphan designation.
The FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, plan to ensure that
the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication
plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries or
other risk minimization tools.
The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting
them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the
additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once
28
Table of Contents
the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to
determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity.
The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of
independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by
the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is
manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including
component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCP requirements.
The testing and approval process for an NDA requires substantial time, effort and financial resources, and takes
several years to complete. Data obtained from preclinical and clinical testing are not always conclusive and may be
susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The FDA may not grant
approval of an NDA on a timely basis, or at all.
After evaluating the NDA and all related information, including the advisory committee recommendation, if any,
and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter,
or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific
conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical
testing in order for FDA to reconsider the application. Even with submission of this additional information, the FDA
ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions
have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes
commercial marketing of the drug with specific prescribing information for specific indications.
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that
contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including
Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance
programs to monitor the product after commercialization, or impose other conditions, including distribution and use
restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and
profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-
marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and
FDA review and approval.
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease
or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects
more than 200,000, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset
the costs of developing and making the drug available in the United States. Orphan drug designation must be requested
before submitting an NDA. Orphan drug designation does not convey any advantage in or shorten the duration of the
regulatory review and approval process.
If the FDA approves a sponsor’s marketing application for a designated orphan drug for use in the rare disease or
condition for which it was designated, the sponsor is eligible for a seven-year period of marketing exclusivity, during
29
Table of Contents
which the FDA may not approve another sponsor’s marketing application for a drug with the same active moiety and
intended for the same use or indication as the approved orphan drug, except in limited circumstances, such as if a
subsequent sponsor demonstrates its product is clinically superior. During a sponsor’s orphan drug exclusivity period,
competitors, however, may receive approval for drugs with different active moieties for the same indication as the
approved orphan drug, or for drugs with the same active moiety as the approved orphan drug, but for different indications.
Orphan drug exclusivity could block the approval of one of our product candidates for seven years if a competitor obtains
approval for a drug with the same active moiety intended for the same indication before we do, unless we are able to
demonstrate that grounds for withdrawal of the orphan drug exclusivity exist, such as that our product is clinically superior.
Further, if a designated orphan drug receives marketing approval for an indication broader than the rare disease or
condition for which it received orphan drug designation, it may not be entitled to exclusivity.
Special FDA Expedited Review and Approval Programs
The FDA has various programs, including fast track designation, priority review, accelerated approval and
breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA
review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the
potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients
earlier than under standard FDA review procedures.
To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a
product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an
unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy
where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety
factors. The FDA may review sections of the NDA for a fast track product on a rolling basis before the complete
application is submitted. The FDA may do so if the sponsor provides a schedule for the submission of the sections of the
NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays
any required user fees upon submission of the first section of the NDA.
The FDA may give a priority review designation to drugs that are designed to treat serious conditions, and if
approved, would provide a significant improvement in treatment, or provide a treatment where no adequate therapy exists.
A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of
ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six and ten-month review periods
are measured from the “filing” date rather than the receipt date for NDAs for new molecular entities, which typically adds
approximately two months to the timeline for review and decision from the date of submission. Most products that are
eligible for fast track designation are also likely to be considered appropriate to receive a priority review.
Rare pediatric disease, or RPD, designation by the FDA enables priority review voucher, or PRV, eligibility upon
U.S. market approval of a designated drug for rare pediatric diseases. The RPD-PRV program is intended to encourage
development of therapies to prevent and treat rare pediatric diseases. The voucher, which is awarded upon NDA or
Biologics License Application, or BLA, approval to the sponsor of a designated RPD can be sold or transferred to another
entity and used by the holder to receive priority review for a future NDA or BLA submission, which reduces the FDA
review time of such future submission from ten to six months. The RPD-PRV program is currently scheduled to sunset as
of September 30, 2026.
In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and
that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval. To qualify,
the FDA must determine that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is
reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the
severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of
approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to
verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may
be subject to accelerated withdrawal procedures. Among FDORA’s provisions are
30
Table of Contents
amendments to the accelerated approval program, including new requirements relating to post-approval studies and
enhanced enforcement and withdrawal authorities for the FDA.
Breakthrough therapy designation is for a drug that is intended, alone or in combination with one or more other
drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. The FDA must take certain actions, such as holding
timely meetings and providing advice, intended to expedite the development and review of an application for approval of a
breakthrough therapy.
Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no
longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be
shortened. We may explore some of these opportunities for our product candidates as appropriate.
Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation
by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling
and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most
changes to the approved product, such as adding new indications, manufacturing changes or other labeling claims, are
subject to further testing requirements and prior FDA review and approval. There also are continuing annual user fee
requirements for any marketed products and the establishments at which such products are manufactured, as well as
application fees for supplemental applications with clinical data.
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that
contraindications, warnings or precautions be included in the product labeling, including a boxed warning, require that
post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require
testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution restrictions or other risk management mechanisms under a REMS, which can materially affect the potential
market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results
of post-marketing studies or surveillance programs.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs
are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced
inspections by the FDA and these state agencies for compliance with cGMP requirements.
Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose
reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide
to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality
control to maintain compliance with cGMP and other regulatory requirements.
The FDA may also subject a drug to official lot release, which requires manufacturers to submit several items to
the FDA with respect to each lot of a drug before it is released to distribution. These items include samples of each lot, a
summary of the manufacturing history of the lot and the results of any tests performed on the lot.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, problems with manufacturing processes, or failure to comply with regulatory requirements, may
result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies
31
Table of Contents
or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other
potential consequences include, among other things:
● restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls;
● fines, warning letters or holds on post-approval clinical trials;
● refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or
revocation of product approvals;
● product seizure or detention, or refusal to permit the import or export of products; or
● injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the
market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved
label, although physicians, in the practice of medicine, may prescribe approved drugs for unapproved indications. The FDA
and other agencies actively enforce the laws and regulations prohibiting their promotion of off-label uses, and a company
that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative
liability.
In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing
Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards
for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of
prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.
Federal and State Fraud and Abuse, Data Privacy and Security, and Transparency Laws and Regulations
In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws and
regulations restrict business practices in the biopharmaceutical industry. These laws may impact, among other things, our
current and future business operations, including our clinical research activities and proposed sales, marketing and
education programs and constrain the business or financial arrangements and relationships with healthcare providers and
other parties through which we may market, sell and distribute any products for which we obtain marketing approval.
These laws include anti-kickback and false claims laws and regulations, data privacy and security, and transparency laws
and regulations, including, without limitation, those laws described below.
The federal Anti-Kickback Statute prohibits any person or entity from, among other things, knowingly and
willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or
arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid
or other federal healthcare programs. The term “remuneration” has been broadly interpreted to include anything of value.
The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on
the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe
harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing,
purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Several
courts have interpreted the statute’s intent requirement to mean that if any one purpose of an arrangement involving
remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.
A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to
have committed a violation. In addition, the government may assert that a claim including items or services resulting
32
Table of Contents
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil
False Claims Act or the civil monetary penalties laws.
Federal civil and criminal false claims laws and civil monetary penalties laws, including the federal civil False
Claims Act, which can be enforced by individuals through civil whistleblower or qui tam actions, prohibits any person or
entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal
government or knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim to the federal government. A claim includes “any request or demand” for money or property presented to
the U.S. government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for
allegedly providing free product to customers with the expectation that the customers would bill federal programs for the
product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’
marketing of products for unapproved, and thus non-reimbursable, uses.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal
criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare
benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or
payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations
that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless
of the payor.
In addition, we may be subject to data privacy and security regulation by both the federal government and the
states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HITECH, and their respective implementing regulations, impose specified requirements on certain
types of individuals and entities relating to the privacy, security and transmission of individually identifiable health
information. Among other things, HITECH makes HIPAA’s security standards directly applicable to “business associates,”
defined as independent contractors or agents of covered entities, which include certain healthcare providers, healthcare
clearinghouses and health plans, that create, receive, maintain or transmit individually identifiable health information in
connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal
penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state
attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek
attorney’s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and
security of health information in certain circumstances, many of which are not pre-empted by HIPAA, differ from each
other in significant ways and may not have the same effect, thus complicating compliance efforts.
The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program,
with specific exceptions, to report annually to the Centers for Medicare & Medicaid Services, or CMS, information related
to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and
applicable group purchasing organizations to report annually to CMS ownership and investment interests held by
physicians and their immediate family members.
We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical
industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government,
state laws that require drug manufacturers to report information related to payments and other transfers of value to
physicians and other healthcare providers or marketing expenditures, and state and local laws that require the registration
of pharmaceutical sales representatives. State legislatures are increasingly focused on pharmaceutical company activities,
and we may be subject to additional new state or federal legislative requirements in the future that could impact our ability
to commercialize our product candidates, if they are approved.
Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe
harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If
our operations are found to be in violation of any of the federal and state laws described above or any other governmental
regulations that apply to us, we may be subject to significant criminal, civil and administrative penalties
33
Table of Contents
including damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject
to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws,
contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from participation
in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely
affect our ability to operate our business and our results of operations. To the extent that any of our product candidates are
sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance,
applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, implementation of
corporate compliance programs, reporting of payments or transfers of value to healthcare professionals, and additional data
privacy and security requirements.
Coverage and Reimbursement
The future commercial success of our product candidates, if approved, will depend in part on the extent to which
third-party payors, such as governmental payor programs at the federal and state levels, including Medicare and Medicaid,
private health insurers and other third-party payors, provide coverage of and establish adequate reimbursement levels for
our product candidates. Third-party payors generally decide which products they will pay for and establish reimbursement
levels for those products. In particular, in the United States, no uniform policy for coverage and reimbursement exists.
Private health insurers and other third-party payors often provide coverage and reimbursement for products based on the
level at which the government, through the Medicare program, provides coverage and reimbursement for such products,
but also on their own methods and approval process apart from Medicare determinations. Therefore, coverage and
reimbursement can differ significantly from payor to payor.
In the United States, the European Union, or EU, and other potentially significant markets for our product
candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of
products, particularly for new and innovative products, which often has resulted in average selling prices lower than they
would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and
regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and
usage. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and
regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical coverage and reimbursement policies and
pricing in general.
Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting
reimbursement levels for products. For example, federal and state governments reimburse products at varying rates
generally below average wholesale price. These restrictions and limitations influence the purchase of products. Third-party
payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the FDA-
approved products for a particular indication. Third-party payors are increasingly challenging the price and examining the
medical necessity and cost-effectiveness of products, in addition to their safety and efficacy. We may need to conduct
expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our product
candidates, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered
medically necessary or cost-effective. A payor’s decision to provide coverage for a product does not imply that an adequate
reimbursement rate will be approved. Adequate third-party payor reimbursement may not be available to enable us to
realize an appropriate return on our investment in product development. Legislative proposals to reform healthcare or
reduce costs under government insurance programs may result in lower reimbursement for our product candidates, if
approved, or exclusion of our product candidates from coverage and reimbursement. The cost containment measures that
third-party payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the
sale of any approved product candidates.
Healthcare Reform
The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional
legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product
candidates. The United States and some foreign jurisdictions are considering enacting or have enacted a number of
additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell
our product candidates profitably, if approved. Among policy makers and payors in the United States and
34
Table of Contents
elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing
healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a
particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the
healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical
products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.
There have been several U.S. government initiatives over the past few years to fund and incentivize certain
comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under the
Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of
2010, or collectively the PPACA. It is also possible that comparative effectiveness research demonstrating benefits in a
competitor’s product could adversely affect the sales of our product candidates.
The PPACA became law in March 2010 and substantially changed the way healthcare is financed by third-party
payors, and significantly impacts the U.S. pharmaceutical industry. Among other measures that may have an impact on our
business, the PPACA establishes an annual, nondeductible fee on any entity that manufactures or imports specified branded
prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that
increases the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, the PPACA extends
manufacturers’ Medicaid rebate liability, expands eligibility criteria for Medicaid programs, and expands entities eligible
for discounts under the Public Health Service Act.
In addition to these provisions, the Affordable Care Act established a number of bodies whose work may have a
future impact on the market for certain pharmaceutical products. These include the Patient-Centered Outcomes Research
Institute, established to oversee, identify priorities in, and conduct comparative clinical effectiveness research and the
Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services, to test innovative
payment and service delivery models to lower Medicare and Medicaid spending. At this time, we are unsure of the full
impact that the PPACA will have on our business.
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the PPACA and
we expect such challenges and amendments to continue. Former President Trump implemented certain directives designed
to delay the implementation of certain PPACA provisions or otherwise circumvent requirements for health insurance
mandated by the PPACA, while Congress has considered legislation that would repeal or repeal and replace all or part of
the PPACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of the
PPACA have been signed into law. For example, the Tax Act includes a provision that repealed, effective January 1, 2019,
the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying
health coverage for all or part of a year that is commonly referred to as the “individual mandate.” In December 2018, a
U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate
is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Act, the
remaining provisions of the PPACA are invalid as well. In June 2021, the U.S. Supreme Court held that the PPACA
requirement to cover state and individual plaintiffs did not have standing to challenge the individual mandate provision of
the PPACA; in so holding, the Supreme Court did not consider larger constitutional questions about the validity of this
provision or the validity of the PPACA in its entirety. Another case challenging the PPACA’s requirement that private
insurers cover certain preventative services is currently pending before the same U.S. District Court Judge in the Northern
District of Texas who ruled against the individual mandate in 2018. In September 2022, the judge held that certain
preventative services violated the U.S. Constitution and set a schedule for additional briefing, which was completed in
January 2023. In March 2023, the judge struck down the requirement with immediate nationwide effect by ruling, in part,
that members of a panel charged under the PPACA with recommending preventative services coverage had been appointed
in an unconstitutional manner. Parties on both sides of the lawsuit have appealed this ruling, and in June 2023 the U.S.
Court of Appeals for the Fifth Circuit approved an agreement by the parties on a stay of the lower court’s ruling pending
the appeal. Oral arguments have been scheduled for March 2024, and it is unclear when or how the court will rule. It is
also unclear how this decision, subsequent decisions and appeals, or any potential future litigation and other efforts to
repeal and replace the PPACA will impact the PPACA, or our business.
35
Table of Contents
Further, there has been increasing legislative, executive branch, and enforcement interest in the United States with
respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement
methodologies for drugs. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the
option of using step therapy for Part B drugs, beginning January 1, 2020. Although a number of these and other proposed
measures will require authorization through additional legislation to become effective, Congress and the Biden
administration have each indicated that it will continue to seek new legislative and/or administrative measures to control
drug costs. For example, the Inflation Reduction Act of 2022, enacted on August 16, 2022, seeks to reduce prescription
drug costs by, among other provisions, allowing Medicare to negotiate prices for certain high-cost prescription drugs in
Medicare Parts B and D, imposing an excise tax on pharmaceutical manufacturers that refuse to negotiate pricing with
Medicare, requiring inflation rebates to limit annual drug price increases in Medicare, redesigning the Medicare Part D
formula, and limiting the cost-sharing for insulin products. It is unclear whether additional drug pricing and other
healthcare reform measures will be enacted, and if enacted, what effect they would have on our business.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts,
restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities
and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included
in their healthcare programs. These measures could reduce future demand for our products or put pressure on our pricing.
Additionally, in May 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to
Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework
for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that
are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no
obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try
Act.
Foreign Regulation
In order to market any product outside of the United States, we would need to comply with numerous and varying
regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials,
marketing authorization, commercial sales and distribution of our product candidates. For example, in the EU, we must
obtain authorization of a clinical trial application, or CTA, in each member state in which we intend to conduct a clinical
trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the
comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in
those countries. The approval process varies from country to country and can involve additional product testing and
additional administrative review periods. The time required to obtain approval in other countries might differ from and be
longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval
in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory
process in others.
Facilities
We are currently in a five-year lease for the space for our principal executive offices in New York, New York and
a three-year lease renewal for the offices in Englewood Cliffs, New Jersey. We believe that our facilities are adequate to
meet our current needs.
36
Table of Contents
Employees and Human Capital Resources
Investing in, developing, and maintaining human capital is critical to our success. As of December 31, 2023, we
had 25 full-time employees, 17 of whom were primarily engaged in research and development activities. A total of eight
employees have an M.D. or Ph.D. degree. We emphasize a number of measures and objectives in managing our human
capital assets, including, among others, employee safety and wellness, talent acquisition and retention, employee
engagement, development and training, diversity and inclusion and compensation and pay equity. None of our employees
are represented by a labor union and we consider our employee relations to be good.
Our human capital resource objectives include, as applicable, identifying, recruiting, retaining, incentivizing and
integrating our existing and new employees and advisors. The principal purposes of our equity and cash incentive plans are
to attract, retain and reward personnel and increase our success and stockholder value thereby.
The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are
committed to their health, safety and wellness.
Information About Our Executive Officers
The following table sets forth information regarding our executive officers:
Name
Executive Officers
Shoshana Shendelman, Ph.D.
Age
45
Position(s)
President, Chief Executive Officer and Chair of the Board
of Directors
Riccardo Perfetti, M.D., Ph.D
63
Chief Medical Officer
Les Funtleyder
54
Chief Financial Officer
Catherine Thorpe
61
Chief Accounting Officer
Adam Hansard
48
Chief Commercial Officer
Constantine Chinoporos
58
Chief Operating Officer and Chief Business Officer
Shoshana Shendelman, Ph.D., age 45, is our founder and has served as our President and Chief Executive
Officer and as chair of our board of directors since January 2016. Prior to founding our company, she founded Clearpoint
Strategy Group LLC, a boutique life sciences consulting firm, where she served as the Managing Director from July 2012
to December 2016, and served as a Senior Advisor from January 2017 to December 2018. Prior to that, she served as a
scientific consultant and analyst at Bridge Scientific Consulting LLC. Dr. Shendelman received her B.S. in biochemistry
from Brandeis University and a Ph.D. in Cellular, Molecular and Biophysical Studies (CMBS) from Columbia University
Vagelos College of Physicians and Surgeons. We believe that Dr. Shendelman’s extensive knowledge of our company as
founder, President and Chief Executive Officer and her management background and experience in the healthcare industry
qualifies her to serve on our board of directors.
Riccardo Perfetti, M.D., Ph.D., age 64, has served as our Chief Medical Officer since August 2018. Prior to
joining us, Dr. Perfetti served as a Senior Medical Officer, Vice President and Head of Global Medical Affairs, Diabetes
37
Table of Contents
and Cardiovascular Business Unit at Sanofi S.A., a publicly traded pharmaceutical company from October 2007 to
September 2018. Prior to joining Sanofi, Dr. Perfetti served in various roles at Amgen Inc., a publicly traded
biopharmaceutical company, including as a Director and Global Development Leader in diabetes, obesity, metabolism and
endocrinology from December 2004 to August 2007. Dr. Perfetti was previously an associate professor of medicine at
University of California in Los Angeles and a professor of medicine at the National Institutes of Health, or NIH. Dr.
Perfetti practiced as an endocrinologist at Cedars-Sinai Medical Center and also served as Director of the Diabetes
Research Laboratory and Director of the Outpatient Diabetes Program. Dr. Perfetti received his M.D. and Ph.D. in
Endocrinology from University La Sapienza in Rome, Italy and received post-graduate training in endocrinology and
molecular biology at NIH.
Les Funtleyder, age 54, has served as our Chief Financial Officer since November 2023, has served as director of
the Company since June 2016 and previously served as our interim Chief Financial Officer from December 2018 to April
2019. Mr. Funtleyder also serves as a healthcare portfolio manager at E Squared Capital Management, LLC since January
2014 and a senior external advisor with McKinsey and Co. since June 2017. Mr. Funtleyder currently serves on the board
of directors of public and private healthcare companies and foundations, including Reviva Pharmaceuticals (Nasdaq:
RVPH) where he also serves as a member of the governance committee and as chair of the audit committee. Mr. Funtleyder
previously served as the director of strategic investments and communications of OPKO Health Inc. (Nasdaq: OPK), a
publicly traded healthcare company. Mr. Funtleyder is also an adjunct professor at Columbia University Medical Center
and an adjunct professor at Columbia University School of Public Health. Mr. Funtleyder received his B.A. from Tulane
University and MPH from Columbia University Mailman School of Public Health. We believe that Mr. Funtleyder’s
extensive experience managing and investing in the healthcare industry qualifies him to serve on our board of directors.
Catherine Thorpe, age 61, has served as our Chief Accounting Officer since June 2023 and our Interim Principal
Financial Officer from June 2023 until November 2023. While serving in this role, Ms. Thorpe also serves as the Managing
Partner of CFGI Stamford Office. Ms. Thorpe has occupied various roles at CFGI, a specialized financial consulting firm,
since 2018. From February 2016 to April 2018, she was the Internal Audit Leader at Datto, Inc., a cybersecurity and data
backup company. Prior to that, she was a Managing Director at GE Capital from 2007 to 2016, and from July 1984 to
December 1991 and from September 2004 to January 2007 she was a Manager at PricewaterhouseCoopers. Ms. Thorpe
holds a bachelor’s degree in accounting from Simmons University and is a Certified Public Accountant.
Adam Hansard, age 48, has served as our Chief Commercial Officer since March 2020. Prior to joining us, he
was Senior Director of New Product Strategy at Alexion Pharmaceuticals, a biopharmaceutical company, from March 2019
to February 2020. From February 2018 to March 2019, he was Vice President of Business Operations at Syntimmune, a
clinical-stage biotech purchased by Alexion in November 2018. From January 2012 to March 2018, Mr. Hansard worked at
Sanofi Genzyme, a biotechnology company and wholly-owned subsidiary of Sanofi, a publicly traded, multinational
pharmaceutical company, where he served as the North American Senior Director, Chief of Staff of MS Oncology and
Immunology and the Senior Director of MS Brand Communications. Mr. Hansard received his Master’s in Business
Communication from Jones International University and his B.S. in Marketing from the University of West Florida.
Constantine Chinoporos, age 58, has served as our Chief Operating Officer since December 2023. Prior to
joining us he was a Chief Business Officer at Albireo Pharmaceuticals, from December 2021 until their acquisition by
Ipsen in March 2023. He served as Chief Business Officer at Boston Pharmaceuticals from November 2015 to October
2021. Prior to that, he held senior positions in business and corporate development, corporate finance, and alliance
management at Sanofi S.A., Genzyme, and Eli Lilly. He currently serves as a strategic advisor to Apollo Therapeutics, a
role which he has held since February 2023. Mr. Chinoporos received an undergraduate degree in History as well as an
MBA from Cornell University.
38
Table of Contents
Other Information
We were incorporated in Delaware in January 2016 and completed the IPO in May 2019. Our principal executive
offices are located at 545 5th Avenue, Suite 1400, New York, New York 10017, and our telephone number is (212) 220-
9226.
We maintain a website at www.appliedtherapeutics.com. The contents of our website are not incorporated in, or
otherwise to be regarded as part of this Annual Report. Unless the context otherwise requires, the terms, “Applied
Therapeutics,” the “Company,” “we,” “us,” “our” and the “ registrant” refer to Applied Therapeutics, Inc.
Investors and others should note that we announce material financial information to our investors using our
investor relations website (http://ir.appliedtherapeutics.com), SEC filings, press releases, public conference calls and
webcasts.
39
Table of Contents
ITEM 1A. RISK FACTORS.
An investment in shares of our common stock involves a high degree of risk. You should carefully consider the
following information about these risks described below, together with other information appearing elsewhere in this
Annual Report, including our financial statements and the related notes and the section titled “Management’s Discussion
and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock.
The occurrence of any of the events or developments described below could harm our business, financial condition, results
of operations and growth prospects. In such an event, the market price of our common stock could decline and you may
lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may
impair our business operations and the market price of our common stock.
Risk Factor Summary
The following is a summary of the risk factors included in this Item 1A and is qualified entirely by the disclosure
included in the rest of this Item 1A:
Risks Related to Our Financial Position and Capital Needs
● We have incurred and expect to continue to incur substantial operating losses and our ability to use our net
operating losses to offset future taxable income may be subject to certain limitations.
● Our operating history makes evaluating our business and future viability more difficult.
● We will require substantial additional funding to finance our operations, and may suffer consequences to our
development programs upon failure to do so.
● Raising additional capital may cause adverse effects.
Risks Related to the Development and Commercialization of Our Product Candidates
● Our success is substantially dependent on the successful clinical development, regulatory approval and
commercialization of our product candidates and may be adversely affected upon failure to do so.
● We or Advanz Pharma may fail to perform under any of the agreements entered into in connection with the
partnership for the commercialization of AT-007, which may subject us to liabilities, and we may fail to achieve
anticipated benefits of the partnership.
● Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and
our results may not be sufficient for the necessary regulatory approvals.
● Clinical drug development involves a lengthy and expensive process and the development of additional product
candidates is risky and uncertain.
● We may be unable to obtain/maintain or receive the benefits of regulatory approval, rare pediatric disease
designation/exclusivity, accelerated registration pathways, breakthrough therapy designations or fast track
designations for our product candidates, as applicable.
● Clinical trials are expensive, time consuming and subject to factors outside our control.
● Our product candidates may cause undesirable side effects, affecting regulatory approval, commercial potential or
result in significant negative consequences following any potential marketing approval.
● Interim, “top line” and preliminary data from our clinical trials may be subject to change.
● The market opportunities for our product candidates may be smaller than we believe or approval we obtain may
narrow our patient population.
● We may face substantial competition.
● We may face risks related to strategic collaborations to develop our product candidates
● Our product candidates may fail to achieve market acceptance necessary for commercial success.
● We may face risks related to any potential international operations.
● We may be adversely affected by product liability lawsuits.
● Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.
40
Table of Contents
Risks Related to Regulatory Compliance
● We are subject to healthcare laws and regulations, which carry substantial penalties for noncompliance.
● Coverage and adequate reimbursement may not be available for our product candidates.
● Healthcare reform measures may have a negative impact on our business and results of operations.
Risks Related to Our Dependence on Third Parties
● Third-parties may conduct our preclinical studies and clinical trials in an unsatisfactory manner.
● We intend to rely on third parties to produce supplies of our product candidates.
● We and our third-party affiliates are subject to environmental, health and safety laws and regulations.
Risks Related to Our Intellectual Property
● Breaches of our license agreements may result in the adverse effects to our ability to continue the development
and commercialization of our product candidates.
● Insufficient patent protection could allow our competitors to develop and commercialize products and technology
similar or identical to ours.
● Obtaining and maintaining our patent rights is expensive, complicated and labor intensive and patent terms may
be inadequate to protect our competitive position on our product candidates.
● We may be subject to claims alleging violations of intellectual property rights.
● Changes in patent law could impair our ability to protect our product candidates.
● We may be unable to protect our intellectual property rights.
● Intellectual property rights do not necessarily address all potential threats to our business.
Risks Related to Our Business Operations, Employee Matters and Managing Growth
● We are highly dependent on the services of our current executive officers.
● We may experience difficulties resulting from the expansion of our organization.
● We may be subject to security breaches in our information technology systems.
● Our employees and the third-parties we deal with may engage in misconduct or improper activities.
● Our business may be adversely affected by the coronavirus outbreak.
Risks Related to Ownership of Our Common Stock
● The market price of our common stock is volatile and has fluctuated substantially.
● Concentration of ownership of our common stock among our existing executive officers, directors and principal
stockholders may prevent new investors from influencing significant corporate decisions.
● We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.
General Risk Factors
● We may be affected by unfavorable research or reports.
● We may use our cash and cash equivalents ineffectively or in ways with which you do not agree.
● We are subject to risks as an “emerging growth company” and a public company.
● We may avail ourselves of defensive and forum selection provisions in our governing documents and under
Delaware law.
41
Table of Contents
Risks Related to Our Financial Position and Capital Needs
We have incurred significant operating losses since inception and anticipate that we will continue to incur
substantial operating losses for the foreseeable future and may never achieve or maintain profitability.
Since inception in January 2016, we have incurred significant operating losses. Our net loss was $119.8 million
and $82.5 million for the years ended December 31, 2023, and 2022 respectively. As of December 31, 2023, we had an
accumulated deficit of $468.6 million. We expect to continue to incur significant expenses and increasing operating losses
for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and
clinical development of our product candidates, organizing and staffing our company, business planning, raising capital,
establishing our intellectual property portfolio and conducting clinical trials. To date, we have never obtained regulatory
approval for, or commercialized, any drugs. It could be several years, if ever, before we have a commercialized drug. The
net losses we incur may fluctuate significantly from quarter to quarter and year-to-year. We anticipate that our expenses
will increase substantially if, and as, we:
● continue the ongoing and planned development of our product candidates;
● initiate, conduct and complete any ongoing, anticipated or future preclinical studies and clinical trials for our
current and future product candidates;
● seek marketing approvals for any product candidates that successfully complete clinical trials;
● establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any current or
future product candidate for which we may obtain marketing approval;
● seek to discover and develop additional product candidates;
● continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product
candidates or technologies;
● maintain, protect and expand our intellectual property portfolio;
● meet the requirements and demands of being a public company;
● defend against any product liability claims or other lawsuits related to our products;
● hire additional clinical, regulatory and scientific personnel; and
● add operational, financial and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts.
Furthermore, we have incurred additional costs associated with operating as a public company, including
significant legal, accounting, investor relations and other expenses.
To become and remain profitable, we must succeed in developing and eventually commercializing drugs that
generate significant revenue. This will require us to be successful in a range of challenging activities, including completing
preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring
commercial-scale manufacturing, marketing and selling any products for which we obtain regulatory approval (including
through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the
preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never
generate revenues that are sufficient to offset our expenses and achieve profitability.
Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately
predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by
regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation
and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.
Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual
basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability
to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline
in the value of our common stock could also cause you to lose all or part of your investment.
42
Table of Contents
Our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability.
We are a clinical-stage company with limited operational history, and our operations to date have been largely
focused on raising capital, organizing and staffing our company, identifying and developing our product candidates, and
undertaking preclinical and clinical development for our product candidates. As an organization, we have not yet
demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a
commercial-scale product or conduct sales and marketing activities necessary for successful commercialization, or arrange
for a third-party to conduct these activities on our behalf. Consequently, any predictions about our future success or
viability may not be as accurate as they could be if we had a longer operating history.
We have encountered, and may continue to encounter unforeseen expenses, difficulties, complications, delays and
other known or unknown factors in achieving our business objectives. We will need to transition at some point from a
company with a research and development focus to a company capable of supporting commercial activities. We may not be
successful in such a transition.
Additionally, we expect our financial condition and operating results to continue to fluctuate from quarter to
quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely
upon the results of any quarterly or annual periods as indications of future operating performance.
We will require substantial additional funding to finance our operations. If we are unable to raise capital when
needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.
As of December 31, 2023, we had $49.9 million in cash and cash equivalents. After giving effect to our issuance
of shares of common stock under the Leerink ATM Agreement in January and February 2024, which resulted in net
proceeds of $12.5 million (after deducting placement agent commissions and other offering expenses), the exercise of our
Common Warrants in January and February 2024, which resulted in net proceeds of $4.0 million, and the March 1, 2024
completion of our sale of a total of 12,285,714 shares of common stock, at a purchase price of $7.00 per share, and
2,000,000 Pre-Funded Warrants, at a purchase price of $6.9999 per Pre Funded Warrant, in a private placement (the
“March 2024 Private Placement”), which resulted in net proceeds of approximately $100 million (before deducting
placement agent commissions and other offering expenses), we have $153.5 million in cash and cash equivalents as of
March 1, 2024. We believe that our cash and cash equivalents as of December 31, 2023, along with proceeds from the
ATM, exercise of our Common Warrants in January and February 2024, the completion of the March 2024 Private
Placement and with the projected clinical and regulatory milestone payments expected in fiscal year 2024 from Advanz
Pharma will be sufficient to fund our operations into 2026, and potentially beyond if drug approvals materialize in the
expected timelines. However, we will need to obtain substantial additional funding in connection with our continuing
operations and planned research and clinical development activities. Our future capital requirements will depend on many
factors, including:
● the timing, progress and results of our ongoing preclinical studies and clinical trials of our product
candidates;
● the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other
product candidates that we may pursue;
● our ability to establish collaborations on favorable terms, if at all;
● the costs, timing and outcome of regulatory review of our product candidates;
● the costs and timing of future commercialization activities, including product manufacturing, marketing,
sales and distribution, for any of our product candidates for which we receive marketing approval;
● the revenue, if any, received from commercial sales of our product candidates for which we receive
marketing approval;
● the cost of any milestone and royalty payments with respect to any approved product candidates;
● the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our
intellectual property rights and defending any intellectual property-related claims;
43
Table of Contents
● the costs of operating as a public company; and
● the extent to which we acquire or in-license other product candidates and technologies.
Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming,
expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results
required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not
achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to
be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing
to achieve our business objectives. We may seek additional capital due to favorable market conditions or strategic
considerations even if we believe we have sufficient funds for our current or future operating plans.
In addition, our ability to access additional capital has been affected by overall macroeconomic trends, among
other things, including rising interest rates, which have caused the price of our common stock to fluctuate significantly
and/or decline. These macroeconomic trends have been exacerbated by recent hostilities between Russia and Ukraine and
between Hamas and Israel, which have contributed to further economic instability in the global financial markets. As a
result, adequate additional financing may not be available to us when needed or on attractive terms. If we are unable to
raise capital when needed or on attractive terms, we could be forced to delay, reduce, or altogether terminate our research
and development programs or future commercialization efforts.
Raising additional capital may cause dilution to our stockholders and restrict our operations or require us to
relinquish rights to our product candidates.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs
through public or private equity or debt financings, including through third-party funding, marketing and distribution
arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these
approaches. We do not have any committed external source of funds. To the extent that we raise additional capital through
the sale of equity or convertible debt securities, your ownership interest in our company may be diluted, and the terms of
these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and
equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take
specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures,
declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.
If we raise additional capital through future collaborations, strategic alliances or third-party licensing
arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research
programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise
additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future
commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and
market ourselves.
Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
We have incurred substantial losses since inception and do not expect to become profitable in the near future, if
ever. In general, under Section 382 of the United States Internal Revenue Code of 1986, as amended, or the Code, a
corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs to
offset future taxable income. We may have experienced ownership changes in the past and may experience ownership
changes in the future as a result of subsequent changes in our stock ownership (some of which shifts are outside our
control). As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset
such taxable income may be subject to limitations.
For NOLs arising in tax years beginning after December 31, 2017, the Code limits a taxpayer’s ability to utilize
NOL carryforwards to 80% of taxable income. In addition, NOLs arising in tax years ending after December 31, 2017
44
Table of Contents
can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before
January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before
January 1, 2018 will continue to have a two-year carryback and 20-year carryforward period. Deferred tax assets for NOLs
will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The limitations in the
carryforward/carryback periods, as well as the limitation on use of NOLs for NOLs arising in tax years beginning after
December 31, 2017 may significantly impact our ability to utilize our NOLs to offset taxable income in the future.
In order to realize the future tax benefits of our NOL carryforwards, we must generate taxable income, of which
there is no assurance. Accordingly, we have provided a full valuation allowance for deferred tax assets as of December 31,
2023 and 2022.
Risks Related to the Development and Commercialization of Our Product Candidates
Our future success is substantially dependent on the successful clinical development, regulatory approval and
commercialization of our product candidates. If we are not able to obtain required regulatory approvals, we will not be
able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.
We have invested a significant portion of our time and financial resources in the development of AT-007, AT-001
and AT-003. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval
for, and, if approved, successfully commercialize our product candidates in a timely manner. We may face unforeseen
challenges in our drug development strategy, and we can provide no assurances that our drug design will prove to be
effective, that we will be able to take advantage of expedited regulatory pathways for any of our product candidates, or that
we will ultimately be successful in our future clinical trials.
We have not obtained regulatory approval for any product candidate, and it is possible that any product candidates
we may seek to develop in the future will not obtain regulatory approval. Neither we nor any future collaborator is
permitted to market any product candidates in the United States or abroad until we receive regulatory approval from the
FDA or applicable foreign regulatory agency. The time required to obtain approval or other marketing authorizations by the
FDA and comparable foreign regulatory authorities is unpredictable and typically takes many years following the
commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval
may change during the course of a product candidate’s clinical development and may vary among jurisdictions.
Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must
demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable
foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from
preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical
data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other
regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our
product candidates either prior to or post-approval, or it may object to elements of our clinical development program,
requiring their alteration.
Of the large number of products in development across the pharmaceutical industry, only a small percentage
successfully complete the FDA or comparable foreign regulatory authorities approval processes and are commercialized.
The lengthy approval or marketing authorization process as well as the unpredictability of future clinical trial results may
result in our failing to obtain regulatory approval or marketing authorization to market our product candidates, which
would significantly harm our business, financial condition, results of operations and prospects.
Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, or
foreign marketing for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval
or other marketing authorization contingent on the performance of costly additional clinical trials, including
45
Table of Contents
post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for
marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA
or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or
desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain,
applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product
candidate and would adversely impact our business and prospects.
In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional
regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product
candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements
upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain
any marketing authorizations we may have obtained.
Furthermore, even if we obtain regulatory approval for our product candidates, we will still need to develop a
commercial organization, establish a commercially viable pricing structure and obtain approval for coverage and adequate
reimbursement from third-party and government payors, including government health administration authorities. If we are
unable to successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue
our business.
We or Advanz Pharma may fail to perform under any of the agreements entered into in connection with the
partnership for commercialization of AT-007, which may subject us to liabilities, and we may fail to achieve anticipated
benefits of the partnership.
In January 2023, we announced a partnership with Advanz Pharma (“Advanz”) for commercialization of AT-007
(govorestat) in Europe, and entered into an Exclusive License and Supply Agreement (the “Advanz Agreement”) with
Advanz. Under the terms of the Advanz Agreement, Advanz receives exclusive commercial rights in the European
Economic Area, Switzerland, and the UK (the “Territory”) for AT-007 in Galactosemia and SORD Deficiency, with certain
rights to future indications for AT-007 in the Territory. In return, we have the right to receive certain near-term development
milestone payments upon clinical trial completion and marketing authorization in Europe as well as commercial sales
milestones, which in the aggregate are expected to amount to over €130 million. We also have the right to receive royalties
on any future net sales of AT-007 in the Territory of 20%. The royalty rate will be payable on a country-by-country basis
until the later of (i) the expiration of the licensed patents covering the composition of matter of AT-007, or (ii) 10 years
after the European Medicines Agency’s grant of marketing authorization for AT-007. The royalties are subject to certain
deductions, including certain secondary finishing costs, certain step-in establishment costs and a portion of fees for any
potential third-party patent licenses if applicable in the future. Following the initial term of the license, as described above,
the royalty rate shall be reduced to 10% and shall continue in perpetuity unless the Advanz Agreement is terminated in
various circumstances in accordance with its terms. We will continue to be responsible for the development, manufacturing
and supply of AT-007, and Advanz will be responsible for packaging, distribution and commercialization in the Territory.
The Advanz Agreement includes a sublicense under the 2016 Columbia Agreement and the 2020 Miami License
Agreement.
Our partnership with Advanz is subject to various risks, including but not limited to the following:
● If Advanz breaches the contractual obligations owed to us pursuant to the Advanz Agreement or any related
agreements, we could be exposed to commercial, regulatory or other liabilities.
● We may be subject to liabilities in connection with the development, manufacturing and supply of AT-007
● under the Advanz Agreement, including with respect to the 2016 Columbia Agreement and the 2020 Miami
License Agreement.
● We may not be able to adequately protect our intellectual property or may become involved in intellectual
property enforcement actions, which may cause us to incur substantial costs as a result of litigation or other
proceedings relating to patent and other intellectual property rights, and such litigation may divert the attention of
our management and scientific personnel and adversely affect our development and commercialization efforts.
46
Table of Contents
● We may have limited control over the commercialization efforts of Advanz, and Advanz may fail to successfully
sell and market AT-007.
● Our ability to receive certain economic benefits from the partnership, including the milestone payments and
royalties, depends on certain contingencies beyond our control.
● In certain circumstances, Advanz may exercise certain step-in rights, including the ability for Advanz to perform
its own supply arrangements, and in some cases, specified development rights in the Territory and assignment of
certain contract rights. In all such circumstances, Advanz must continue to pay royalties and milestone payments,
but may recoup certain of its manufacturing and development establishment costs, and deduct such costs from
royalties owed.
Any of these factors could cause us to incur higher costs, disrupt the supply of our product candidates or approved
products, delay the approval of our product candidates or prevent or disrupt the commercialization of our approved
products. As a result, we may not achieve some or all economic benefits expected from the partnership.
The development of additional product candidates is risky and uncertain, and we can provide no assurances
that we will be able to replicate our approach to drug development for other disease indications.
Efforts to identify, acquire or in-license, and then develop, product candidates require substantial technical,
financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially
show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development,
approved products or commercial revenues for many reasons, including the following:
● the methodology used may not be successful in identifying potential product candidates;
● competitors may develop alternatives that render any product candidates we develop obsolete;
● any product candidates we develop may be covered by third parties’ patents or other exclusive rights;
● a product candidate may be shown to have harmful side effects or other characteristics that indicate it is
unlikely to be effective or otherwise does not meet applicable regulatory criteria;
● a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or
at all; and
● a product candidate may not be accepted as safe and effective by physicians, patients, the medical
community or third-party payors.
We have limited financial and management resources and, as a result, we may forego or delay pursuit of
opportunities with other product candidates or for other indications that later prove to have greater market potential. Our
resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market
opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate,
we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements
in circumstances under which it would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to
drug development for other disease indications. If we are unsuccessful in identifying and developing additional product
candidates or are unable to do so, our business may be harmed.
Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials
and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the
necessary regulatory approvals.
Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the
same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical
studies and Phase 1 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics
and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and
earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product
candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical
studies or having successfully advanced through earlier clinical trials.
47
Table of Contents
In addition, the design of a clinical trial can determine whether its results will support approval of a product, and
flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization,
we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support
regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier clinical trials.
Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or
prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors,
including changes in regulatory policy during the period of our product candidate development. Any such delays could
negatively impact our business, financial condition, results of operations and prospects.
Clinical drug development involves a lengthy and expensive process. We may incur additional costs and
encounter substantial delays or difficulties in our clinical trials.
We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval
from the FDA or other comparable regulatory authority, and we may never receive such approvals. It is impossible to
predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory
approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must
complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our
product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to
complete and is uncertain as to outcome.
A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are
often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates
performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of
their products.
We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or
prevent our ability to receive marketing approval or commercialize our product candidates, including the following:
● delays in reaching a consensus with regulatory authorities on the design or implementation of our clinical
trials;
● regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a
clinical trial or conduct a clinical trial at a prospective trial site;
● delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs,
and clinical trial sites;
● the number of patients required for clinical trials of our product candidates may be larger than we anticipate,
enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these
clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or we may fail
to recruit suitable patients to participate in a trial;
● clinical trials of our product candidates may produce negative or inconclusive results;
● imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a
class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing
facilities;
● occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its
potential benefits;
● changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
or
● we may decide, or regulators may require us, to conduct additional clinical trials or abandon product
development programs.
Any inability to successfully complete preclinical and clinical development could result in additional costs to us or
impair our ability to generate revenue from future drug sales or other sources. In addition, if we make manufacturing or
formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified
48
Table of Contents
product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the
exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing drugs to
market before we do, which could impair our ability to successfully commercialize our product candidates and may harm
our business, financial condition, results of operations and prospects.
Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse
events associated with our product candidates, we may:
● be delayed in obtaining marketing approval, or not obtain marketing approval at all;
● obtain approval for indications or patient populations that are not as broad as intended or desired;
● obtain approval with labeling that includes significant use or distribution restrictions or safety warnings,
including in the form of a risk evaluation and mitigation strategy, or REMS;
● be subject to additional post-marketing testing requirements;
● be required to perform additional clinical trials to support approval or be subject to additional post-marketing
testing requirements;
● have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its
distribution in the form of a modified REMS;
● be subject to the addition of labeling statements, such as warnings or contraindications;
● be sued; or
● experience damage to our reputation.
Our product development costs will also increase if we experience delays in testing or obtaining marketing
approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be
restructured or be completed on schedule, if at all.
Further, we, the FDA or an IRB may suspend our clinical trials at any time if it appears that we or our
collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA’s current Good
Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds
deficiencies in our investigational new drug applications, or INDs, or the conduct of these trials. Therefore, we cannot
predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays
in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the
commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from
our product candidates may be delayed.
All of our current product candidates that have proceeded to clinical trials target inhibition of aldose reductase.
There can be no assurance that aldose reductase inhibitors will ever receive regulatory approval.
All of our current product candidates that have proceeded to clinical trials target inhibition of the aldose reductase
enzyme. There are no currently approved aldose reductase inhibitors on the market outside of Japan, India and China, and
there can be no assurance that aldose reductase inhibitors will ever receive regulatory approval in all other countries,
including the United States. Prior attempts to inhibit this enzyme were hindered by nonselective, nonspecific inhibition,
which resulted in limited efficacy and significant off-target safety effects. Our current product candidates, including AT-
007, AT-001 and AT-003, may face similar or different challenges that prevent their successful commercialization.
We may not be able to obtain or maintain rare pediatric disease designation or exclusivity for our product
candidates, which could limit the potential profitability of our product candidates.
We have obtained orphan drug designation and rare pediatric disease designation, from the FDA for AT-007 for
the treatment of Galactosemia and PMM2-CDG. The FDA may grant orphan drug designation to a drug intended to treat a
rare disease or condition, which is defined as a disease or condition that either affects fewer than 200,000 individuals in the
United States, or if it affects more than 200,000 individuals, there is no reasonable expectation that sales of the drug in the
United States will be sufficient to offset the costs of developing and making the drug available in the United
49
Table of Contents
States. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and
approval process.
For the purposes of the rare pediatric disease program, a “rare pediatric disease” is a serious or life-threatening
disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years or a
rare disease or conditions within the meaning of the Orphan Drug Act. Under the FDA’s rare pediatric disease priority
review voucher, or RPD-PRV, program, upon the approval of an NDA for the treatment of a rare pediatric disease, the
sponsor of such application would be eligible for an RPD-PRV that can be used to obtain priority review for a subsequent
NDA. The sponsor of the application may transfer (including by sale) the RPD-PRV to another sponsor. The voucher may
be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not
yet submitted the application. Congress has extended the RPD-PRV program until September 30, 2024, with potential for
vouchers to be granted until 2026. This program has been subject to criticism, including by the FDA. As such it is possible
that even though we have obtained qualification for a RPD-PRV, the program may no longer be in effect at the time of
approval. Also, although priority review vouchers may be sold or transferred to third parties, there is no guaranty that we
will be able to realize any value if we obtained, and subsequently were able to sell a priority review voucher. The RPD-
PRV program is currently scheduled to sunset as of September 30, 2026.
A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development
or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive
marketing approval.
We may seek a breakthrough therapy designation for one or more product candidates. A breakthrough therapy is
defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or
life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. For product candidates that have been designated as
breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify
the most efficient path for clinical development while minimizing the number of patients placed in ineffective control
regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if
supported by clinical data at the time of the submission of the NDA.
Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that
one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and
instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a
product candidate may not result in a faster development process, review or approval compared to product candidates
considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In
addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that
the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review
or approval will not be shortened.
We have sought, and may in the future seek, fast track designation from the FDA for our product candidates.
Even if granted, fast track designation may not actually lead to a faster development, regulatory review or approval
process.
If a product candidate is intended for the treatment of a serious or life-threatening condition and demonstrates the
potential to address unmet needs for this condition, the sponsor may apply for FDA fast track designation. If fast track
designation is obtained, the FDA may prioritize interactions with the sponsor concerning the designated development
program and initiate review of sections of an NDA before the application is complete, known as “rolling review.” Fast
track designation would not ensure that we would experience a faster development, regulatory review or approval process
compared to conventional FDA procedures or that we would ultimately obtain regulatory approval. Additionally, the FDA
may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical
development program.
50
Table of Contents
We intend to seek approval from the FDA through the use of accelerated registration pathways. If we are
unable to obtain approval under an accelerated pathway, we may be required to conduct additional preclinical studies
or clinical trials, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the
timing of obtaining, necessary marketing approvals. Even if we receive approval from the FDA to utilize an accelerated
registration pathway, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-
marketing requirements, the FDA may seek to withdraw accelerated approval.
We intend to seek an accelerated approval development pathway for our product candidates. Under the accelerated
approval provisions of the Federal Food, Drug, and Cosmetic Act, or the FDCA, and the FDA’s implementing regulations,
the FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides
meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or
intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be
a positive therapeutic effect that is clinically meaningful in the context of a given disease. For the purposes of accelerated
approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other
measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical
endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is
reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated
approval development pathway may be used in cases in which the advantage of a new drug over available therapy may not
be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If
granted, accelerated approval is contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-
approval confirmatory studies to verify and describe the drug’s clinical profile or risks and benefits for accelerated
approval. The FDA may require that any such confirmatory studies be initiated or substantially underway prior to the
submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug’s clinical
profile or risks and benefits, the FDA may withdraw its approval of the drug. The Food and Drug Omnibus Reform Act, or
FDORA, which was signed into law on December 29, 2022, made amendments to the accelerated approval program,
among them new requirements relating to post-approval studies and enhanced enforcement and withdrawal authorities for
the FDA, including in the event that a sponsor fails to comply with applicable requirements under the program. Because we
are still in early stages of our clinical trials, we can provide no assurances that our biomarker-based approach will be
successful in demonstrating a causal link to the relevant outcomes we are evaluating. If our approach is not successful, we
may be required to conduct longer clinical trials.
If we choose to pursue accelerated approval, we intend to seek feedback from the FDA or will otherwise evaluate
our ability to seek and receive such accelerated approval. There can be no assurance that, after our evaluation of the
feedback from the FDA or other factors, we will decide to pursue or submit an NDA for accelerated approval or any other
form of expedited development, review or approval. Furthermore, even if we submit an application for accelerated
approval, there can be no assurance that the application will be accepted or that approval will be granted on a timely basis,
or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting
approval of any type. We might not be able to fulfill the FDA’s requirements in a timely manner, which would cause
delays, or approval might not be granted because our submission is deemed incomplete by the FDA. A failure to obtain
accelerated approval or any other form of expedited development, review or approval for a product candidate would result
in a longer time period to commercialize such product candidate, could increase the cost of development of such product
candidate and could harm our competitive position in the marketplace.
Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-marketing
requirements, including the completion of confirmatory post-market clinical trial(s) to verify the clinical benefit of the
product, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to
withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post-market study with
due diligence, a post-market study does not confirm the predicted clinical benefit, other evidence shows that the product is
not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to be
false or misleading.
A failure to obtain accelerated approval or any other form of expedited development, review or approval for a
product candidate that we may choose to develop would result in a longer time period prior to commercializing such
51
Table of Contents
product candidate, could increase the cost of development of such product candidate and could harm our competitive
position in the marketplace.
Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be
delayed, made more difficult or rendered impossible by multiple factors outside our control.
Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter
difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our
product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our
trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient
population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of
competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients
to clinical sites and the eligibility criteria for the trial. Because our focus includes rare disorders, there are limited patient
pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Accordingly,
enrollment of our clinical trials could take significantly longer than projected, which would delay any potential approval of
our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we
may have difficulty maintaining enrollment of such patients in our clinical trials.
Our efforts to build relationships with patient communities may not succeed, which could result in delays in
patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may
make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or
failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have
a harmful effect on our ability to develop our product candidates or could render further development impossible. In
addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and,
while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual
performance.
For additional information regarding delays in enrollment and retention of patients, see “Risks Related to Our
Business Operations, Employee Matters and Managing Growth—Our business may be adversely affected by the
coronavirus outbreak.”
Our product candidates may cause undesirable side effects or have other properties that could delay or prevent
their regulatory approval, limit their commercial potential or result in significant negative consequences following any
potential marketing approval.
During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and
discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused
these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these
determinations, if they occur.
In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials,
or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries,
discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went
undetected in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after
investigational drugs are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a
commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side
effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or,
if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business,
prospects, operating results and financial condition.
52
Table of Contents
Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time
may change as more patient data become available and are subject to audit and verification procedures that could result
in material changes in the final data.
From time to time, we may publish interim, “top-line” or preliminary data from our clinical trials. Interim data
from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Preliminary or “top-line” data also remain
subject to audit and verification procedures that may result in the final data being materially different from the preliminary
data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data
are available. Differences between preliminary or interim data and final data could significantly harm our business
prospects and may cause the trading price of our common stock to fluctuate significantly.
The incidence and prevalence for target patient populations of our product candidates have not been
established with precision. If the market opportunities for our product candidates are smaller than we believe they are
or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.
We currently focus our drug development on product candidates for the treatment of diseases with high unmet
medical need. Our eligible patient population and pricing estimates may differ significantly from the actual market
addressable by our product candidates. Our estimates of both the number of people who have these diseases, as well as the
subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are
based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific
literature, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the
estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than
expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or
may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to
identify or access. If the market opportunities for our product candidates are smaller than we estimate, we may not be able
to achieve our forecast revenue, which could hinder our business plan and adversely affect our business and results of
operations.
We may face substantial competition, which may result in others developing or commercializing drugs before
or more successfully than us.
The development and commercialization of new drugs is highly competitive. We may face potential competition
with respect to our current product candidates and may face competition with respect to any other product candidates that
we may seek to develop or commercialize in the future from pharmaceutical and biotechnology companies, academic
institutions, government agencies and other public and private research institutions.
Our competitors may have an advantage over us due to their greater size, resources and institutional experience. In
particular, these companies have greater experience and expertise in securing reimbursement, government contracts and
relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory
approvals and distribution relationships to market products and marketing approved drugs. These companies also have
significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against
existing and potential competitors, our business and financial condition may be harmed.
As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to,
which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop
therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful
than we are in manufacturing and marketing their drugs. These advantages could render our product candidates obsolete or
non-competitive before we can recover the costs of such product candidates’ development and commercialization.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources
being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. These
53
Table of Contents
third-parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel,
establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs.
We may explore strategic collaborations that may never materialize or we may be required to relinquish
important rights to and control over the development and commercialization of our product candidates to any future
collaborators.
Over time, our business strategy includes acquiring or in-licensing additional product candidates for treatments of
diseases with high unmet medical need. As a result, we intend to periodically explore a variety of possible strategic
collaborations in an effort to gain access to additional product candidates or resources. These strategic collaborations may
include partnerships with large strategic partners, particularly for the development of DPN treatments using AT-001. At the
current time however, we cannot predict what form such a strategic collaboration might take. We are likely to face
significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and
time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms,
or at all. We are unable to predict when, if ever, we will enter into any strategic collaborations because of the numerous
risks and uncertainties associated with establishing them.
Future collaborations could subject us to a number of risks, including:
● we may be required to undertake the expenditure of substantial operational, financial and management
resources;
● we may be required to issue equity securities that would dilute our stockholders’ percentage ownership of our
company;
● we may be required to assume substantial actual or contingent liabilities;
● we may not be able to control the amount and timing of resources that our strategic collaborators devote to
the development or commercialization of our product candidates;
● strategic collaborators may select indications or design clinical trials in a way that may be less successful
than if we were doing so;
● strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or
abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product
candidate for clinical testing;
● strategic collaborators may not pursue further development and commercialization of products resulting from
the strategic collaboration arrangement or may elect to discontinue research and development programs;
● strategic collaborators may not commit adequate resources to the marketing and distribution of our product
candidates, limiting our potential revenues from these products;
● disputes may arise between us and our strategic collaborators that result in the delay or termination of the
research, development or commercialization of our product candidates or that result in costly litigation or
arbitration that diverts management’s attention and consumes resources;
● strategic collaborators may experience financial difficulties;
● strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may
use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or
expose us to potential litigation;
● business combinations or significant changes in a strategic collaborator’s business strategy may adversely
affect a strategic collaborator’s willingness or ability to complete its obligations under any arrangement;
● strategic collaborators could decide to move forward with a competing product candidate developed either
independently or in collaboration with others, including our competitors; and
● strategic collaborators could terminate the arrangement or allow it to expire, which would delay the
development and may increase the cost of developing our product candidates.
54
Table of Contents
Even if any product candidates receive marketing approval, they may fail to achieve market acceptance by
physicians, patients, third-party payors or others in the medical community necessary for commercial success.
Even if any product candidates receive marketing approval, they may fail to gain market acceptance by
physicians, patients, third-party payors and others in the medical community. If such product candidates do not achieve an
adequate level of acceptance, we may not generate significant drug revenue and may not become profitable. The degree of
market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors,
including but not limited to:
● the convenience and ease of administration compared to alternative treatments and therapies;
● the willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies;
● the efficacy and potential advantages compared to alternative treatments and therapies;
● the effectiveness of sales and marketing efforts;
● the strength of our relationships with patient communities;
● the cost of treatment in relation to alternative treatments and therapies, including any similar generic
treatments;
● our ability to offer such drug for sale at competitive prices;
● the strength of marketing and distribution support;
● the availability of third-party coverage and adequate reimbursement;
● the prevalence and severity of any side effects; and
● any restrictions on the use of the drug together with other medications.
Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits
of our product candidates may require significant resources and may never be successful. Such efforts may require more
resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect
sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the
failure of our product candidates to find market acceptance would harm our business.
Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing
regulatory oversight.
Even if we obtain regulatory approvals for our product candidates, such approvals will be subject to ongoing
regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record keeping
and submission of safety and other post-market information. Any regulatory approvals that we receive for our product
candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed
or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4
trials, and surveillance to monitor the quality, safety and efficacy of the drug. Such regulatory requirements may differ
from country to country depending on where we have received regulatory approval.
In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and
periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing
practices, or cGMP, requirements and adherence to commitments made in the NDA or foreign marketing application. If we,
or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated
severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees
with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug,
the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or
suspension of manufacturing.
If we fail to comply with applicable regulatory requirements following approval of our product candidates, a
regulatory authority may, among other actions:
● issue an untitled letter or warning letter asserting that we are in violation of the law;
55
Table of Contents
● seek an injunction or impose administrative, civil or criminal penalties or monetary fines;
● suspend or withdraw regulatory approval;
● suspend any ongoing clinical trials;
● refuse to approve a pending NDA or comparable foreign marketing application or any supplements thereto
submitted by us or our partners;
● restrict the marketing or manufacturing of the drug;
● seize or detain the drug or otherwise require the withdrawal of the drug from the market;
● refuse to permit the import or export of product candidates; or
● refuse to allow us to enter into supply contracts, including government contracts.
Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular,
a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a
company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and
administrative penalties.
Any government investigation of alleged violations of law could require us to expend significant time and
resources in response and could generate negative publicity. The occurrence of any event or penalty described above may
inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations
and prospects.
The FDA’s and other regulatory authorities’ policies may change and additional laws or government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are not able to
maintain regulatory compliance with the FDCA, Cures Act, or other applicable requirements, we may lose any marketing
approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our
business, prospects, financial condition and results of operations.
In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the
U.S. administration may impact our business and industry. It is difficult to predict how executive actions, including
executive orders, may be implemented and the extent to which they will affect the FDA’s ability to exercise its regulatory
authority. If legislative, administrative or executive actions impose constraints on the FDA’s ability to engage in oversight
and implementation activities in the normal course, our business may be negatively impacted.
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell our product candidates, we may not be successful in commercializing them, if and when they are
approved.
To successfully commercialize any product candidate that may result from our development programs, we will
need to build out our sales and marketing capabilities, either on our own or with others. The establishment and
development of our own commercial team or the establishment of a contract sales force to market any product candidate
we may develop will be expensive and time-consuming and could delay any drug launch. Moreover, we cannot be certain
that we will be able to successfully develop this capability. We may seek to enter into collaborations with other entities to
utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on
favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our
product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate
sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced
and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We will
likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product
candidates. Without an internal team or the support of a third-party to perform marketing and sales functions, we may be
unable to compete successfully against these more established companies.
56
Table of Contents
Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain
approval outside the United States, which would limit our market opportunities.
Approval of a product candidate in the United States by the FDA does not ensure approval of such product
candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority
does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product
candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and
marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory
authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and
more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries
outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in
that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to
approval. Obtaining approval for our product candidates in the European Union from the European Commission following
the opinion of the European Medicines Agency, or the EMA, is a lengthy and expensive process. Even if a product
candidate is approved, the EMA may limit the indications for which the drug may be marketed, require extensive warnings
on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of
approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in
significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in
certain countries.
Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries.
Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory
requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates
will be harmed and our business, financial condition, results of operations and prospects could be harmed.
If we commercialize our product candidates outside the United States, a variety of risks associated with
international operations could harm our business.
We intend to seek approval to market our product candidates outside the United States, and may do so for future
product candidates. If we market approved products outside the United States, we expect that we will be subject to
additional risks in commercialization, including:
● different regulatory requirements for approval of therapies in foreign countries;
● reduced protection for intellectual property rights;
● unexpected changes in tariffs, trade barriers and regulatory requirements;
● economic weakness, including inflation, or political instability in particular foreign economies and markets;
● compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
● foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and
other obligations incident to doing business in another country;
● foreign reimbursement, pricing and insurance regimes;
● workforce uncertainty in countries where labor unrest is more common than in the United States;
● production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and
● business interruptions resulting from geopolitical actions, including war and terrorism, international
hostilities, or natural disasters including earthquakes, typhoons, floods and fires.
We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal
requirements imposed by many of the individual countries in which we may operate, with which we will need to comply.
Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be
challenging.
57
Table of Contents
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit
commercialization of any product candidate that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical
trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot
successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial
liabilities. Regardless of merit or eventual outcome, liability claims may result in:
● decreased demand for any product candidate that we may develop;
● loss of revenue;
● substantial monetary awards to trial participants or patients;
● significant time and costs to defend the related litigation;
● withdrawal of clinical trial participants;
● increased insurance costs;
● the inability to commercialize any product candidate that we may develop; and
● injury to our reputation and significant negative media attention.
Any such outcomes could negatively impact our business, financial condition, results of operations and prospects.
Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.
Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all
liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a
clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and
pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks
that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain
appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. We
have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate
insurance. Such conditions have resulted in higher premium costs, higher policy deductibles, and lower coverage limits.
For some risks, we may not have or maintain insurance coverage because of cost or availability.
Risks Related to Regulatory Compliance
Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to
federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and
other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could
face substantial penalties.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary
role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our
current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-
party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without
limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly
referred to as the Physician Payments Sunshine Act and regulations.
Ensuring that our business arrangements with third-parties comply with applicable healthcare laws and regulations
will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply
with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and
regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that
may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare
and Medicaid, additional reporting requirements and oversight if we become subject to a
58
Table of Contents
corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual
damages, reputational harm and the curtailment or restructuring of our operations.
If the physicians or other providers or entities with whom we expect to do business are found not to be in
compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating
to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and
management personnel from their normal responsibilities. In addition, there could be public announcements of the results
of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results
to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings
could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales,
marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other
proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in
the marketplace.
Coverage and adequate reimbursement may not be available for our product candidates, which could make it
difficult for us to sell profitably, if approved.
Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on
the extent to which reimbursement for these drugs and related treatments will be available from third-party payors,
including government health administration authorities, managed care organizations and other private health insurers.
Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy
for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy
and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent
of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a
payor-by-payor basis. Therefore, one payor’s determination to provide coverage for a drug does not assure that other
payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor’s decision
to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor
determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy,
and on what tier of its formulary it will be placed. The position on a payor’s list of covered drugs, or formulary, generally
determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of
such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers
prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs.
Patients are unlikely to use our product candidates, if approved, unless coverage is provided and reimbursement is adequate
to cover a significant portion of the cost of our products.
Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for
particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we
commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and
reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage
and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully
commercialize any product candidates that we develop.
Healthcare reform measures may have a negative impact on our business and results of operations.
In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and
regulatory changes and proposed changes, as well as judicial challenges, regarding the healthcare system that could prevent
or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to
profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue
to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality
of healthcare. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA,
changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for
drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for
physician-administered drugs. In addition, this legislation provided authority for limiting the
59
Table of Contents
number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this
legislation could decrease the coverage and price that we receive for any approved products. While the MMA applies only
to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result
in a similar reduction in payments from private payors.
Further, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care
and Education Reconciliation Act of 2010, or, collectively, the PPACA, was passed, which substantially changed the way
healthcare is financed by both governmental and private payors in the United States. Some of the provisions of the PPACA
have yet to be fully implemented, while certain provisions have been subject to executive, judicial and Congressional
challenges. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act includes a provision that repealed, effective
January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to
maintain qualifying health coverage for all or part of a year, which is commonly referred to as the “individual mandate.”.
On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled
that the individual mandate was a critical and inseverable feature of the PPACA, and therefore, because it was repealed as
part of the Tax Act, the remaining provisions of the PPACA were invalid as well. The U.S. Supreme Court heard arguments
in the case in November 2020 and issued its decision in June 2021, ruling that the plaintiffs lacked the standing to
challenge the individual mandate provision. In so holding, the Supreme Court did not consider larger constitutional
questions about the validity of this provision or the validity of the PPACA in its entirety. Another case challenging the
PPACA’s requirement that insurers cover certain preventative services is currently pending before the same U.S. District
Court Judge in the Northern District of Texas who ruled against the individual mandate in 2018. In September 2022, the
judge held that the PPACA requirement to cover certain preventative services violated the U.S. Constitution and set a
schedule for additional briefing, which was completed in January 2023. In March 2023, the judge struck down the
requirement with immediate nationwide effect by ruling, in part, that members of a panel charged under the PPACA with
recommending preventative services coverage had been appointed in an unconstitutional manner. Parties on both sides of
the lawsuit have appealed this ruling, and in June 2023 the U.S. Court of Appeals for the Fifth Circuit approved an
agreement by the parties on a stay of the lower court’s ruling pending the appeal. Oral arguments have been scheduled for
March 2024, and it is unclear how this decision, subsequent decisions and appeals, or any potential future litigation and
other efforts to repeal and replace the PPACA will impact the PPACA. Congress may consider additional legislation to
repeal or repeal and replace other elements of the PPACA. We continue to evaluate the effect that the PPACA and its
possible repeal and replacement may have on our business and the potential profitability of our product candidates.
Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include
aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011,
which began in 2013, and due to subsequent legislative amendments to the statute, including the BBA, which will remain
in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among
other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to
five years.
Additional changes that affect our business include the expansion of programs such as Medicare payment for
performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015. At this time, the
full impact of the introduction of the Medicare quality payment program on overall physician reimbursement is unclear.
Further, in the United States there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce
the cost of prescription drugs under government payor programs, and review the relationship between pricing and
manufacturer patient programs. While some of the proposed measures will require authorization through additional
legislation to become effective, the U.S. Congress have indicated that they will continue to seek new legislative and/or
administrative measures to control drug costs. For example, the Inflation Reduction Act of 2022 also seeks to reduce
prescription drug costs by, among other provisions, allowing Medicare to negotiate prices for certain high-cost
60
Table of Contents
prescription drugs in Medicare Parts B and D, imposing an excise tax on pharmaceutical manufacturers that refuse to
negotiate pricing with Medicare, requiring inflation rebates to limit annual drug price increases in Medicare, redesigning
the Medicare Part D formula, and limiting cost-sharing for insulin products. It is unclear whether additional drug pricing
and other healthcare reform measures will be enacted, and if enacted, what effect they would have on our business. We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the
amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced
demand for our current or any future product candidates or additional pricing pressures. We cannot predict the likelihood,
nature or extent of government regulation that may arise from future legislation or administrative action in the United
States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing
or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or
any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may
not achieve or sustain profitability.
Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to
Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework
for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that
are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without
enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no
obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right
to Try Act.
We expect that these and other healthcare reform measures that may be adopted in the future may result in more
rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug, which
could have an adverse effect on demand for our product candidates if they are approved. Any reduction in reimbursement
from Medicare or other government programs may result in a similar reduction in payments from private payors. The
implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our product candidates.
Risks Related to Our Dependence on Third Parties
We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.
We do not own or operate facilities for drug manufacturing, storage and distribution, or testing. We are dependent
on third parties to manufacture the clinical supplies of our current and any future product candidates. The facilities used by
our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections
that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are
completely dependent on, our contract manufacturing partners for compliance with the cGMP requirements, for
manufacture of both active drug substance and finished drug product. If our contract manufacturers cannot successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we
will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control
over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified
personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of
our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product
candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof,
for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of
our clinical trials, product testing and potential regulatory approval of our product candidates.
We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product
candidates to be used, if approved, for commercialization. We do not yet have a commercial supply agreement for
commercial quantities of drug substance or drug product. If we are not able to meet market demand for any approved
product, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect
on our business and financial condition.
61
Table of Contents
Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured product candidates ourselves, including:
● inability to meet our product specifications and quality requirements consistently;
● delay or inability to procure or expand sufficient manufacturing capacity;
● issues related to scale-up of manufacturing;
● costs and validation of new equipment and facilities required for scale-up;
● our third-party manufacturers may not be able to execute our manufacturing procedures and other logistical
support requirements appropriately;
● our third-party manufacturers may fail to comply with cGMP requirements and other inspections by the FDA
or other comparable regulatory authorities;
● our inability to negotiate manufacturing agreements with third parties under commercially reasonable terms,
if at all;
● breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time
that is costly or damaging to us;
● reliance on single sources for drug components;
● lack of qualified backup suppliers for those components that are currently purchased from a sole or single-
source supplier;
● our third-party manufacturers may not devote sufficient resources to our product candidates;
● we may not own, or may have to share, the intellectual property rights to any improvements made by our
third-party manufacturers in the manufacturing process for our product candidates;
● operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or supplier; and
● carrier disruptions or increased costs that are beyond our control.
In addition, if we enter into a strategic collaboration with a third-party for the commercialization of our current or
any future product candidates, we will not be able to control the amount of time or resources that they devote to such
efforts. If any strategic collaborator does not commit adequate resources to the marketing and distribution of our product
candidates, it could limit our potential revenues.
Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability
to successfully commercialize our current or any future product candidates once approved. Some of these events could be
the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.
Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers
must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we
do, or interrupt our, business.
Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the
generation, storage, use and disposal of hazardous materials, including the components of our product candidates and other
hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety
laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation,
discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these
hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending
their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our
commercialization efforts, research and development efforts and business operations, damages and significant cleanup
costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that
the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes
generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting
damages, costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may
curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety
laws and regulations are complex, change frequently and have tended to become more
62
Table of Contents
stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply
with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other
sanctions. We do not currently carry environmental insurance coverage.
We rely on third-parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if
those third parties perform in an unsatisfactory manner, it may harm our business.
We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and
clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to
have limited influence over their actual performance. We rely upon CROs to monitor and manage data for our clinical
programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs’
activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is
conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the
CROs does not relieve us of our regulatory responsibilities.
We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are
regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International
Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development.
Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial
sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of
our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and
applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical
trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these
regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay
the regulatory approval process.
Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data
developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating
with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating
activities. Such parties may:
● have staffing difficulties;
● fail to comply with contractual obligations;
● experience legal or regulatory compliance issues; or
● undergo changes in priorities or become financially distressed.
These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may
subject us to unexpected cost increases that are beyond our control. If our CROs do not successfully carry out their
contractual duties or obligations, fail to meet expected deadlines, or fail to comply with regulatory requirements, or if the
quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or
regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may
not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a
result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our
costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their
activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and
resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial
entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development
activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our
intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access
and exploit our proprietary technology.
If our relationship with any of these CROs terminates, we may not be able to enter into arrangements with
alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial
63
Table of Contents
cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences
work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines.
While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter
challenges or delays in the future or that these delays or challenges will not have a negative impact on our business,
financial condition and prospects.
In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from
time to time and receive compensation in connection with such services. Under certain circumstances, we may be required
to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a
principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may
therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial
itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA
and may ultimately lead to the denial of marketing approval of our product candidates.
Risks Related to Our Intellectual Property
Licensing of intellectual property is of critical importance to our business and involves complex legal, business
and scientific issues. If we breach our license agreements with Columbia University or any of the other agreements
under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the
ability to continue the development and commercialization of the related product.
The licensing of intellectual property is of critical importance to our business and to our current and future product
candidates, and we expect to enter into additional such agreements in the future. In particular, our current product
candidates AT-007, AT-001 and AT-003 are dependent on our license agreement with The Trustees of Columbia University
in the City of New York, or Columbia University. Pursuant to that license agreement with Columbia University, or the 2016
Columbia Agreement, Columbia University granted us an exclusive license under two important patent families, and a
nonexclusive license to certain know-how, owned by Columbia University to develop, manufacture or commercialize
certain compounds, including AT-001, AT-003 and AT-007, for the diagnosis and treatment of human and animal diseases
and conditions. The license grant is worldwide, with the exception of the patent family that covers AT-001 and AT-003. The
license grant for the patent family that covers AT-001 and AT-003 excludes patent rights in China, Taiwan, Hong Kong and
Macao, which Columbia University has exclusively licensed to a third-party. We cannot prevent Columbia University’s
third-party licensee from developing, manufacturing or commercializing certain compounds, including AT-001 and AT-003,
but not including AT-007, in China, Taiwan, Hong Kong and Macao, and we cannot develop, manufacture or
commercialize AT-001 or AT-003 in these territories, which could have a negative effect on our business.
We do not have the right to control the preparation, filing, prosecution and maintenance of patents and patent
applications covering the technology that we license under either of the Columbia Agreements. Therefore, we cannot
always be certain that these patents and patent applications will be prepared, filed, prosecuted and maintained in a manner
consistent with the best interests of our business. Although we have a right to have our comments considered in connection
with the prosecution process, if Columbia University fails to prosecute and maintain such patents, or loses rights to those
patents or patent applications as a result of its control of the prosecution activities, the rights we have licensed may be
reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of
such licensed rights could be adversely affected.
If we fail to meet our obligations under the Columbia Agreement in any material respect and fail to cure such
breach in a timely fashion, then Columbia University may terminate the Columbia Agreement. If the Columbia Agreement
is terminated, and we lose our intellectual property rights under the Columbia Agreement, this may result in complete
termination of our product development and any commercialization efforts for the product candidates that are subject to the
agreement, including AT-007, AT-001, and AT-003. While we would expect to exercise all rights and remedies available to
us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the Columbia Agreement,
we may not be able to do so in a timely manner, at an acceptable cost or at all.
64
Table of Contents
Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual
property and technology in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and
commercializing competitive products in territories included in all of our licenses.
If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the
scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and
commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our
product candidates and technology may be adversely affected.
Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and
other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to
seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product
candidates and our technology that are important to our business.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves
complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance,
scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future
patent applications may not result in patents being issued which protect our technology or product candidates or which
effectively prevent others from commercializing competitive technologies and product candidates. Since patent
applications in the United States and most other countries are confidential for a period of time after filing, and some remain
so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any
particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, an interference
proceeding in the United States can be initiated by such third-party, or by the U.S. Patent and Trademark Office, or
USPTO, itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our
applications.
The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file,
prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely
manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is
too late to obtain patent protection.
We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent
protection for our product candidates in every country or territory in which we may sell our products, if approved. In
addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and
state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all
countries outside the United States, or from selling or importing products that infringe our patents in and into the United
States or other jurisdictions.
Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued,
and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they
may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from
competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be
able to circumvent our patents by developing similar or alternative products in a non-infringing manner.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents
may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of
exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop
others from using or commercializing similar or identical technology and products, or limit the duration of the patent
protection of our technology and product candidates. Given the amount of time required for the development, testing and
regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such
candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours.
65
Table of Contents
Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third
parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was
funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such
patent rights and technology. When new technologies are developed with government funding, the government generally
obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the
invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to
third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government
can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of
the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of
federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to
certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the
government of such rights could harm our competitive position, business, financial condition, results of operations and
prospects.
Obtaining and maintaining our patent rights depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by government patent agencies, and our patent protection
could be reduced or eliminated for noncompliance with these requirements.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. In addition, periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will
have to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our
owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our
service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require
compliance with several procedural, documentary, fee payment and other similar provisions during the patent application
process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our
licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not
limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly
legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering
our products or technologies, we may not be able to stop a competitor from marketing products that are the same as or
similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse
can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations,
however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial
or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter
the market and this circumstance could harm our business.
In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited
time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and
maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent
owner.
Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate
amount of time.
Given the amount of time required for the development, testing and regulatory review of product candidates such
as AT-007, AT-001, and AT-003, patents protecting such candidates might expire before or shortly after such candidates are
commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries
where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration
Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent; provided that
the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved
indication (or any additional indications approved during the period of extension). Furthermore, only one patent per
approved product can be extended and only those claims covering the approved product, a method for using it or a method
for manufacturing it may be extended. However, the applicable authorities, including the FDA
66
Table of Contents
and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our
assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more
limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in
development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might
otherwise be the case.
Third-parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise
violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact
on the success of our business.
Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate
to develop, manufacture, market and sell our current and any future product candidates and use our proprietary
technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of
third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation
regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with,
adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product
candidates and technology, including interference proceedings, post grant review and inter partes review before the
USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in
the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or
to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent
jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative
impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the
validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this is a high
burden and requires us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is
no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given
the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that
we will not infringe patents that may be granted in the future. Other companies and research institutions have filed, and
may file in the future, patent applications related to AR inhibitors and their therapeutic use. Some of these patent
applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate
proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent
offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent
applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending
patent claims can be revised before issuance, there may be applications now pending which may later result in issued
patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may
fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is
invalid or not infringed by our product candidates or activities. If a patent holder believes that our product candidate
infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover,
we may face patent infringement claims from nonpracticing entities that have no relevant drug revenue and against whom
our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against
us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that
is the subject of the actual or threatened suit.
If we are found to infringe a third-party’s valid and enforceable intellectual property rights, we could be required
to obtain a license from such third-party to continue developing, manufacturing and marketing our product
candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees,
milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially
reasonable terms or at all.
The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established
companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider
attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital
resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to
be a competitor may be unwilling to assign or license rights to us. We also may be unable to license
67
Table of Contents
or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our
investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or
maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or
product candidate, which could have an adverse effect on our business, financial condition, results of operations and
prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors
and other third-parties access to the same technologies licensed to us, and it could require us to make substantial licensing
and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and
commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary
damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other
intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of
infringement could prevent us from manufacturing and commercializing our current or any future product candidates or
force us to cease some or all of our business operations, which could harm our business. Even if we are successful in
defending against such claims, litigation can be expensive and time-consuming and would divert management’s attention
from our core business. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an
adverse effect on the price of our common stock.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a
similar negative impact on our business, financial condition, results of operations and prospects.
We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or
disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as
our own intellectual property.
Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or
other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to
ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their
work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including
trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be
necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims,
litigation could result in substantial costs and be a distraction to management.
In addition, we may in the future be subject to claims by our former employees or consultants asserting an
ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is
our policy to require our employees and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we
cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will
not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be
self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties,
or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.
We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other
intellectual property rights, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our
other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims,
which can be expensive and time-consuming and are likely to divert significant resources from our core business, including
distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement
proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may
68
Table of Contents
refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology
in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed
patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk
of not issuing. The initiation of a claim against a third-party might also cause the third-party to bring counterclaims against
us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States,
defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement
or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected
with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading
statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant
proceedings such as ex parte reexaminations, inter partes review, post-grant review, or oppositions or similar proceedings
outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal
assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating
prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications
that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against
challenge by a third-party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would
lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of
patent protection could harm our business.
We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights,
particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be
harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on
commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and
even if successful, may result in substantial costs and distract our management and other employees.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property
litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or
developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the
price of our common stock.
We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can
because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly,
despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from
successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of
patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.
Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of
patents in general, thereby impairing our ability to protect our current and any future product candidates.
Changes in either the patent laws or interpretation of the patent laws in the United States could increase the
uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents.
Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the
claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was
entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, the
United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are
met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-
party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes
that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-
party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a
patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation
proceedings. However, the America Invents Act and its implementation could increase the uncertainties and costs
surrounding the prosecution of our patent applications and the enforcement or
69
Table of Contents
defense of our issued patents, all of which could have an adverse effect on our business, financial condition, results of
operations, and prospects.
In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope
of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In
addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has
created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the
federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could
weaken our ability to obtain new patents or to enforce patents that we own, have licensed or might obtain in the future.
Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that
enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our
ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.
We may not be able to protect our intellectual property rights throughout the world, which could negatively
impact our business.
Filing, prosecuting and defending patents covering our current and any future product candidates in all countries
throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or
our licensors have not obtained patent protection to develop their own products and, further, may export otherwise
infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as
that in the United States. These products may compete with our products in jurisdictions where we do not have any issued
or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to
prevent them from so competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in
foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the
enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology
products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in
violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and
proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent
applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any
lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to
obtain a significant commercial advantage from the intellectual property that we develop or license.
Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to third parties. In addition, many countries limit the enforceability of patents against government agencies or government
contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of
such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to
our business, our competitive position may be impaired, and our business, financial condition, results of operations and
prospects may be adversely affected.
Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor
will discover them or that our trade secrets will be misappropriated or disclosed.
Since we rely on third parties to help us discover, develop and manufacture our current and any future product
candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current
or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and
development programs that may require us to share trade secrets under the terms of our research and development
partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality
agreements and, if applicable, material transfer agreements, consulting agreements or other similar
70
Table of Contents
agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing
proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential
information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the
need to share trade secrets and other confidential information increases the risk that such trade secrets become known by
our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s
discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and
results of operations.
In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and
consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may
not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to
these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have
or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses
and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies
will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to
these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any
such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is
licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or
violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party
illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and
the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade
secrets.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would
be harmed.
In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets,
including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We
seek to protect our trade secrets, in part, by entering into nondisclosure and confidentiality agreements with parties who
have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract
manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent
assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may
breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses
and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our
intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-
consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing
or unwilling to protect trade secrets.
Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our
trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive
from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were
to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to
whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were
to be disclosed to or independently developed by a competitor, our competitive position would be harmed.
We also seek to preserve the integrity and confidentiality of our data and other confidential information by
maintaining physical security of our premises and physical and electronic security of our information technology systems.
While we have confidence in these individuals, organizations and systems, agreements or security measures may be
breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party
illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome
is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential
information may otherwise become known or be independently discovered by competitors, in which case
71
Table of Contents
we would have no right to prevent them, or those to whom they communicate it, from using that technology or information
to compete with us.
Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for
marketing from the products of our competitors. We have selected trademarks for some of our later stage product
candidates and filed applications to register those trademarks for our current or any future product candidates. For other
earlier stage product candidates, we have not yet selected trademarks or begun the process of applying to register
trademarks. Our pending trademark applications, and any future trademark applications may not be approved. Third parties
may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks
are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition
and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our
trademarks, and we may not have adequate resources to enforce our trademarks.
In addition, any proprietary name we propose to use with our current or any other product candidate in the United
States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark.
The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion
with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to
expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under
applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.
Intellectual property rights do not necessarily address all potential threats to our business.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual
property rights have limitations and may not adequately protect our business. The following examples are illustrative:
● others may be able to make compounds or formulations that are similar to our product candidates but that are
not covered by the claims of any patents, should they issue, that we own or license;
● we or our licensors might not have been the first to make the inventions covered by the issued patents or
pending patent applications that we own or license;
● we or our licensors might not have been the first to file patent applications covering certain of our inventions;
● others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights;
● it is possible that our pending patent applications will not lead to issued patents;
● issued patents that we own or license may not provide us with any competitive advantages, or may be held
invalid or unenforceable as a result of legal challenges;
● our competitors might conduct research and development activities in the United States and other countries
that provide a safe harbor from patent infringement claims for certain research and development activities, as
well as in countries where we do not have patent rights, and then use the information learned from such
activities to develop competitive drugs for sale in our major commercial markets;
● we may not develop additional proprietary technologies that are patentable; and
● the patents of others may have an adverse effect on our business.
72
Table of Contents
Risks Related to Our Business Operations, Employee Matters and Managing Growth
We are highly dependent on the services of our Chief Executive Officer and Chairman, Dr. Shoshana
Shendelman, and our Chief Medical Officer, Dr. Riccardo Perfetti, and if we are not able to retain these members of our
management team or recruit and retain additional management, clinical and scientific personnel, our business will be
harmed.
We are highly dependent on our Chief Executive Officer and Chairman, Dr. Shoshana Shendelman, and our Chief
Medical Officer, Dr. Riccardo Perfetti. Each of them may currently terminate their employment with us at any time. The
loss of the services of either of these persons could impede the achievement of our research, development and
commercialization objectives.
Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the
development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will
be critical to our success. The loss of the services of our executive officers or other key employees could impede the
achievement of our research, development and commercialization objectives and seriously harm our ability to successfully
implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may
take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and
experience required to successfully develop, gain regulatory approval of and commercialize our product candidates.
Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key
personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for
similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and
research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us
in formulating our research and development and commercialization strategy. Our consultants and advisors may have
commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are
unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.
Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive
officers into our management team and our ability to develop an effective working relationship among senior management.
Our failure to integrate these individuals and create effective working relationships among them and other members of
management could result in inefficiencies in the development and commercialization of our product candidates, harming
future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently
maintain “key person” life insurance on the lives of our executives or any of our employees.
We expect to expand our organization, and we may experience difficulties in managing this growth, which
could disrupt our operations.
As of December 31, 2023, we had 25 full-time employees. As the clinical development of our product candidates
progresses, we also expect to experience significant growth in the number of our employees and the scope of our
operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our product candidates
receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue
to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit
and train additional qualified personnel. Due to our limited financial resources and the limited experience of our
management team in managing a company with such anticipated growth, we may not be able to effectively manage the
expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to
significant costs and may divert our management and business development resources. Any inability to manage growth
could delay the execution of our business plans or disrupt our operations.
73
Table of Contents
Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or
suffer security breaches, which could result in a significant disruption of our product development programs and our
ability to operate our business effectively, and adversely affect our business and operating results.
Our internal computer systems, cloud-based computing services and those of our current and any future
collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data
corruption, cyber-based attacks (including phishing attempts, denial of service attacks, and malware or ransomware
incidents), unauthorized access, natural disasters, terrorism, war, international hostilities and telecommunication and
electrical failures. While we have not experienced any significant system failure, accident or security breach to date, if such
an event were to occur and cause interruptions in our operations, it could result in a disruption of our development
programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other
similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays
in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore,
federal, state and international laws and regulations, such as the European Union’s General Data Protection Regulation,
which took effect in May 2018, can expose us to enforcement actions and investigations by regulatory authorities, and
potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail. In
addition, our software systems include cloud-based applications that are hosted by third-party service providers with
security and information technology systems subject to similar risks. To the extent that any disruption or security breach
were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability, our competitive position could be harmed and the further development and
commercialization of our product candidates could be delayed.
Risks of unauthorized access and cyber-attacks have increased as most of our personnel, and the personnel of
many third-parties with which we do business, have adopted remote working arrangements as a result of the Covid-19
pandemic, and may increase as a result of recent hostilities between Russia and Ukraine. Improper or inadvertent employee
behavior, including data privacy breaches by employees, contractors and others with permitted access to our systems, may
also pose a risk that sensitive data may be exposed to unauthorized persons or to the public. If a system failure or security
breach occurs and interrupts our operations or the operations at one of our third-party vendors, it could result in intellectual
property and other proprietary or confidential information being lost or stolen or a material disruption of our drug
development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials could result in
delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent
that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or
inappropriate disclosure of confidential or proprietary information, including protected health information or personal data
of employees or former employees, access to our clinical data, or disruption of the manufacturing process, we could incur
liability and the further development of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks
by hackers or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information
and/or our financial information and adversely affect our business or reputation or result in legal or regulatory proceedings.
In addition, if a ransomware attack or other cyber-attack occurs, either internally or at our third-party vendors, we could be
prevented from accessing our systems or data, which may cause interruptions or delays in our business, cause us to incur
remediation costs or subject us to demands to pay ransom, or adversely affect our business reputation.
Our employees, principal investigators, consultants and commercial partners may engage in misconduct or
other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and
commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the
regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities,
comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information
or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the
healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-
dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such
misconduct also could involve the improper use of information obtained in the course of
74
Table of Contents
clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and
cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or
losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply
with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves
or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines,
disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare
and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or
similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the
curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial
condition, results of operations and prospects.
Any future acquisitions or strategic collaborations may increase our capital requirements, dilute our
stockholders, cause us to incur debt or assume contingent liabilities and/or subject us to other risks.
From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or
acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out
our business plan. Any potential acquisition or strategic partnership may entail numerous risks, including:
● increased operating expenses and cash requirements;
● the assumption of additional indebtedness or contingent or unknown liabilities;
● assimilation of operations, intellectual property and drugs of an acquired company, including difficulties
associated with integrating new personnel;
● the diversion of our management’s attention from our existing drug programs and initiatives in pursuing such
a strategic partnership, merger or acquisition;
● retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key
business relationships;
● risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing drugs or product candidates and regulatory approvals; and
● our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs.
In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume
or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future
amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could
impair our ability to grow or obtain access to technology or drugs that may be important to the development of our
business.
We have identified a material weakness in our internal control over financial reporting during the year ended
December 31, 2023 related to deficiencies in our controls over the financial statement close process. If we are unable to
maintain an effective system of disclosure controls and procedures and internal control over financial reporting, we
may not be able to accurately report our financial results in a timely manner, which may adversely affect investor
confidence in us and materially and adversely affect our business and financial results.
In connection with our audit as of and for the period ended December 31, 2023, we identified a material weakness
in our internal control over financial reporting relating to deficiencies in our controls over the financial statement close
process. Specifically, there were deficiencies in the design and operation of internal controls over the review of complex
accounting issues involving significant judgment or estimates with respect to certain transactions. See “Item 9A. Controls
and Procedures” for more information.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not
be prevented or detected on a timely basis. Effective internal controls are necessary for us to provide
75
Table of Contents
reliable financial reports and prevent fraud. We have and continue to take steps to remediate the material weakness, but
there is no assurance that any remediation efforts will ultimately have the intended effects.
If we identify any new material weaknesses in the future, any such newly identified material weakness could limit
our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of
our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law
requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements,
investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure
stockholders that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid
potential future material weaknesses.
Risks Related to Ownership of Our Common Stock
The market price of our common stock is volatile and has fluctuated substantially, which could result in
substantial losses for purchasers of our common stock.
The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has
experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a
result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased it. In
addition to the factors discussed in this “Risk Factors” section and elsewhere in this Annual Report, the market price for
our common stock has been, and is likely to continue to be influenced by the following:
● the commencement, enrollment, results of , or any delays in our planned or future clinical trials of our
product candidates or those of our competitors;
● the success of competitive drugs or therapies;
● regulatory or legal developments in the United States and other countries;
● the success of competitive products or technologies;
● developments or disputes concerning patent applications, issued patents or other proprietary rights;
● the recruitment or departure of key personnel;
● the level of expenses related to our product candidates or clinical development programs;
● the results of our efforts to discover, develop, acquire or in-license additional product candidates;
● actual or anticipated changes in estimates as to financial results, development timelines or recommendations
by securities analysts;
● our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so
at acceptable prices;
● disputes or other developments relating to proprietary rights, including patents, litigation matters and our
ability to obtain patent protection for our technologies;
● significant lawsuits, including patent or stockholder litigation;
● variations in our financial results or those of companies that are perceived to be similar to us;
● changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for
any approved drug;
● market conditions in the pharmaceutical and biotechnology sectors;
● general economic, political, and market conditions and overall fluctuations in the financial markets in the
United States and abroad; and
● investors’ general perception of us and our business.
These and other market and industry factors have caused the market price and demand for our common stock to
fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling
their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.
Furthermore, we believe our stock has been, and may in the future be, adversely affected as a result of actions by third-
parties. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock
declines and their activities can negatively affect our stock price.
76
Table of Contents
Some companies that have experienced volatility in the trading price of their shares have been the subject of
securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable
judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in
payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices.
Defending against litigation is costly and time-consuming, and could divert our management’s attention and our resources.
Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings,
motions or other interim proceedings or developments, which could have a negative effect on the market price of our
common stock.
Concentration of ownership of our common stock among our existing executive officers, directors and
principal stockholders may prevent new investors from influencing significant corporate decisions.
Based upon shares of our common stock outstanding as of December 31, 2023, our executive officers, directors
and stockholders who owned more than 10% of our outstanding common stock, in the aggregate, beneficially own shares
representing approximately 26.5% of our outstanding common stock. If our executive officers, directors and stockholders
who owned more than 10% of our outstanding common stock acted together, they may be able to significantly influence all
matters requiring stockholder approval, including the election and removal of directors and approval of any merger,
consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions
could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the
management of our company in ways with which other stockholders disagree.
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital
appreciation, if any, will be your sole source of gain.
You should not rely on an investment in our common stock to provide dividend income. We have never declared
or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the
growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying
dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable
future. Investors seeking cash dividends should not purchase our common stock.
Future sales of common stock by holders of our common stock, or the perception that such sales may occur,
could depress the market price of our common stock.
Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject
to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares
intend to sell shares, could reduce the market price of our common stock. As of December 31, 2023, we had outstanding
84,869,832 shares of common stock. A substantial number of such shares are currently restricted as a result of securities
laws or lock-up agreements but will be able to be sold in the future.
We further have registered all shares of common stock that we may issue in the future or have issued to date under
our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume
limitations applicable to affiliates and certain lock-up agreements. Sales of a large number of the shares issued under these
plans in the public market could have an adverse effect on the market price of our common stock.
General Risk Factors
If research analysts do not publish research or reports, or publish unfavorable research or reports, about us,
our business or our market, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that industry or financial
analysts publish about us or our business. Equity research analysts may discontinue research coverage of our common
stock, and such lack of research coverage may adversely affect the market price of our common stock. We do not have any
control over the analysts or the content and opinions included in their reports. The price of our shares could decline if one
or more equity research analysts downgrade our shares or issue other unfavorable commentary or research
77
Table of Contents
about us. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, demand for
our shares could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.
We have broad discretion in the use of our cash and cash equivalents and may use them ineffectively, in ways
with which you do not agree or in ways that do not increase the value of your investment.
Our management has broad discretion in the application of our cash and cash equivalents, and could spend the
proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by
our management to apply these funds effectively could result in additional operating losses that could have a negative
impact on our business, cause the price of our common stock to decline and delay the development of our product
candidates. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or
that loses value.
We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging
growth companies may make our common stock less attractive to investors.
We are an “emerging growth company,” or EGC, as defined in the Jumpstart Our Business Startups Act of 2012,
or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are
applicable to other public companies that are not EGCs, including:
● being permitted to provide only two years of audited financial statements, in addition to any required
unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” disclosure;
● not being required to comply with the auditor attestation requirements in the assessment of our internal
control over financial reporting;
● not being required to comply with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing
additional information about the audit and the financial statements;
● reduced disclosure obligations regarding executive compensation; and
● not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved.
We cannot predict whether investors will find our common stock less attractive because we will rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market
for our common stock and our share price may be more volatile. We currently take advantage of some or all of these
reporting exemptions until we are no longer an EGC. We will remain an EGC until the earlier of (i) December 31, 2024,
(ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion, (iii) the last day of
the first fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common
stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (iv) the date on which we have
issued more than $1.0 billion in non-convertible debt during the prior three-year period. Even after we no longer qualify as
an EGC, we may still qualify as a “smaller reporting company” or “non-accelerated filer,” which would allow us to take
advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements.
In addition, under Section 107(b) of the JOBS Act, EGCs can delay adopting new or revised accounting standards
until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this
exemption from new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt
new or revised accounting standards as other public companies that are not EGCs.
78
Table of Contents
We have incurred increased costs as a result of operating as a public company, and our management will be
required to devote substantial time to new compliance initiatives.
As a public company, and particularly after we are no longer an EGC, we incur and will continue to incur
significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act,
and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC have imposed various requirements
on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate
governance practices. Our management and other personnel will need to devote a substantial amount of time to comply
with these requirements. Moreover, these rules and regulations increase our legal and financial compliance costs and make
some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more
difficult and more expensive for us to obtain director and officer liability insurance.
Pursuant to Section 404, we will be required to furnish a report by our management on our internal control over
financial reporting. However, while we remain an EGC, we will not be required to include an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with
Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control
over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal
resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of
internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as documented and implement a continuous reporting and improvement process for
internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered
public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial
reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a
loss of confidence in the reliability of our financial statements.
Provisions in our corporate charter documents and under Delaware law could make an acquisition of us,
which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or
remove our current management.
Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other
change in control of us that stockholders may consider favorable, including transactions in which you might otherwise
receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the
future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our
board of directors is responsible for appointing the members of our management team, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for
stockholders to replace members of our board of directors. Among other things, these provisions:
● establish a classified board of directors such that not all members of the board are elected at one time;
● allow the authorized number of our directors to be changed only by resolution of our board of directors;
● limit the manner in which stockholders can remove directors from the board;
● establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings
and nominations to our board of directors;
● require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by
our stockholders by written consent;
● limit who may call stockholder meetings;
● authorize our board of directors to issue preferred stock without stockholder approval, which could be used
to institute a stockholder rights plan, or so-called “poison pill,” that would work to dilute the stock ownership
of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board
of directors; and
● require the approval of the holders of at least 662/3% of the votes that all our stockholders would be entitled
to cast to amend or repeal certain provisions of our charter or bylaws.
79
Table of Contents
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the
Delaware General Corporation Law, or DGCL, which prohibits a person who owns in excess of 15% of our outstanding
voting stock from merging or combining with us for a period of three years after the date of the transaction in which the
person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a
prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change
in control transaction. They could also have the effect of discouraging others from making tender offers for our common
stock, including transactions that may be in your best interests. These provisions may also prevent changes in our
management or limit the price that investors are willing to pay for our stock.
Our governing documents designate certain courts as the sole and exclusive forum for certain types of actions
and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a
favorable judicial forum for disputes with us or our directors, officers or employees.
Our amended and restated certificate of incorporation provides that, with respect to any state actions or
proceedings under Delaware statutory or common law, the Court of Chancery of the State of Delaware is the exclusive
forum for:
● any derivative action or proceeding brought on our behalf;
● any action asserting a breach of fiduciary duty;
● any action asserting a claim against us or any of our directors, officers, employees or agents arising under the
DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws;
● any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated
certificate of incorporation or our amended and restated bylaws; and
● any action asserting a claim against us or any of our directors, officers, employees or agents that is governed
by the internal-affairs doctrine.
In addition, our amended and restated bylaws provide that, unless we consent in writing to the selection of an
alternative forum, the federal district courts of the United States are, to the fullest extent permitted by law, the exclusive
forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.
These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds
favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and
our directors, officers and other employees. If a court were to find an exclusive-forum provision in our amended and
restated certificate of incorporation or our amended and restated bylaws to be inapplicable or unenforceable in an action,
we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our business.
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
ITEM 1C. CYBERSECURITY.
We leverage well-known and established third parties as industry partners to support our key business processes
and utilize the services of reputable external advisory firms for running important functions such as cybersecurity
assessments and technical security management activities, including network security management.
We engaged an independent cybersecurity advisory service firm to perform a focused cybersecurity assessment to
better understand our current cybersecurity threats and risks and build a foundation for establishing a cybersecurity risk
assessment framework to identify, assess and manage cybersecurity risks arising from our business operations.
To date, risks from cybersecurity threats, including those resulting from any previous cybersecurity incidents,
have not materially affected us, including our operations or financial standing. We do not believe that cybersecurity threats
resulting from any previous cybersecurity incidents of which we are aware are reasonably likely to materially affect us.
80
Table of Contents
For additional information regarding risks from cybersecurity threats, please refer to Item 1A, “Risk Factors,” in this
annual report on Form 10-K.
One of the key functions of our Board of Directors is informed oversight of our risk management processes,
including risks from cybersecurity threats. Our Board of Directors is responsible for monitoring and assessing strategic risk
exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. Our
Board of Directors administers its cybersecurity risk oversight function directly as a whole, as well as through the Audit
Committee of the Board of Directors (the “Audit Committee”). The Audit Committee oversees our risk management
program, which focuses on the most significant risks we face. Audit Committee meetings include discussions of specific
risk areas throughout the year, including, among others, those relating to cybersecurity. Our Chief Financial Officer or
Chief Operating Officer reports on our enterprise risk profile on an annual basis or as needed. Our Audit Committee also
engages with external counsel on legal matters related to cybersecurity incident management and reporting.
Our Chief Financial Officer and Chief Operating Officer are jointly responsible for managing cybersecurity risks
and implementing the required policies across the Company. Our Chief Executive Officer is responsible for making
strategic decisions and approving external communication releases related to cybersecurity risks or incidents.
ITEM 2. PROPERTIES.
Our corporate headquarters are located at 545 Fifth Ave, Suite 1400, New York, NY 10017 where we lease office
space pursuant to a lease agreement that commenced on October 31, 2019 and expires on October 31, 2024. We also
occupy space for offices in Englewood Cliffs, New Jersey pursuant to a lease which commenced on November 1, 2020 for
a three year period and subsequently renewed through 2026. We believe that our existing facilities are suitable and
adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and
we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of
our operations.
ITEM 3. LEGAL PROCEEDINGS.
We are not a party to any material legal proceedings, and we are not aware of any material claims or actions
pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims
arising from our ordinary course of business, the resolution of which we do not anticipate would have a material adverse
impact on our financial position, results of operations or cash flows.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES.
Market Information
On May 16, 2019, our common stock began trading on the Nasdaq Global Market under the symbol “APLT.”
Prior to that time, there was no public market for our common stock.
Stockholders
As of December 31, 2023, there were approximately 26 stockholders of record of our common stock. The actual
number of holders of our common stock is greater than this number of record holders, and includes stockholders who are
beneficial owners, but whose shares are held in street names by brokers or held by other nominees. This number of holders
of record also does not include stockholders whose shares may be held in trust by other entities.
81
Table of Contents
Dividend Policy
We have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any
cash dividends on our common stock in the foreseeable future. We intend to retain all available funds and any future
earnings to fund the development and expansion of our business. Any future determination to pay dividends will be at the
discretion of our board of directors and will depend upon a number of factors, including our results of operations, financial
condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors that our board
of directors deems relevant.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
On October 12, 2023, we entered into an exchange agreement with entities affiliated with Venrock Healthcare
Capital Partners, pursuant to which we exchanged an aggregate of 5,658,034 shares of common stock, owned by the
Exchanging Stockholders for pre-funded warrants to purchase an aggregate of 5,658,034 shares of common stock (subject
to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an
exercise price of $0.001 per share.
ITEM 6. [RESERVED]
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
You should read the following discussion and analysis of our financial condition and results of operations together
with our financial statements and the related notes included elsewhere in this Annual Report. Some of the information
contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to
our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and
uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual
Report, our actual results could differ materially from the results described in or implied by these forward-looking
statements.
Overview
We are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against
validated molecular targets in indications of high unmet medical needs. We focus on molecules and pathways whose role in
the disease process is well known based on prior research, but have previously failed to yield successful products due to
poor efficacy and tolerability. Our unique approach to drug development leverages recent technological advances to design
improved drugs, employs early use of biomarkers to confirm biological activity and focuses on abbreviated regulatory
pathways. Our first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative
stress conditions, and is implicated in multiple diseases. Prior attempts to inhibit this enzyme were hindered by
nonselective, nonspecific inhibition, which resulted in limited efficacy and significant off-target safety effects. The
detrimental consequences of AR activation have been well established by decades of prior research. Our AR program
currently includes three small molecules, which are all potent and selective inhibitors of AR, but are engineered to have
unique tissue permeability profiles to target different disease states, including diabetic complications, heart disease and rare
metabolic diseases. The result of this unique multifaceted approach to drug development is a portfolio of highly specific
and selective product candidates that we believe are significantly de-risked and can move quickly through the development
process.
AT-007 (also called govorestat) is a novel central nervous system, or CNS, penetrant ARI that we are developing
for the treatment of rare metabolic diseases, including Galactosemia and SORD Deficiency. Galactosemia is
82
Table of Contents
a devastating rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose, and for
which there is no known cure or approved treatment available. The U.S. Food and Drug Administration, or FDA, has
granted both orphan drug designation and rare pediatric disease designation to AT-007 for the treatment of Galactosemia
and in June 2021, the FDA granted Fast Track Designation to AT-007 for the treatment of Galactosemia. In clinical studies,
AT-007 significantly reduced plasma galactitol levels in both adults and children with Galactosemia. Galactitol is a toxic
metabolite of galactose, which is formed in Galactosemia patients by aberrant activity of AR when galactose is present at
high levels. In a study in children with Galactosemia ages 2-17, we demonstrated that the galactitol reduction induced by
AT-007 treatment resulted in clinical benefit on activities of daily living, behavioral symptoms, cognition, fine motor skills
and tremor over 18 months of treatment. Change in clinical outcome measures correlated with galactitol level.
We submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the
fourth quarter of 2023, which was subsequently validated and accepted for review in December 2023. A New Drug
Application (NDA) was submitted in December 2023 to the US FDA, and the FDA accepted the filing of the NDA for
govorestat (AT-007) for the treatment of Classic Galactosemia in February of 2024. The NDA was granted Priority Review
status, and the FDA assigned a Prescription Drug User Free Act (PDUFA) target action date of August 28, 2024. The FDA
also noted that it is planning to hold an advisory committee meeting to discuss the application. The NDA and MAA
submission packages include clinical outcomes data from the Phase 3 registrational ACTION-Galactosemia Kids study in
children ages 2-17 with Galactosemia, the Phase 1/2 ACTION-Galactosemia study in adult patients with Galactosemia, and
preclinical data.
AT-007 is also being studied in a rare disease caused by deficiency in the enzyme Sorbitol Dehydrogenase. Aldose
Reductase is the first enzyme in the polyol pathway, converting glucose to sorbitol. AR is then followed by Sorbitol
Dehydrogenase, which converts sorbitol to fructose. Patients with SORD Deficiency accumulate very high levels of
sorbitol in their cells and tissues as a result of the enzyme deficiency, which results in tissue toxicities such as peripheral
neuropathy and motor neuron disease. Recent research in drosophila and cell models of SORD Deficiency demonstrated
that treatment with an ARI that blocks sorbitol production may provide benefit in this disease. Preclinical studies on AT-
007 have demonstrated significant reduction in sorbitol levels in fibroblasts from SORD deficient patients. Treatment with
AT-007 in the drosophila model of SORD prevented the disease phenotype and protected from neuronal degeneration. On
October 25, 2021, we reported data from a pilot open-label study in eight SORD Deficiency patients. AT-007 reduced
blood sorbitol levels by approximately 66% from baseline through 30 days of treatment. AT-007 was safe and well
tolerated in all treated patients. In December 2021, we initiated a Phase 2/3 registrational study in patients with SORD
Deficiency, which is ongoing at multiple clinical sites in the US and Europe. On February 16, 2023, we announced that in a
pre-specified interim analysis of the ongoing Phase 3 INSPIRE trial, AT-007 reduced sorbitol levels by a mean of
approximately 52% (or approximately 16,000ng/ml) over 90 days of treatment (p<0.001 vs. placebo) in patients with
SORD Deficiency. At baseline, the mean blood sorbitol level of SORD patients included in this interim analysis was
approximately 29,000ng/ml, with a range of approximately 22,000ng/ml-38,000ng/ml. On February 15, 2024 we
announced positive interim 12-month results from the ongoing Phase 3 INSPIRE trial, in which the primary endpoints and
several key secondary endpoints were achieved. The interim 12-month analysis demonstrated statistically significant
correlation between sorbitol level and the prespecified CMT-FOM composite clinical endpoint (10-meter walk-run test, 4
stair climb, sit to stand test,6-minute walk test and dorsiflexion) (p=0.05). AT-007 treatment also provided sustained
reduction in sorbitol level in patients with SORD Deficiency over 12 months of treatment, which was statistically
significant compared to placebo (p<0.001). Lastly, AT-007 treatment also resulted in a highly statistically significant effect
(p=0.01) on the CMT Health Index (CMT-HI), an important patient-reported outcome measure of disease severity and
well-being, which was a secondary endpoint in the study. Aspects of the CMT-HI that demonstrated a treatment effect
included lower limb function, mobility, fatigue, pain, sensory function, and upper limb function. AT-007 was safe and well
tolerated, with similar incidence of adverse events between active and placebo-treated groups. We plan to meet with
regulatory agencies to discuss the interim analysis to determine whether an NDA and MAA could be submitted based on
the current data to date.
We also plan to initiate a clinical development program on AT-007 in another pediatric rare disease, called PMM2-
CDG. PMM2-CDG is a glycosylation disorder caused by deficiencies in the enzyme phosphomannomutase 2, which leads
to CNS symptoms similar to Galactosemia, including low IQ, tremor, and speech and motor problems. Aldose Reductase
is over-activated in this disease as a compensatory consequence of PMM2 deficiency, and a CNS
83
Table of Contents
penetrant ARI may be a compelling clinical option. Initial data in fibroblast cell lines derived from PMM2-CDG patients
demonstrates that AT-007 treatment increases phosphomannomutase 2 activity. The FDA has granted pediatric rare disease
designation and orphan designation for AT-007 in PMM2-CDG.
AT-001 (also called caficrestat) is a novel ARI with broad systemic exposure and peripheral nerve permeability
that we are developing for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart, for which no
treatments are available. We completed a Phase 1/2 clinical trial evaluating AT-001 in approximately 120 patients with
type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. In September 2019, we
announced the initiation of a Phase 3 registrational trial of AT-001 in DbCM. The study, called ARISE-HF, was designed to
evaluate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of
progression to overt heart failure. Although we did experience enrollment delays in 2020 associated with the Covid-19
pandemic, modifications were made to the trial to include additional sites and geographies to address Covid-19-related
issues. On January 4, 2024, we reported topline results from the ARISE-HF study. AT-001 (caficrestat) demonstrated a
strong trend in stabilizing cardiac functional capacity, while the placebo group declined over 15 months. The placebo-
treated group declined by a mean of -0.31 ml/kg/min over 15 months of treatment, while the AT-001 1500mg twice daily
treated group remained primarily stable, with a mean change of -0.01 ml/kg/min over 15 months. While a trend favored
active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant
(p=0.210). Approximately 38% of study subjects were on SGLT2 or GLP-1 therapies for treatment of diabetes, while 62%
were not. In a pre-specified subgroup analysis of the primary endpoint in patients not concomitantly treated with SGLT2 or
GLP-1 therapies, the placebo group declined by a mean of -0.54 ml/kg/min, while the 1500mg BID AT-001 treated group
improved by a mean of 0.08 ml/kg/min over 15 months of treatment, with a difference between groups of 0.62 ml/kg/min
(p=0.040). Additionally, in this subgroup analysis, the number of patients who experienced a clinically significant
worsening in cardiac functional capacity of 6% or more was substantially higher in the placebo group (46%) as compared
to the 1500mg BID AT-001 treated group (32.7%), odds ratio 0.56 (p=0.035). A 6% change in cardiac functional capacity
has been shown to predict long-term survival and hospitalization for heart failure. The effect of AT-001 was dose
dependent, with the low dose (1000mg BID) demonstrating an intermediate effect between the high dose and placebo. AT-
001 was generally safe and well tolerated, with no substantial differences in serious adverse events between AT-001 treated
groups as compared to placebo.
As we advance our product candidates forward in additional indications, such as SORD deficiency, PMM2-CDG
and retinopathy, we anticipate potential moderate growth in our clinical development and operations teams to support the
additional clinical trials, as well as addition of a medical affairs team to support the late stage indications and preparations
for commercialization.
AT-003 is a novel ARI designed to cross through the back of the eye when dosed orally, and has demonstrated
strong retinal penetrance, for the treatment of diabetic retinopathy, or DR. DR is an ophthalmic disease that occurs in
diabetic patients and for which treatments are currently limited to high-cost biologics requiring intravitreal administration.
DR has been linked to AR activity, including elevations in sorbitol and subsequent changes in retinal blood vessels, which
distorts vision and leads to permanent blindness.
AT-104 is a preclinical dual selective PI3K inhibitor. Due to recent regulatory changes impacting development of
the PI3K inhibitor class of compounds, the Company has discontinued its early stage preclinical PI3K program and further
development of AT-104. The compound and all rights associated with the technology were returned to Columbia
University.
Since inception in 2016, our operations have focused on developing our product candidates, organizing and
staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting
clinical trials. We do not have any product candidates approved for sale and have not generated any product revenue.
We have incurred significant operating losses since inception in 2016. Our ability to generate product revenue
sufficient to achieve profitability will depend on the successful development and commercialization of one or more of our
product candidates. Our net loss was $119.8 million for the year ended December 31, 2023. As of December 31, 2023, we
had an accumulated deficit of $468.6 million. We expect to continue to incur significant expenses and increasing operating
losses for the foreseeable future in connection with our ongoing activities. Furthermore, we expect
84
Table of Contents
to incur additional costs associated with operating as a public company, including significant legal, accounting, investor
relations and other expenses. As of December 31, 2023, we had cash and cash equivalents of $49.9 million.
June 2022 Offering
On June 27, 2022, we completed an underwritten public offering (the “June 2022 Offering”) of 20,000,000 shares
of common stock, 10,000,000 Pre-Funded Warrants to purchase shares of common stock, and accompanying Common
Warrants to purchase up to 30,000,000 shares of common stock. The shares and accompanying Common Warrants were
offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common
Warrants were offered at a price to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8
million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the
Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not
exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common
stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after
exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to
June 27, 2022 beneficially owned more than 9.99% of our outstanding common stock may not exercise any portion of their
Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than
19.99% of our outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to
adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or
similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s
stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common
Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the
holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to
such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or
any of the other rights or privileges to which the Company’s stockholders are entitled.
April 2023 Offering
On April 26, 2023, we completed a sale of a total of 9,735,731 shares of common stock, at a purchase price of
$0.946 per share, and 22,000,000 Pre-Funded Warrants to purchase common stock, at a purchase price of $0.945 per Pre-
Funded Warrant, in a private placement (the “April 2023 Private Placement”) to a select group of accredited investors (the
“2023 Purchasers”), pursuant to a Securities Purchase Agreement, dated as of April 23, 2023, by and between us and the
2023 Purchasers. The April 2023 Private Placement resulted in net proceeds to us of approximately $27.5 million, after
deducting underwriting discounts, commissions and offering expenses. The Pre-Funded Warrants are immediately
exercisable from the date of issuance and do not have an expiration date. They have an exercise price of $0.001. Holders
may not exercise any Pre-Funded Warrants that would cause the aggregate number of shares of common stock beneficially
owned by the holder to exceed 9.99% of our outstanding common stock immediately after exercise. The Pre-Funded
Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock
combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no
consideration of assets to our stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded
Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or
other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such
transaction. The Pre-Funded Warrants do not entitle the holders thereof to any voting rights or any of the other rights or
privileges to which holders of common stock are entitled.
Leerink ATM Agreement
On August 11, 2023, we entered into the Leerink ATM Agreement with Leerink Partners LLC, pursuant to which
we may offer and sell, from time to time, shares of common stock having an aggregate offering price of up to $75.0 million
through Leerink Partners LLC as sales agent. Under the Leerink ATM Agreement, the sales agent may sell shares of
common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) of
the Securities Act of 1933, as amended. We will pay the sales agent a commission rate of up to 3% of the
85
Table of Contents
gross offering proceeds of any shares sold and has agreed to provide the sales agent with indemnification and contribution
against certain liabilities. The Leerink ATM Agreement contains customary representations and warranties.
As of December 31, 2023, we had sold an aggregate of 17,615,976 shares of our common stock, pursuant to the
Leerink ATM Agreement with an average sale price of $2.04 per share, resulting in net proceeds of $36.9 million, after
deducting underwriting discounts, commissions and offering expenses.
On January 31, 2024, the Company sold an additional 1,000,000 shares of the company’s common stock pursuant
to the Leerink ATM Agreement with an average sale price of $3.13 per share, resulting in net proceeds of $3.0 million,
after deducting underwriting discounts, commissions and offering expenses.
On February 16, 2024, the Company sold an additional 2,000,000 shares of the company’s common stock
pursuant to the Leerink ATM Agreement with an average sale price of $4.90 per share, resulting in net proceeds of $9.5
million, after deducting underwriting discounts, commissions and offering expenses.
Venrock Warrant Exchange
On October 12, 2023, we entered into an exchange agreement with entities affiliated with Venrock Healthcare
Capital Partners, pursuant to which we exchanged an aggregate of 5,658,034 shares of common stock, owned by the
Exchanging Stockholders for pre-funded warrants to purchase an aggregate of 5,658,034 shares of common stock (subject
to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock), with an
exercise price of $0.001 per share.
March 2024 Private Placement
On March 1, 2024, the Company completed its sale of a total of 12,285,714 common shares, at a purchase price of
$7.00 per share, and 2,000,000 Pre-Funded Warrants at a purchase price of $6.999 per Pre-Funded Warrant, in a private
placement to a select group of purchasers (the “2024 Purchasers”) pursuant to a Securities Purchase Agreement (the
“Securities Purchase Agreement”) (the transaction, the “March 2024 Private Placement”). The March 2024 Private
Placement resulted in gross proceeds to the Company of approximately $100 million, before deducting placement agent
commissions and other offering expenses.
The Pre-Funded Warrants are immediately exercisable from the date of issuance and do not have an expiration
date. They have an exercise price of $0.001. Holders may not exercise any Pre-Funded Warrants that would cause the
aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s
outstanding common stock immediately after exercise. The Pre-Funded Warrants are subject to adjustment in the event of
certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the
common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of
certain corporate transactions, the holders of the Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-
Funded Warrants, the kind and amount of securities, cash or other property that the holders would have received had they
exercised the Pre-Funded Warrants immediately prior to such transaction. The Pre-Funded Warrants do not entitle the
holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are entitled.
The securities issued have the benefit of the Registration Rights Agreement (the “Registration Rights
Agreement”), dated as of February 27, 2024, by and among the Company and the 2024 Purchasers, requiring the Company
to prepare and file a registration statement with the SEC as soon as reasonably practicable, but in no event later March 28,
2024 (the “Filing Deadline”), and to use commercially reasonable efforts to have the registration statement declared
effective within 30 days of the Filing Deadline, subject to extension under the terms of the Registration Rights Agreement.
The Company intends to use the net proceeds to fund research and development and registration of its pipeline candidates,
and for working capital and general corporate purposes.
86
Table of Contents
Components of Our Results of Operations
Revenue
Since inception, we have not generated any product revenue and do not expect to generate any revenue from the
sale of products in the near future. We have generated revenue solely from licensing of intellectual property and sale of
research and development services. If our development efforts for our product candidates are successful and result in
regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in
the future from a combination of product sales or payments from collaboration or license agreements.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our
discovery efforts and the development of our product candidates, and include:
● employee-related expenses, including salaries, related benefits and stock-based compensation expense for
employees engaged in research and development functions;
● fees paid to consultants for services directly related to our product development and regulatory efforts;
● expenses incurred under agreements with contract research organizations, or CROs, as well as contract
manufacturing organizations, or CMOs, and consultants that conduct and provide supplies for our preclinical
studies and clinical trials;
● costs associated with preclinical activities and development activities;
● costs associated with our technology and our intellectual property portfolio; and
● costs related to compliance with regulatory requirements.
We expense research and development costs as incurred. Costs for external development activities are recognized
based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors.
Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of
costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses.
Research and development costs also include costs incurred in connection with certain licensing arrangements.
Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties
under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are
recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we will record
any milestone payments in Identifiable intangible assets, commence amortization and, unless the asset is determined to
have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the
expected product life cycle, whichever is shorter.
Research and development activities are central to our business model. We expect that our research and
development expenses will continue to increase for the foreseeable future as we continue clinical development for our
product candidates and continue to discover and develop additional product candidates. If any of our product candidates
enter into later stages of clinical development, they will generally have higher development costs than those in earlier
stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Historically, we
have incurred research and development expenses that primarily relate to the development of AT-007, AT-001 and
87
Table of Contents
our ARI program. As we advance our product candidates, we expect to allocate our direct external research and
development costs across each of the indications or product candidates.
The following table summarizes our research and development expenses for the years ended December 31, 2023
and 2022:
(in thousands)
Product pipeline research and development expenses
AT-001
AT-007
Personnel-related expenses
Stock-based compensation
Other expenses
Total research and development expenses
General and Administrative Expenses
Year Ended
December 31,
2023
2022
$
$
19,540
24,319
6,387
3,005
654
53,905
$
$
20,809
23,902
6,648
3,618
657
55,634
General and administrative expenses consist primarily of salaries and other related costs, including stock-based
compensation, for personnel in our executive, finance, and commercial functions. General and administrative expenses also
include professional fees for legal, accounting, auditing, tax and consulting services; travel expenses; and facility-related
expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs.
Commercial expenses consist of payroll expense for commercial personnel, as well as marketing, market research,
market access, and other focused investments to support launch of drug candidates, and generate evidence of commercial
potential and value proposition. Commercial expenses are included in general and administrative expenses.
We expect that our general and administrative expenses will increase in the future as we increase our general and
administrative headcount to support our continued research and development and potential commercialization of our
product candidates. We also expect to incur increased expenses associated with being a public company, including costs of
accounting, audit, legal, regulatory and tax compliance services; director and officer insurance costs; and investor and
public relations costs.
Other Income (Expense), Net
Other income (expense), net consists of interest income (expense), net, other income (expense), net and changes in
fair value of warrant liabilities. Interest income (expense), net consists primarily of our interest income on our cash and
cash equivalents and marketable securities. Other income (expense), net consists primarily of realized gains and losses on
sales of marketable securities. Changes in fair value of warrant liabilities consists of mark to market changes on our
common warrants that are classified as liabilities.
88
Table of Contents
Results of Operations
The following table summarizes our results of operations:
(in thousands)
REVENUE:
License revenue
Research and development services revenue
Total revenue
COSTS AND EXPENSES:
Research and development
General and administrative
Total costs and expenses
LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE), NET:
Interest income
Change in fair value of warrant liabilities
Other expense
Total other income (expense), net
Net loss
Year Ended
December 31,
2023
2022
$
$
9,219
774
9,993
—
—
—
53,905
20,623
74,528
(64,535)
55,634
27,316
82,950
(82,950)
1,372
(56,573)
(27)
(55,228)
685
(66)
(177)
442
$ (119,763) $ (82,508)
Research and Development Expenses
The following table summarizes our research and development expenses:
(in thousands)
Clinical and pre-clinical
Drug manufacturing and formulation
Personnel expenses
Stock-based compensation
Regulatory and other expenses
Total research and development expenses
Year Ended
December 31,
2023
$ 39,841
2,429
6,283
3,005
2,347
$ 53,905
2022
$ 42,928
957
6,648
3,619
1,482
$ 55,634
$
Increase/(Decrease)
(3,087)
1,472
(365)
(614)
865
(1,729)
$
Research and development expenses for the year ended December 31, 2023, were $53.9 million, compared to
$55.6 million for the year ended December 31, 2022. The decrease of approximately $1.7 million was primarily related to:
● a decrease in clinical and pre-clinical expense of $3.1 million, primarily due to decreased expense
related to CROs;
● an increase in drug manufacturing and formulation costs of $1.5 million primarily related to purchases
of raw materials, offset by the release of legacy accruals;
● a decrease in personnel expenses of $0.4 million related to a decrease in headcount;
● a decrease in stock-based compensation of $0.6 million related to a decrease in headcount, which
resulted in forfeitures of stock options and restricted stock units; and
● an increase in regulatory and other expenses of $0.9 million primarily related to an overall increase in
consulting fees.
89
Table of Contents
General and Administrative Expenses
The following table summarizes our general and administrative expenses:
(in thousands)
Legal and professional fees
Commercial expenses
Personnel expenses
Stock-based compensation
Insurance expenses
Other expenses
Total general and administrative expenses
Year Ended
December 31,
2023
$ 6,780
123
3,714
4,355
2,274
3,377
$ 20,623
2022
$ 6,854
2,193
5,537
5,543
3,682
3,507
$ 27,316
$
Increase/(Decrease)
(74)
(2,070)
(1,823)
(1,188)
(1,408)
(130)
(6,693)
$
General and administrative expenses were $20.6 million for the year ended December 31, 2023, compared to
$27.3 million for the year ended December 31, 2022. The decrease of approximately $6.7 million was primarily related to:
● a decrease in commercial expenses of $2.1 million related to decreased spend relating to commercial
operations;
● a decrease in personnel expenses of $1.8 million related to a decrease in headcount;
● a decrease in stock-based compensation of $1.2 million related to a decrease in headcount, which
resulted in options and restricted stock units being forfeited during the current period;
● a decrease in insurance expenses of $1.4 million related to decreased director and officers’ liability
insurance costs; and
● a decrease in other expenses of $0.1 million.
Interest Income
Interest income was $1.4 million for the year ended December 31, 2023, as compared to $0.7 million for the year
ended December 31, 2022. The overall increase was related to a combination of an increase in average cash balance and an
increase in interest rates during 2023.
Change in Fair Value of Warrant Liabilities
Change in the fair value of warrant liabilities was $56.6 million for the year ended December 31,2023, as
compared to $0.1 million for the year ended December 31, 2022. The increase in the fair value of warrant liabilities is
primarily related to changes in our common share price throughout 2023.
Other Expense
Other expense was a $27,000 loss for the year ended December 31, 2023, compared to $0.2 million for the year
ended December 31, 2022. The decrease in other expense related to the gains recognized on the sale of all marketable
securities during the year ended December 31, 2023.
90
Table of Contents
Liquidity and Capital Resources
Since our inception and through December 31, 2023, we have not generated any revenue and have incurred
significant operating losses and negative cash flows from our operations. The exclusive licensing agreement with Advanz
Pharma for commercialization rights to AT-007 in Europe is expected to provide a source of capital to the Company based
on clinical and regulatory milestones. If actualization of these milestones aligns with the projected timelines, and product
approvals are received in the timeframes expected, this source of capital may be sufficient to cover operating expenses
through expected product approvals. However, there are no guarantees that this will materialize, and delays or unexpected
data could disrupt this potential source of liquidity. Broadly, we have not yet established an ongoing source of product
revenue sufficient to cover our operating costs and we are dependent on debt and equity financing to fund our operations.
As of December 31, 2023, our cash, cash equivalents were $49.9 million. Additionally, in January and February 2024, we
issued additional shares under the Leerink ATM Agreement that resulted in net proceeds of $12.5 million, after deducting
placement agent commissions and other offering expenses, and $4.0 million from the exercise of our common warrants. On
March 1, 2024, we completed our March 2024 Private Placement which resulted in gross proceeds of $100.0 million,
before deducting placement agent commissions and other offering expenses. We believe that our cash and cash equivalents
as of December 31, 2023, along with proceeds from the ATM, exercise from our Common Warrants in January and
February 2024, the completion of the March 2024 Private Placement and with the projected clinical and regulatory
milestone payments expected in fiscal year 2024 from Advanz Pharma will be sufficient to fund our operations into 2026,
and potentially beyond if clinical trial completion and marketing authorization in Europe as well as commercial sales
milestones materialize in the expected timelines. Additionally, the Priority Review Voucher (PRV), which would be granted
upon a potential Galactosemia NDA approval could substantially extend our cash runway.
Cash Flows
The following table summarizes our cash flows for each of the periods presented:
(in thousands)
Net cash used in operating activities
Net cash provided by investing activities
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Operating Activities
Year Ended
December 31,
2023
2022
$ (55,173) $ (78,093)
13,170
27,692
$ (37,231)
13,872
74,542
$ 33,241
During the year ended December 31, 2023, operating activities used cash of $55.2 million, due to our net losses of
$119.8 million, a decrease in operating lease liability of $0.4 million, a decrease in financed insurance premium of $1.5
million, and a decrease of $2.8 million in accounts payable. This is partially offset by an increase of $1.9 million in prepaid
expense, an increase of $0.7 million in accrued expenses and other liabilities, $7.4 million in non-cash stock-based
compensation expense, $2.1 million of amortization of insurance premium, $56.6 million in changes in fair value of our
warrant liabilities, $0.4 million in amortization of operating lease right-of-use assets, and an increase of $0.3 million of
other liabilities.
During the year ended December 31, 2022, operating activities used cash of $78.1 million, due to our net losses of
$82.5 million, a decrease in operating lease liability of $0.4 million, a decrease in financed insurance premium of $3.1
million, a decrease of $1.6 million in accrued expense, and a decrease in accounts payable of $4.9 million. This is partially
offset by increases of $0.4 million in prepaid expense, $0.4 million of issuance of options in-lieu of bonus, $9.2 million in
non-cash stock-based compensation expense, and $3.6 million of amortization of insurance premium, an increase of $0.1
million in change in fair value of warrant liability, and $0.4 million in amortization of operating lease right-of-use assets.
91
Table of Contents
Investing Activities
Net cash provided by investing activities for the year ended December 31, 2023, was $13.9 million relating to the
proceeds from the sale of available-for-sale securities of $4.9 million and maturities of available-for-sale securities of $8.9
million.
Net cash provided by investing activities for the year ended December 31, 2022, was $13.2 million relating to our
purchases of available-for-sale marketable securities for $64.2 million and proceeds from the maturities of available-for-
sale marketable securities for $77.4 million.
Financing Activities
During the year ended December 31, 2023, net cash provided by financing activities was $74.5 million, primarily
from proceeds from the issuance of shares and pre-funded warrants of $64.5 million, $10.3 million from the exercise of
common warrants, proceeds from financed insurance premium of $1.5 million, $0.1 million from exercise of stock options
for common stock under the equity incentive plan, partially offset by repayment of short-term borrowings of $1.9 million.
During the year ended December 31, 2022, net cash provided by financing activities was $27.7 million, primarily
from the cash proceeds from the June 2022 offering of $27.8 million, $49,000 from the exercise of stock options for
common stock under the 2019 Plan, and $3.1 million from the proceeds from financed insurance premium. This was
partially offset by the repayment of short-term borrowings of $3.3 million.
Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we
advance the preclinical activities and clinical trials of our product candidates. We believe that our expenses may increase
significantly if and as we:
● continue the ongoing and planned development of our product candidates;
● initiate, conduct and complete any ongoing, anticipated or future preclinical studies and clinical trials for our
current and future product candidates;
● seek marketing approvals for any product candidates that successfully complete clinical trials;
● establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any current or
future product candidate for which we may obtain marketing approval;
● seek to discover and develop additional product candidates;
● continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product
candidates or technologies;
● maintain, protect and expand our intellectual property portfolio;
● hire additional clinical, regulatory and scientific personnel; and
● add operational, financial and management information systems and personnel, including personnel to
support our product development and planned future commercialization efforts.
Furthermore, we have and expect to incur additional costs associated with operating as a public company,
including significant legal, accounting, investor relations and other expenses.
Due to the numerous risks and uncertainties associated with the development of our product candidates and
programs, and because the extent to which we may enter into collaborations with third parties for development of our
product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and
92
Table of Contents
operating expenses associated with completing the research and development of our product candidates. Our future funding
requirements, both near and long-term, will depend on many factors, including:
● the initiation, scope, progress, timing, costs and results of our ongoing and planned clinical trials for our
product candidates;
● the outcome, timing and cost of meeting regulatory requirements established by the FDA and other
comparable foreign regulatory authorities;
● the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property
rights;
● the cost of defending potential intellectual property disputes, including patent infringement actions;
● the achievement of milestones or occurrence of other developments that trigger payments under the
Columbia Agreements or other agreements we may enter into;
● the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under
future collaboration agreements, if any;
● the effect of competing technological and market developments;
● the cost and timing of completion of clinical or commercial-scale manufacturing activities;
● the costs of operating as a public company;
● the extent to which we in-license or acquire other products and technologies;
● our ability to establish and maintain collaborations on favorable terms, if at all;
● the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions
where we choose to commercialize our product candidates, if approved; and
● the initiation, progress, timing and results of the commercialization our product candidates, if approved, for
commercial sale.
A change in the outcome of any of these variables with respect to the development of a product candidate could
mean a significant change in the costs and timing associated with the development of that product candidate.
Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to
finance our cash needs through offerings of securities, PIPE, debt financings, collaborations or other strategic transactions.
The terms of financing may adversely affect the holdings or the rights of our stockholders. Funding may not be available to
us on acceptable terms, or at all. If we are unable to obtain funding, we may be required to delay, limit, reduce or terminate
some or all of our research and product development, product portfolio expansion or future commercialization efforts. If
we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of financial condition and results of operations is based on our
financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S.
GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions
that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and
liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various
other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate
our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different
assumptions or conditions.
While our significant accounting policies are described in greater detail in Note 1 to our financial statements
appearing elsewhere in this Annual Report, we believe that the following accounting policies are those most critical to the
judgments and estimates used in the preparation of our financial statements.
93
Table of Contents
Revenue Recognition
Under ASU 2014-09, Revenue from Contracts with Customers (Topic 606), or ASC 606, as amended by ASU
2016-08, 2016-10, 2016-12 and 2016-20, we recognize revenue in an amount that reflects the consideration to which we
expect to be entitled in exchange for the transfer of promised goods or services to customers. To determine revenue
recognition for contracts with customers that are within the scope of ASC 606, the Company performs the following steps:
(1) identifies the contract with the customer, (2) identifies the performance obligations in the contract, (3) determines the
transaction price, (4) allocates the transaction price to the performance obligations in the contract, and (5) recognizes
revenue when (or as) the entity satisfies a performance obligation.
We have entered into an agreement (Advanz Agreement) to license our intellectual property, or IP, related to
Galactosemia and SORD to develop, manufacture and/or commercialize drug products with Mercury Pharma Group
Limited, trading as Advanz Pharma Holdings, (“Advanz Pharma”). The agreement contains multiple performance
obligations, including licenses of IP, research and development services, and the manufacturing and supply material right.
Payments to us under this agreement may include nonrefundable fees, payments for research activities, payments based
upon the achievement of certain milestones and royalties on any resulting net product sales.
The transaction price is the amount of consideration that we expect to be entitled to in exchange for transferring
promised goods or services to the customer based on the contract terms at inception of a contract. We estimate an amount
of variable consideration, if any, by using either the expected value or the most likely amount method depending on which
method we expect to better predict the amount of consideration to which we will be entitled, and only to the extent that it is
probable that that a significant reversal in the amount of cumulative revenue recognized will not occur in the future when
the uncertainty is resolved. The determination of whether it is probable that a significant reversal of revenue will occur in
the future depends on the likelihood and magnitude of the reversal. Factors that could increase the likelihood or magnitude
of a reversal of revenue include (a) the susceptibility of the amount of consideration to factors outside the entity’s
influence, such as the outcome of clinical trials, the timing of initiation of clinical trials by the counterparty and the
approval of drug product candidates by regulatory agencies, (b) situations in which the uncertainty is not expected to be
resolved for a long period of time, and (c) the level of the Company’s predictive experience in the field with similar types
of contracts. At the end of each reporting period, we will update the estimated transaction price and allocate the updated
consideration to the separate performance obligations in the same manner as described below.
At inception of a contract, we allocate the transaction price to the distinct performance obligations based upon
their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a promised good
or service separately to a customer. The best evidence of standalone selling price is an observable price of a good or service
when sold separately by an entity in similar circumstances to similar customers. Since we typically do not have such
evidence, we estimate standalone selling price so that the amount that is allocated to each performance obligation equals
the amount that we expect to receive for transferring the promised goods or services. The methods that the Company uses
to make such estimates include (1) the adjusted market assessment approach, under which we forecast and analyze
Galactosemia and SORD sales in the appropriate market, the phase of clinical development as well as considering recent
similar license arrangements within the same phase of clinical development, therapeutic area, type of agreement, etc. and
(2) the expected cost of satisfying the performance obligations plus a margin, or the expected cost plus a margin approach.
We recognize revenue when, or as, we satisfy a performance obligation by transferring a promised good or service
to a customer and the customer obtains control of the good or service. Revenue related to the grant of a license of
functional IP that is distinct from the other promised goods or services in the contract and therefore represents a
performance obligation is recognized at the point in time that we have the right to payment for the license, the customer has
legal title to the license and can direct the use of the license (for example, to grant sublicenses) to benefit from its right to
use the intellectual property, the customer has the significant risks and rewards of ownership of the license and the
customer has accepted the asset (license) by signing the license agreement.
Recognition of revenue related to research and development services that are a distinct performance obligation is
deferred at inception of a contract and is recognized as the services are performed to satisfy the performance obligation
based on the costs incurred as a percentage of the estimated total costs to be incurred to satisfy the
94
Table of Contents
performance obligation. The Advanz Agreement requires that Advanz Pharma receive regular updates and data on any
research and development services as the services are performed. In accordance with ASC 606-10-25-27, we determined
that Advanz Pharma simultaneously benefits from the research and development services that are satisfied over time. We
believe this method most faithfully depicts performance in transferring the promised services while research and
development services are ongoing.
Accrued Research and Development Expenses
We expense all costs incurred in performing research and development activities. Research and development
expenses include materials and supplies, preclinical expenses, manufacturing expenses, contract services and other outside
expenses. As part of the process of preparing our financial statements, we are required to estimate our accrued research and
development expenses. We make estimates of our accrued expenses as of each balance sheet date in the financial
statements based on facts and circumstances known to us at that time. There may be instances in which payments made to
our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees,
we estimate the time period over which services will be performed and the level of effort to be expended in each period. If
the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the
amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts
actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.
To date, there have not been any material adjustments to our prior estimates of accrued research and development
expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and
development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are
delivered or the services are performed.
Research and development costs also include costs incurred in connection with certain licensing arrangements.
Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties
under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are
recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we will record
any milestone payments in Identifiable intangible assets, less accumulated amortization and, unless the asset is determined
to have an indefinite life, we will amortize the payments on a straight-line basis over the remaining agreement term or the
expected product life cycle, whichever is shorter.
Warrant Liabilities
We account for our common warrant liabilities by measuring the fair value at inception and are then subsequently
measured on a recurring basis, with changes in fair value recognized in other income (expense) within our statement of
operations.
We utilized a Black-Scholes option pricing model to estimate the fair value of our warrant liabilities, which
utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement. Certain inputs used in
this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of our control,
including a potential change in control. A significant change in one or more of these inputs used in the calculation of the
fair value may cause a significant change to the fair value of our warrant liabilities, which could also result in material non-
cash gains or losses being reported in the Company’s statement of operations.
The inputs we utilized to value our warrant liabilities are highly subjective. The assumptions used in calculating
the fair value of our warrant liabilities represent our best estimates, but these estimates involve inherent uncertainties and
the application of management judgment. As a result, if factors change and we use different assumptions, the fair value of
the warrant liabilities may be materially different in the future.
95
Table of Contents
Stock-Based Compensation
We account for our stock-based compensation as expense in the statements of operations based on the awards’
grant date fair values. We account for forfeitures as they occur by reversing any expense recognized for unvested awards.
Stock-Based Compensation–Stock Options
We estimate the fair value of options granted using the Black-Scholes option pricing model. The Black-Scholes
option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price
volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends. Due to
a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the
historical volatility of a group of similar companies that are publicly traded. The historical volatility is calculated based on
a period of time commensurate with the expected term assumption. The computation of expected volatility is based on the
historical volatility of a representative group of companies with similar characteristics to us, including stage of product
development and life science industry focus. We use the simplified method as allowed by the SEC Staff Accounting
Bulletin No.107, Share-Based Payment, to calculate the expected term for options granted as we do not have sufficient
historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is
based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend
yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our
common stock. The fair value of stock-based payments is recognized as expense over the requisite service period which is
generally the vesting period.
Stock-Based Compensation–Restricted Stock Units
We account for restricted stock units in accordance with the authoritative guidance for stock-based compensation.
The fair value of restricted stock units is measured at the grant date based on the closing market price of our common stock
on the date of grant and is recognized as expense on a straight-line basis over the period of vesting. Forfeitures are
recognized as a reduction of stock-based compensation expense as they occur.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest
entities.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position
and results of operations is disclosed in Note 1 to our financial statements appearing elsewhere in this Annual Report.
Emerging Growth Company Status
The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take
advantage of an extended transition period to comply with new or revised accounting standards applicable to public
companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of
this provision and, as a result, we will comply with new or revised accounting standards when they are required to be
adopted by public companies that are not emerging growth companies.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate
sensitivities and foreign currency sensitivities.
96
Table of Contents
Interest Rate Sensitivity
Our exposure to market risk relates to our cash and cash equivalents of $49.9 million as of December 31, 2023.
The primary objective of our investment activities is to preserve principal while at the same time maximizing the income
we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to
market risk where the interest rates may cause the value of the instruments to fluctuate. To minimize this risk, we intend to
maintain a portfolio which may include cash, cash equivalents and short-term investment securities available-for-sale in a
variety of securities.
We do not believe that our cash has significant risk of default or illiquidity. While we believe our cash and cash
equivalents does not contain excessive risk, we cannot provide absolute assurance that in the future our investments will
not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash at one or more
financial institutions that are in excess of federally insured limits. Inflation generally affects us by increasing our cost of
labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during
the periods presented.
As of December 31, 2023, we had $0.3 million of outstanding short-term debt relating to our financed directors’
and officers’ insurance premium. The interest rate on this short-term loan is fixed at 5.39% per annum, and when
considering the remaining outstanding balance and the remaining term of the agreement ending in the second quarter of
2024, we do not believe that the loan is subject to material interest rate risk.
Foreign Currency Sensitivity
Our primary operations are transacted in U.S. Dollars, however, certain service agreements with third parties are
denominated in currencies other than the U.S. Dollar, primarily the Euro. As such, we are subject to foreign exchange risk
and therefore, fluctuations in the value of the U.S. Dollar against the Euro may impact the amounts reported for expenses
and obligations incurred under such agreements. We do not participate in any foreign currency hedging activities and we do
not have any other derivative financial instruments. We did not recognize any significant exchange rate loss during the year
ended December 31, 2023. A hypothetical 10% change in foreign exchange rates during any of the periods presented
would not have a material impact on our financial condition or results of operations.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The information required by this item is set forth in the financial statements filed with this report and are herein
and incorporated by reference.
97
Table of Contents
Report of Independent Registered Public Accounting Firm
The Stockholders and the Board of Directors of Applied Therapeutics, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Applied Therapeutics, Inc. (the Company) as of December
31, 2023 and 2022, the related statements of operations, comprehensive loss, stockholders’ equity (deficit) and cash flows
for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the
“financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two
years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express
an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the
Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to
the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an
audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining,
on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall
presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2017.
New York, New York
March 6, 2024
F-1
Table of Contents
Applied Therapeutics, Inc.
Balance Sheets
(in thousands except share and per share data)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Investments
Current portion of security deposits and leasehold improvements
Prepaid expenses and other current assets
Total current assets
Noncurrent portion of security deposits and leasehold improvements
Operating lease right-of-use asset
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)/EQUITY
CURRENT LIABILITIES:
Current portion of operating lease liabilities
Accounts payable
Accrued expenses and other current liabilities
Warrant liabilities
Total current liabilities
NONCURRENT LIABILITIES:
Noncurrent portion of operating lease liabilities
Clinical holdback - long-term portion
Total noncurrent liabilities
Total liabilities
STOCKHOLDERS’ (DEFICIT)/EQUITY:
Common stock, $0.0001 par value; 200,000,000 shares authorized as of
December 31, 2023 and December 31, 2022; 84,869,832 shares issued and outstanding as
of December 31, 2023 and 48,063,358 shares issued and outstanding as of
December 31, 2022
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of
December 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of
December 31, 2023 and December 31, 2022
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders' (deficit)/equity
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)/EQUITY
As of
December 31,
2023
As of
December 31,
2022
$
$
$
$
$
$
49,898
—
254
4,234
54,386
—
447
54,833
429
1,742
15,286
53,725
71,182
38
759
797
71,979
16,657
13,923
57
6,671
37,308
198
857
38,363
477
4,534
14,756
13,657
33,424
414
464
878
34,302
8
5
—
451,432
—
(468,586)
(17,146)
54,833
$
—
352,828
51
(348,823)
4,061
38,363
$
The Notes to Financial Statements are an integral part of these statements.
F-2
Table of Contents
Applied Therapeutics, Inc.
Statements of Operations
(in thousands except share and per share data)
REVENUE:
License revenue
Research and development services revenue
Total revenue
COSTS AND EXPENSES:
Research and development
General and administrative
Total costs and expenses
LOSS FROM OPERATIONS
OTHER INCOME (EXPENSE), NET:
Interest income
Change in fair value of warrant liabilities
Other expense
Total other income (expense), net
Net loss
Net loss per share attributable to common stockholders—basic and diluted
Weighted-average common stock outstanding—basic and diluted
Year Ended
December 31,
2023
2022
$
$
9,219
774
9,993
—
—
—
53,905
20,623
74,528
(64,535)
55,634
27,316
82,950
(82,950)
1,372
(56,573)
(27)
(55,228)
(119,763) $
(1.42) $
$
$
84,244,494
685
(66)
(177)
442
(82,508)
(2.18)
37,825,431
The Notes to Financial Statements are an integral part of these statements.
F-3
Table of Contents
Applied Therapeutics, Inc.
Statements of Comprehensive Loss
(in thousands)
Net Loss
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities
Other comprehensive gain (loss), net of tax
Comprehensive loss, net of tax
Year Ended
December 31,
2023
$ (119,763)
2022
$ (82,508)
(51)
(51)
$ (119,814)
158
158
$ (82,350)
The Notes to Financial Statements are an integral part of these statements.
F-4
Table of Contents
Applied Therapeutics, Inc.
Statements of Stockholders’ Equity (Deficit)
(in thousands, except share and per share data)
BALANCE, December 31, 2021
Issuance of common stock, pre-funded warrants,
and common warrants sold for cash, net of
issuance costs of $96
Exercise of pre-funded warrants
Exercise of stock options
Restricted Stock Units released for common
issued under Equity Incentive Plan
Stock-based compensation expense
Issuance of options in-lieu of bonus
Net loss
Other comprehensive income (loss)
BALANCE, December 31, 2022
Exchange of common stock for prefunded
warrants
Issuance of common stock, prefunded warrants
and reissuance of treasury stock, net of issuance
costs of $4.0 million
Exercise of common warrants
Exercise of pre-funded warrants
Exercise of stock options
Restricted stock units released for common issued
under Equity Incentive Plan
Stock-based compensation expense
Net loss
Other comprehensive income (loss)
BALANCE, December 31, 2023
Common Stock
Shares
26,215,514
Amount
3
$
Treasury Stock
Shares
Amount
Additional
Paid-in
Capital
Accumulated Other
Accumulated
Deficit
Comprehensive
Income (Loss)
Total
Stockholders’
Equity
— $
— $
328,958
$
(266,315)
$
(107)
$
62,539
20,000,000
1,750,000
47,602
50,242
—
—
—
—
48,063,358
—
21,693,673
10,250,000
4,250,000
85,619
527,182
—
—
—
84,869,832
$
2
—
—
—
—
—
—
—
5
—
2
1
—
—
—
—
—
—
8
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
12,801
1,417
49
—
9,162
441
—
—
352,828
5,658,034
(12,900)
12,900
(5,658,034)
—
—
—
12,900
—
—
—
—
—
—
— $
—
—
—
—
— $
51,500
26,754
—
90
—
7,360
—
—
451,432
—
—
—
—
—
—
(82,508)
—
(348,823)
—
—
—
—
—
—
—
—
—
—
—
—
158
51
—
—
—
—
—
12,803
1,417
49
—
9,162
441
(82,508)
158
4,061
—
64,402
26,755
—
90
—
—
(119,763)
—
(468,586)
$
$
—
—
—
(51)
— $
—
7,360
(119,763)
(51)
(17,146)
The Notes to Financial Statements are an integral part of these statements.
F-5
Table of Contents
Applied Therapeutics, Inc.
Statements of Cash Flows
(in thousands)
OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Amortization of insurance premium
Amortization of operating lease right-of-use assets
Amortization of leasehold improvements
Change in operating lease liability
Change in fair value of warrant liabilities
Changes in operating assets and liabilities:
Financed insurance premium
Prepaid expenses
Accounts payable
Accrued expenses and other current liabilities
Other liabilities
Net cash used in operating activities
INVESTING ACTIVITIES:
Purchase of available-for-sale securities
Proceeds from sale of available-for-sale securities
Proceeds from maturities of available-for-sale securities
Net cash provided by investing activities
FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and reissuance of treasury stock, net of
issuance costs
Proceeds from financed insurance premium
Repayments of short-term borrowings
Exercise of stock options for common stock under Equity Incentive Plan
Exercise of Warrants
Net cash provided by financing activities
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Operating lease right-of-use asset obtained in exchange for operating lease liabilities
Offering costs in accrued expenses
Conversion of warrant liabilities to equity for warrant exercises
Unrealized gain (loss) on marketable securities
Reclassification of prefunded warrant liability to equity
$
$
$
$
$
$
The Notes to Financial Statements are an integral part of these statements.
F-6
Year Ended
December 31,
2023
2022
$
(119,763)
$
(82,508)
7,360
2,111
353
1
(367)
56,573
(1,546)
1,872
(2,792)
730
295
(55,173)
—
4,944
8,928
13,872
64,514
1,546
(1,858)
90
10,250
74,542
33,241
16,657
49,898
$
$
(57)
$
112
$
16,505
(51)
$
— $
9,603
3,589
441
2
(442)
66
(3,105)
359
(4,927)
(1,635)
464
(78,093)
(64,218)
—
77,388
13,170
27,811
3,105
(3,273)
49
—
27,692
(37,231)
53,888
16,657
21,835
—
1,417
158
6,827
Table of Contents
NOTES TO AUDITED FINANCIAL STATEMENTS
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Operations and Business
Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline
of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the
Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase
(“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in
Delaware on January 20, 2016 and is headquartered in New York, New York.
Basis of Presentation
The Company’s fiscal year ends on December 31 and its first three quarters end on March 31, June 30 and
September 30. The accompanying financial statements are prepared in conformity with accounting principles generally
accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer
to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates
(“ASU”) of the Financial Accounting Standards Board (“FASB”).
The Company is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012
(the “JOBS Act”). Section 107(b) of the JOBS Act provides that an emerging growth company can take advantage of an
extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company
will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for
other public companies.
Liquidity and Going Concern
Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each
reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial
doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are
issued. As of December 31, 2023, financing through the Company’s April 2023 Private Placement, Leerink ATM
Agreement and warrant exercises has resulted in net proceeds of $74.7 million, after deducting placement agent
commissions and other offering expenses (see Note 8 and Note 9). Additionally, in January and February 2024, the
Company issued additional shares under the Leerink ATM Agreement that resulted in net proceeds of $12.5 million, after
deducting placement agent commissions and other offering expenses (see Note 16), and $4.0 million from the exercise of
common warrants. Further, on March 1, 2024, we completed our March 2024 Private Placement (as defined herein) which
resulted in gross proceeds of approximately $100.0 million, before deducting placement agent commissions and other
offering expenses. The Company continues to actively pursue several potential long-term financing options, including
equity capital, debt, convertible debt, and synthetic royalty financing. Additionally, the Company is in active dialogue with
several potential partners regarding business development opportunities related to one or more of its programs. There can
be no assurances that the Company’s discussions with any of the current counterparties will be successful, and the
Company expects to continue to pursue additional opportunities.
As reflected in the accompanying financial statements, the Company incurred a net loss of $119.8 million for the
year ended December 31, 2023 and has an accumulated deficit of $468.6 million as of December 31, 2023. The exclusive
licensing agreement with Advanz Pharma for commercialization rights to AT-007 in Europe provides a source of capital to
the Company based on clinical and regulatory milestones. The Company received a $10.7 million upfront payment from
Advanz Pharma in January 2023 in conjunction with signing the agreement. If actualization of these milestones aligns with
the projected timelines, and product approvals are received in the timeframes expected, this source of capital may be
sufficient to cover operating expenses through expected product approvals and potential revenues. However, there are no
guarantees that this will materialize timely or at all, and delays or unexpected data
F-7
Table of Contents
could disrupt this potential liquidity. Broadly, the Company has not yet established an ongoing source of revenues
sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. The Company
currently expects that its existing cash and cash equivalents of $49.9 million as of December 31, 2023 and $116.5 million
received from the Leerink ATM, warrant exercises and private placement in January, February and March 2024, will fund
its operating expenses and capital requirements for at least twelve months from the date of these audited financial
statements are issued.
Risks and Uncertainties
The Company is subject to risks common to companies in the biotechnology industry, including but not limited to,
risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that
it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates,
dependence on key personnel, protection of proprietary technology, compliance with government regulations, development
by competitors of technological innovations and reliance on third-party manufacturers.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and
the Company's ability to continue as a going concern as of the date of the financial statements and the reported amounts of
revenue and expenses during the reporting period. In preparing the financial statements, management used estimates in the
following areas, among others: prepaid and accrued expenses; warrant liabilities valuation; license revenue; research and
development services revenue; stock-based compensation expense; the likelihood of realization of deferred tax assets; and
the evaluation of the existence of conditions and events that raise substantial doubt regarding the Company’s ability to
continue as a going concern. Actual results could differ from those estimates.
Significant Accounting Policies
Fair Value Measurements
Certain assets and liabilities are reported on a recurring basis at fair value. Fair value is defined as the exchange
price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation
techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable
inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three
levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs
that are observable or can be corroborated by observable market data.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and
similar techniques.
Cash and Cash Equivalents
The Company considers all short-term, highly liquid investments, with an original maturity of three months or
less, to be cash equivalents. The Company maintains its cash in bank deposit accounts which, at times, may exceed
federally insured limits. The Company has not experienced any losses in these accounts and does not believe it is exposed
to any significant credit risk on cash and cash equivalents.
F-8
Table of Contents
Investments
The Company determines the appropriate classification of its investments at the date of purchase and reevaluates
the classifications at the balance sheet date. Marketable debt securities with maturities of 12 months or less are classified as
short-term. Marketable debt securities with maturities greater than 12 months are classified as long-term. The Company’s
marketable securities are accounted for as available for sale (“AFS”). AFS securities are reported at fair value. Unrealized
gains and losses, after applicable income taxes, are reported in accumulated other comprehensive income/(loss). Realized
gains or losses on the sale of marketable securities are determined using the specific identification method and are recorded
as a component of other income (expense), net.
The Company conducts an other-than-temporary impairment (“OTTI”) analysis on a quarterly basis or more often
if a potential loss-triggering event occurs. The Company considers factors such as the duration, severity and the reason for
the decline in value, the potential recovery period and whether the Company intends to sell. For AFS securities, the
Company also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities
before recovery of their amortized cost basis and (ii) the amortized cost basis cannot be recovered as a result of credit
losses. As of December 31, 2023, the Company did not have an investment portfolio.
Leases
At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on the
unique facts and circumstances present in that arrangement. Lease classification, recognition, and measurement are then
determined at the lease commencement date. For arrangements that contain a lease the Company (i) identifies lease and
non-lease components, (ii) determines the consideration in the contract, (iii) determines whether the lease is an operating or
financing lease; and (iv) recognizes lease right-of-use (“ROU”) assets and liabilities. Lease liabilities and their
corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The
interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental
borrowing rate based on the information available at the lease commencement date, which represents an internally
developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease
payments in a similar economic environment.
Most leases include options to renew and, or, terminate the lease, which can impact the lease term. The exercise of
these options is at the Company’s discretion and the Company does not include any of these options within the expected
lease term as the Company is not reasonably certain it will exercise these options. The Company has elected to combine
lease components (for example fixed payments including rent) with non-lease components (for example, non-dedicated
parking and common-area maintenance costs) on our real estate asset classes.
Fixed, or in substance fixed, lease payments on operating leases are recognized over the expected term of the lease
on a straight-line basis. Fixed lease expense on operating leases is recognized within operating expenses within the
statements of operations. The Company has operating leases for our corporate offices. The Company has elected the short-
term lease exemption and, therefore, do not recognize a ROU asset or corresponding liability for lease arrangements with
an original term of 12 months or less. Leasehold improvements and assets under financing lease arrangements are
amortized over the lesser of the asset’s estimated useful life or the term of the respective lease. Maintenance costs are
expensed as incurred.
Operating leases are included in operating lease right-of-use asset, current portion of operating lease liabilities, and
noncurrent portion of operating lease liabilities in the balance sheet as of December 31, 2023 and 2022.
Clinical hold-back, long-term
As part of the regulatory approval process for taking its products to market, the Company enters into certain
Clinical Trial Agreements (CTAs) which include, among other things, the compensation and payment schedule the
participating medical institutions and physicians will receive for all costs in connection with the clinical trial (or study)
under the terms of the CTA. As individual patients are enrolled in the study by the participating medical institution or
F-9
Table of Contents
physician, the Company pays certain per study fees according to the CTA for the duration of the trial. As invoices are
received by the Company from the medical institution or physician, the Company retains an agreed upon percentage of
total invoiced costs, generally ranging between 5% - 10%, that is withheld from payment until the end of the study.
These retained amounts are recorded as clinical holdback, a liability, on the accompanying balance sheets, and all
expenses incurred in connection with these CTA activities are expensed as services are provided, which are included as
research and development expenses on the accompanying statements of operations.
The following table shows the activity within the clinical holdback liability accounts for the year ended December
31, 2023:
(in thousands)
Balance as of December 31, 2022
Clinical holdback retained
Clinical holdback paid
Balance as of December 31, 2023
Deferred Offering Costs
$
$
464
295
—
759
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated
with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of
the equity financing, these costs are recorded in the statement of stockholders’ (deficit) equity as a reduction of proceeds
generated as a result of the offering. Should a planned equity financing be abandoned, the deferred offering costs would be
expensed immediately as a charge to operating expenses in the statement of operations.
As of December 31, 2023 and 2022, the Company did not have any deferred offering costs recorded.
Warrant Liabilities
The Company accounts for common warrant liabilities by measuring the fair value at inception and subsequently
remeasures on a recurring basis, with changes in fair value recognized in other income (expense) within the Company’s
statement of operations.
The Company utilized a Black-Scholes option pricing model to estimate the fair value of the warrant liabilities,
which utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement. Certain inputs
used in the Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the
Company’s control, including a potential change in control outside of the Company’s control. A significant change in one
or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the
Company’s warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company’s
consolidated statement of operations.
The inputs utilized to value the warrant liabilities are highly subjective. The assumptions used in calculating the fair
value of the warrant liabilities represent the best estimates, but these estimates involve inherent uncertainties and
application of management’s judgment. As a result, if factors change and the Company uses different assumptions, the fair
value of the warrant liabilities may be materially different in the future.
Treasury Stock
The Company records treasury stock activities under the cost method. Treasury stock is included in authorized and
issued shares but excluded from outstanding shares. The re-issuance of treasury stock is accounted for on a first in, first-out
basis and any differences between the cost of treasury stock and the re-issuance proceeds are charged or credited to
additional paid-in capital.
F-10
Table of Contents
Revenue Recognition
Under ASU 2014-09, Revenue from Contracts with Customers (Topic 606), or ASC 606, as amended by ASU
2016-08, 2016-10, 2016-12 and 2016-20, the Company recognizes revenue in an amount that reflects the consideration to
which it expects to be entitled in exchange for the transfer of promised goods or services to customers. To determine
revenue recognition for contracts with customers that are within the scope of ASC 606, the Company performs the
following steps: (1) identifies the contract with the customer, (2) identifies the performance obligations in the contract, (3)
determines the transaction price, (4) allocates the transaction price to the performance obligations in the contract, and (5)
recognizes revenue when (or as) the entity satisfies a performance obligation.
The Company has entered into an agreement to license its intellectual property, or IP, related to Galactosemia and
SORD to develop, manufacture and/or commercialize drug products with Mercury Pharma Group Limited, trading as
Advanz Pharma Holdings, (“Advanz Pharma”). The agreement contains multiple performance obligations, including
licenses of IP, research and development services, and the manufacturing and supply material right. Payments to the
Company under this agreement may include nonrefundable fees, payments for research activities, payments based upon the
achievement of certain milestones and royalties on any resulting net product sales.
The Company identifies agreements as contracts that create enforceable rights and obligations when the
agreement is approved by the parties, the Company can identify the rights of the parties and the payment terms, the
contract has commercial substance and it is probable that the Company will collect substantially all of the consideration to
which it will be entitled in exchange for the goods and services that will be transferred to the customer. The counterparty is
considered to be a customer when it has contracted with the Company to obtain goods and services that are the output of
the Company’s ordinary activities (i.e., development of pharmaceutical products) in exchange for consideration.
A performance obligation is a promise to transfer distinct goods or services to a customer. Performance
obligations that are both capable of being distinct and distinct within the context of the contract are considered to be
separate performance obligations. Performance obligations are capable of being distinct if the counterparty is able to
benefit from the good or service on its own or together with other resources that are readily available to it. Performance
obligations are distinct within the context of the contract when each performance obligation is separately identifiable. In
assessing whether the Company’s promises to transfer goods or services to the customer are separately identifiable, the
Company considers factors in ASC 606, including whether the Company uses the goods or services as inputs to produce or
deliver a combined output or outputs specified by the customer, whether one or more of the goods or services significantly
modify or customize one of the other goods or services in the contract, and whether the goods or services are highly
interdependent or highly interrelated. If a promised good or service is not distinct, it is combined with other promised
goods or services until the Company identifies a bundle of goods or services that is distinct, which is accounted for as a
single performance obligation. The determination of whether promised goods or services in a contract are distinct may
require significant judgment.
The transaction price is the amount of consideration that the Company expects to be entitled to in exchange for
transferring promised goods or services to the customer based on the contract terms at inception of a contract. The
Company estimates an amount of variable consideration, if any, by using either the expected value or the most likely
amount method depending on which method the Company expects to better predict the amount of consideration to which it
will be entitled, and only to the extent that it is probable that a significant reversal in the amount of cumulative revenue
recognized will not occur in the future when the uncertainty is resolved. The determination of whether it is probable that a
significant reversal of revenue will occur in the future depends on the likelihood and magnitude of the reversal. Factors that
could increase the likelihood or magnitude of a reversal of revenue include (a) the susceptibility of the amount of
consideration to factors outside the entity’s influence, such as the outcome of clinical trials, the timing of initiation of
clinical trials by the counterparty and the approval of drug product candidates by regulatory agencies, (b) situations in
which the uncertainty is not expected to be resolved for a long period of time, and (c) the level of the Company’s predictive
experience in the field with similar types of contracts. At the end of each reporting period, the Company will update the
estimated transaction price and allocate the updated consideration to the separate performance obligations in the same
manner as described below.
F-11
Table of Contents
At inception of a contract, the Company allocates the transaction price to the distinct performance obligations
based upon their relative standalone selling prices. Standalone selling price is the price at which an entity would sell a
promised good or service separately to a customer. The best evidence of standalone selling price is an observable price of a
good or service when sold separately by an entity in similar circumstances to similar customers. Since the Company
typically does not have such evidence, it estimates standalone selling price so that the amount that is allocated to each
performance obligation equals the amount that the Company expects to receive for transferring the promised goods or
services. The methods that the Company uses to make such estimates include (1) the adjusted market assessment approach,
under which the Company forecasts and analyzes Galactosemia and SORD sales in the appropriate market, the phase of
clinical development as well as considering recent similar license arrangements within the same phase of clinical
development, therapeutic area, type of agreement, etc. and (2) the expected cost of satisfying the performance obligations
plus a margin, or the expected cost plus a margin approach.
The Company recognizes revenue when, or as, it satisfies a performance obligation by transferring a promised
good or service to a customer and the customer obtains control of the good or service. Revenue related to the grant of a
license of functional IP that is distinct from the other promised goods or services in the contract and therefore represents a
performance obligation is recognized at the point in time that the Company has the right to payment for the license, the
customer has legal title to the license and can direct the use of the license (for example, to grant sublicenses) to benefit
from its right to use the intellectual property, the customer has the significant risks and rewards of ownership of the license
and the customer has accepted the asset (license) by signing the license agreement.
Recognition of revenue related to research and development services that are a distinct performance obligation is
deferred at inception of a contract and is recognized as the services are performed to satisfy the performance obligation
based on the costs incurred as a percentage of the estimated total costs to be incurred to satisfy the performance obligation.
The Agreement requires that Advanz Pharma receives regular updates and data on any research and development services
as the services are performed. In accordance with ASC 606-10-25-27, the Company determined that Advanz Pharma
simultaneously benefits from the research and development services that are satisfied over time. The Company believes
this method most faithfully depicts its performance in transferring the promised services while research and development
services are ongoing.
Milestone payments are considered to be variable consideration and are not included in the transaction price at
inception of the contract if it is uncertain that the milestone will be achieved. Rather, when it becomes probable that the
milestone will be achieved and, therefore, there will not be a significant reversal of revenue in future periods, the respective
amount to be earned is included in the transaction price, allocated to the distinct performance obligations based on their
relative standalone selling price and recognized as revenue, as described above. Sales based milestones and sales-based
royalty payments related to a license of IP are recognized as revenue when the respective sales occur.
Research and Development
The Company expenses all costs incurred in performing research and development activities. Research and
development expenses include salaries and other related costs, materials and supplies, preclinical expenses, manufacturing
expenses, contract services and other outside expenses. As part of the process of preparing the financial statements, the
Company is required to estimate accrued research and development expenses. The Company makes estimates of the
accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known at that
time. In addition, there may be instances in which payments made to the Company’s vendors will exceed the level of
services provided and result in a prepayment of the expense in which case such amounts are reflected as prepaid expenses
and other current assets. In accruing service fees, the Company estimates the time period over which services will be
performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the
level of effort varies from the estimate, the Company adjusts the accrual or the amount of prepaid expenses accordingly.
Nonrefundable advance payments for goods or services to be received in the future for use in research and development
activities are deferred and capitalized in prepaid expenses and other current assets. The capitalized amounts are expensed
as the related goods are delivered or the services are performed.
Research and development costs also include costs incurred in connection with certain licensing arrangements.
Before a compound receives regulatory approval, the Company records upfront and milestone payments made to third
F-12
Table of Contents
parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments
are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, the Company
will record any milestone payments in identifiable intangible assets, less accumulated amortization and, unless the asset is
determined to have an indefinite life, the Company will amortize the payments on a straight-line basis over the remaining
agreement term or the expected product life cycle, whichever is shorter.
General and Administrative
General and administrative expenses consist primarily of salaries and other related costs, including stock-based
compensation, for personnel in the Company’s executive and finance functions. General and administrative expenses also
include professional fees for legal, accounting, auditing, tax and consulting services; travel expenses; and facility-related
expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs.
Commercial expenses consist of payroll expense for commercial personnel, as well as marketing, market research,
market access, and other focused investments to support launch of drug candidates, generate evidence of commercial
potential and value proposition, and maximize potential business development deal leverage. Commercial expenses are
included in general and administrative expenses.
Stock-Based Compensation
The Company accounts for its stock-based compensation as expense in the statements of operations based on the
awards’ grant date fair values. The Company accounts for forfeitures as they occur by reversing any expense recognized
for unvested awards.
Stock-Based Compensation–Stock Options
The Company estimates the fair value of options granted using the Black-Scholes option pricing model. The Black-
Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock
price volatility, (b) the calculation of expected term of the award, (c) the risk-free interest rate and (d) expected dividends.
Due to a lack of company-specific historical and implied volatility data, the Company has based its estimate of expected
volatility on the historical volatility of a group of similar companies that are publicly traded. The historical volatility is
calculated based on a period of time commensurate with the expected term assumption. The computation of expected
volatility is based on the historical volatility of a representative group of companies with similar characteristics to the
Company, including stage of product development and life science industry focus. The Company uses the simplified
method as allowed by the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 107,
Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient
historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is
based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend
yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its
common stock.
The fair value of stock-based payments is recognized as expense over the requisite service period which is generally
the vesting period.
Stock-Based Compensation–Restricted Stock Units
The Company accounts for restricted stock units in accordance with the authoritative guidance for stock-based
compensation. The fair value of restricted stock units is measured at the grant date based on the closing market price of the
Company’s common stock on the date of grant and is recognized as expense on a straight-line basis over the period of
vesting. Forfeitures are recognized as a reduction of stock-based compensation expense as they occur.
F-13
Table of Contents
Income Taxes
The Company uses the asset and liability method of accounting for deferred income taxes. Under this method,
deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between
the carrying amounts and the tax basis of assets and liabilities at currently enacted tax rates. These temporary differences
primarily relate to net operating loss carryforwards available to offset future taxable income. Valuation allowances are
established, if necessary, to reduce a deferred tax asset to the amount that will more likely than not be realized.
The Company recognizes tax liabilities from an uncertain tax position only if it is more likely than not that the tax
position will not be sustained upon examination by the taxing authorities, based on the technical merits of the tax position.
There are no uncertain tax positions that have been recognized in the accompanying financial statements. The Company is
required to file tax returns in the U.S. federal jurisdiction and in the state of New York. The Company’s policy is to
recognize interest and penalties related to uncertain tax benefits, if any, as part of income tax expense. No such interest and
penalties have been accrued as of December 31, 2023 and 2022.
Net Loss per Share
Basic net loss per share is calculated by dividing net loss available to common stockholders by the weighted-average
common stock outstanding. Diluted net loss per share is calculated similarly, except that it includes the dilutive effect of the
assumed exercise of securities, including outstanding warrants and the effect of shares issuable under the Company’s stock-
based compensation plan, if such effect is dilutive.
Segment Information
Operating segments are defined as components of an enterprise for which separate discrete information is available
for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The
Company and the Company’s chief operating decision-maker, the Company’s chief executive officer, views the Company’s
operations and manages its business as a single operating segment, which is the business of discovering and developing its
product candidates.
Recent Accounting Pronouncements
Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates
are either not applicable or are not expected to be significant to the financial statements of the Company.
2. LICENSE AGREEMENTS
Columbia University
In October 2016, the Company entered into a license agreement (the “2016 Columbia Agreement”) with the
Trustees of Columbia University (“Columbia University”) to obtain an exclusive royalty-bearing sublicensable license in
respect to certain patents. As part of the consideration for entering into the 2016 Columbia Agreement, the Company issued
to Columbia University shares equal to 5% of its outstanding common stock on a fully diluted basis at the time of issue.
The common stock had a fair value of $0.5 million at the time of issuance. The Company will be required to make further
payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and
regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual
net sales, in each case in connection with products covered by the 2016 Columbia Agreement. The Company will also be
required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages on the Company’s, its
affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the
Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent
upon the approval of the licensed products, in the mid-six figures beginning on the 10th anniversary of the effective date of
the 2016 Columbia Agreement. When we grant sublicenses under the 2016
F-14
Table of Contents
Columbia Agreement, we are required to pay Columbia University a portion of the net sublicensing revenue received from
such third parties, at percentages between 10% and 20%, depending on the stage of development at the time such revenue
is received from such third parties. The Advanz Agreement includes a sublicense under the 2016 Columbia Agreement.
The 2016 Columbia Agreement will terminate upon the expiration of all the Company’s royalty payment
obligations in all countries. The Company may terminate the 2016 Columbia Agreement for convenience upon 90 days’
written notice to Columbia University. At its election, Columbia University may terminate the 2016 Columbia Agreement,
or convert the licenses granted to the Company into non-exclusive, non-sublicensable licenses, in the case of (a) the
Company’s uncured material breach upon 30 days’ written notice (which shall be extended to 90 days if the Company is
diligently attempting to cure such material breach), (b) the Company’s failure to achieve the specified development and
funding milestone events, or (c) the Company’s insolvency.
In January 2019, the Company entered into a second license agreement with Columbia University (the “2019
Columbia Agreement”). Pursuant to the 2019 Columbia Agreement, Columbia University granted the Company a royalty-
bearing, sublicensable license that is exclusive with respect to certain patents, and non-exclusive with respect to certain
know-how, in each case to develop, manufacture and commercialize PI3k inhibitor products. The license grant is
worldwide. Under the 2019 Columbia Agreement, the Company is obligated to use commercially reasonable efforts to
research, discover, develop and market licensed products for commercial sale in the licensed territory, and to comply with
certain obligations to meet specified development and funding milestones within defined time periods. Columbia
University retains the right to conduct, and grant third parties the right to conduct, non-clinical academic research using the
licensed technology; provided that such research is not funded by a commercial entity or for-profit entity or results in rights
granted to a commercial or for-profit entity. As consideration for entering into the 2019 Columbia Agreement, the
Company made a nominal upfront payment to Columbia University. The Company will be required to make further
payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and
regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual
net sales, in each case in connection with products covered by the 2019 Columbia Agreement. The Company will also be
required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages on the Company’s, its
affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the
Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent
upon the approval of the licensed products, in the mid-six figures beginning on the tenth anniversary of the effective date of
the 2019 Columbia Agreement.
In July 2022, following regulatory changes impacting development of the class of PI3k inhibitors and the
Company’s decision to discontinue its early stage preclinical PI3k program, the Company and Columbia entered into an
agreement terminating the 2019 Columbia Agreement (the “2022 Columbia Termination Agreement”) as of July 25, 2022.
Under the terms of the 2022 Columbia Termination Agreement, the Company assigned certain regulatory documents
regarding the preclinical PI3k inhibitor AT-104 to Columbia and granted Columbia a non-exclusive royalty free license
(with rights to sublicense any future Columbia licensee) under certain know-how, technical information and data relating to
AT-104 that was developed by the Company during the term of the 2019 Columbia Agreement.
In March 2019, and in connection with the 2016 Columbia Agreement, the Company entered into a research
services agreement (the “2019 Columbia Research Agreement”) with Columbia University with the purpose of analyzing
structural and functional changes in brain tissue in an animal model of Galactosemia, and the effects of certain compounds
whose intellectual property rights were licensed to the Company as part of the 2016 Columbia Agreement on any such
structural and functional changes. The 2019 Columbia Research Agreement had a term of 12 months from its effective
date and expired in accordance with its terms.
On October 3, 2019, and in connection with the 2019 Columbia Agreement, the Company entered into a research
services agreement (the “PI3k Columbia Research Agreement” and collectively with the 2016 Columbia Agreement, 2019
Columbia Agreement and 2019 Columbia Research Agreement, the “Columbia Agreements”) with Columbia University
with the purpose of analyzing PI3k inhibitors for the treatment of lymphoid malignancies. The PI3k Columbia Research
Agreement had a term of 18 months from its effective date and expired in accordance with its terms.
F-15
Table of Contents
During the years ended December 31, 2023 and 2022, the Company recorded $0.2 million in expense related to the
Columbia Agreements. In aggregate, the Company has incurred $2.9 million in expense from the execution of the
Columbia Agreements through December 31, 2023.
As of December 31, 2023 and 2022, the Company had $29,000 and $0.1 million, respectively, due to Columbia
University included in accrued expenses and no amounts included in accounts payable.
University of Miami
2020 Miami License Agreement
On October 28, 2020, the Company entered into a license agreement with the University of Miami (the “2020
Miami License Agreement”) relating to certain technology that is co-owned by the University of Miami (UM), the
University of Rochester (UR) and University College London (UCL). UM was granted an exclusive agency from UR and
UCL to license each of their rights in the technology. Pursuant to the 2020 Miami License Agreement, UM, on behalf of
itself and UR and UCL, granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to
certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain
know-how, in each case to research, develop, make, have made, use, sell and import products for use in treating and/or
detecting certain inherited neuropathies, in particular those caused by mutation in the sorbitol dehydrogenase (SORD)
gene. The license grant is worldwide. Under the 2020 Miami License Agreement, the Company is obligated to use
commercially reasonable efforts to develop, manufacture, market and sell licensed products in the licensed territory, and to
comply with certain obligations to meet specified development milestones within defined time periods. UM retains for
itself, UR, and UCL the right to use the licensed patent rights and licensed technology for their internal non-commercial
educational, research and clinical patient care purposes, including in sponsored research and collaboration with commercial
entities.
Under the terms of the 2020 Miami License Agreement, the Company was obligated to pay UM an up-front non-
refundable license fee of $1.1 million, and a second non-refundable license fee of $0.5 million due on the first anniversary
of the date of the license. The Company will be required to make further payments to UM of up to an aggregate $2.2
million for the achievement of specified patenting and development milestones, and up to an aggregate of $4.1 million for
achievement of late stage regulatory milestones. The Company will also be required to pay royalties ranging from 0.88% -
5% on the Company’s, the Company’s affiliates’ and the Company’s sublicensees’ net sales of licensed products. When the
Company sublicenses the rights granted under the 2020 Miami License Agreement to one or more third parties, the
Company will be required to pay to UM a portion of the non-royalty sublicensing revenue received from such third parties
ranging from 15% – 25%. The Advanz Agreement includes a sublicense under the 2020 Miami License Agreement.
The 2020 Miami License Agreement terminates upon the expiration of all issued patents and filed patent
applications or 10 years after the first commercial sale of the last product or process for which a royalty is due, unless
earlier terminated. In addition, the 2020 Miami License Agreement may be terminated by the Company at any time upon
60 days prior written notice to UM, and may be terminated by either the Company or UM upon material breach of an
obligation if action to cure the breach is not initiated within 60 days of receipt of written notice.
The Company recorded $0.1 million in research and development expense during the year-ended December 31,
2023, related to the Miami License Agreement. As of December 31, 2023, the Company had $0.4 million in accrued
expenses.
The Company recorded $0.1 million in research and development expense during the year-ended December 31,
2022, related to the Miami License Agreement. As of December 31, 2022, the Company had $0.3 million in accrued
expenses.
F-16
Table of Contents
2020 Miami Option Agreement
On October 28, 2020, the Company entered into an option agreement with the University of Miami (the “2020
Miami Option Agreement”) concerning certain research activities and technology relating to SORD neuropathy that may
be pursued and developed by UM. Under the 2020 Miami Option Agreement, if UM conducts such research activities, then
UM is obligated to grant us certain option rights to access and use the research results and to obtain licenses to any
associated patent rights upon us making specified payments to UM within specified time limits. If the Company elects to
obtain option rights the Company will be required to make payments to UM in the low-six figures to the low-seven figures,
depending upon the rights the Company elects to obtain, and the Company will be obligated to make certain milestone
payments in the high-six figures to mid-seven figures if UM conducts and completes certain research activities within
specified time periods and the Company elects to receive rights to use the results of that research.
2020 Miami Sponsored Research Agreement
On December 14, 2020, the Company entered into a research agreement with the University of Miami (the “2020
Miami Research Agreement”), under which the University of Miami will conduct a research study relating to SORD
neuropathy and deliver a final report on the study to the Company. The term of the research agreement was from December
14, 2020 through December 30, 2021, and was extended through August 31, 2022, whereby the research study was
completed. The total consideration for the 2020 Miami Research Agreement was $0.3 million.
During the years ended December 31, 2023 and 2022, the Company recorded $0 and $0.1 million in research and
development expenses, respectively, in relation to the 2020 Miami Research Agreement. As of December 31, 2023 and
2022, the Company had $0.1 million and $1.0 million, respectively, in accrued expenses.
Bayh-Dole Act
Some of the intellectual property rights the Company has licensed, including certain rights licensed in the
agreements described above, may have been generated through the use of U.S. government funding. As a result, the U.S.
government may have certain rights to intellectual property embodied in the Company’s current or future product
candidates under the Bayh-Dole Act of 1980, or Bayh-Dole Act, including the grant to the government of a non-exclusive,
worldwide, freedom to operate license under any patents, and the requirement, absent a waiver, to manufacture products
substantially in the United States. To the extent any of the Company’s current or future intellectual property is generated
through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.
3. FAIR VALUE MEASUREMENTS
The following tables summarize, as of December 31, 2023 and 2022, the Company's financial assets and liabilities
that are measured at fair value on a recurring basis, according to the fair value hierarchy described in the significant
accounting policies section.
(in thousands)
Cash
Money market funds
Total cash and cash equivalents
Total financial assets measured at fair value on
a recurring basis
Warrant liabilities - Common Warrants
Total financial liabilities measured at fair value
on a recurring basis
Level 1
$ 24,887
25,011
$ 49,898
$ 49,898
—
As of December 31, 2023
Level 2
Level 3
$ — $
—
$ — $
— $
—
— $
$ — $
— $
— 53,725
Total
24,887
25,011
49,898
49,898
53,725
$
— $ — $ 53,725
$
53,725
F-17
Table of Contents
(in thousands)
Cash
Money market funds
Total cash and cash equivalents
U.S. government agency debt securities
Total marketable securities
Total financial assets measured at fair value on
a recurring basis
Warrant liabilities - Common Warrants
As of December 31, 2022
Level 2
Level 3
Level 1
$
1,337
15,320
$ 16,657
$
$
— $
—
— $
— 13,923
— $ 13,923
$
$
$
$ 16,657
—
$ 13,923
— 13,657
— $
—
— $
—
— $
— $
Total
1,337
15,320
16,657
13,923
13,923
30,580
13,657
Total financial liabilities measured at fair value
on a recurring basis
$
— $
— $ 13,657
$
13,657
Investments in U.S. government agency debt securities have been classified as Level 2 as they are valued using
quoted prices in less active markets or other directly or indirectly observable inputs. Fair values of U.S. government agency
debt securities were derived from a consensus or weighted average price based on input of market prices from multiple
sources at each reporting period. During the period ended December 31, 2023 and 2022, there were no transfers of
financial assets between Level 1 and Level 2.
On June 27, 2022 the Company issued 30,000,000 warrants to purchase shares of common stock (the “Common
Warrants”) and 10,000,000 pre-funded warrants to purchase common stock (the “Pre-Funded Warrants”) in connection
with the June 2022 Offering (see Note 1 and Note 8 for more information on the June 2022 Offering). The Common
Warrants were accounted for as liabilities under ASC 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity
(“ASC 815-40”), as these warrants provide for a settlement provision that does not meet the requirements of the indexation
guidance under ASC 815-40. The Pre-Funded Warrants were initially recorded at fair value as a liability as the Company
could be required to settle the Pre-Funded Warrants in cash under certain circumstances. In December 2022, the Company
amended the Pre-Funded Warrants to remove the potential requirement that they could be settled in cash under certain
circumstances. Upon the amendment to the Pre-Funded Warrants, the Pre-funded Warrants liability was reclassified to
equity, using their fair value as of the amendment date.
The Common Warrant liabilities were measured at fair value at inception and are then subsequently measured on a
recurring basis, with changes in fair value recognized in other income (expense) within the Company’s statement of
operations.
The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common and Pre-
Funded Warrants, which utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement.
Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside
of the Company’s control, including a potential change in control outside of the Company’s control. A significant change in
one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the
Company’s warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company’s
consolidated statement of operations.
The Common Warrants were remeasured using a Black-Scholes option pricing model with a range of assumptions
included below as of December 31, 2023 and 2022. The Pre-Funded warrants were remeasured and
F-18
Table of Contents
reclassified to equity using the Black-Scholes option pricing model with a range of assumptions included below as of
December 31, 2022:
Expected term (in years)
Volatility
Risk-free interest rate
Dividend yield
December 31,
December 31,
2023
2022
2.4
109.46 %
4.32 %
0.00 %
3.7
91.53 %
4.11 %
0.00 %
As of December 31, 2023, the Company utilized a probability-weighted approach that considered the probability
of a change in control at the Company in the Black-Scholes option pricing model, whereby a 20% probability of change in
control was used for years two and three and a 5% probability was used for years four and five in the term of the
agreements.
As of December 31, 2022, the Company utilized a probability-weighted approach that considered the probability
of a change in control at the Company in the Black-Scholes option pricing model, whereby a 10.0% probability of change
in control was used for each of the remaining years in the term of the agreements.
The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for
which fair value is determined using Level 3 inputs (in thousands):
Balance as of January 1, 2023
Warrants exercised
Change in fair value
Balance as of December 31, 2023
Warrant Liabilities
$
$
13,657
(16,505)
56,573
53,725
The inputs utilized by management to value the warrant liabilities are highly subjective. The assumptions used in
calculating the fair value of the warrant liabilities represent the Company’s best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses
different assumptions, the fair value of the warrant liability for Common Warrants may be materially different in the future.
4. INVESTMENTS
Marketable Securities
Marketable securities, which the Company classifies as available-for-sale securities, primarily consisted of U.S.
government debt obligations as of December 31, 2022. Marketable securities with remaining effective maturities of twelve
months or less from the balance sheet date are classified as short-term; otherwise, they are classified as long-term on the
balance sheets.
F-19
Table of Contents
The following tables provide the Company’s marketable securities by security type (in thousands):
As of December 31, 2023
Gross
Gross
Unrealized Unrealized Estimated
Losses
Fair Value
Gains
As of December 31, 2022
Gross
Gross
Cost
Unrealized Unrealized Estimated
Fair Value
Losses
Gains
Cost
$ — $ — $ — $ — $ 13,873
$ — $ — $ — $ — $ 13,873
$
$
50
50
$ — $ 13,923
$ — $ 13,923
(in thousands)
US
government
agency debt
security
Total
As of December 31, 2023, the Company did not have an investment portfolio.
Contractual maturities of the Company’s marketable securities are summarized as follows (in thousands):
As of December 31, 2023
Gross
Gross
Unrealized Unrealized Estimated
Cost Gains
Losses
Fair Value
Cost
As of December 31, 2022
Gross
Gross
Unrealized Unrealized Estimated
Fair Value
Losses
Gains
$ — $ — $ — $ — $ 13,873
$
50
$ — $ 13,923
—
—
—
$ — $ — $ — $ — $ 13,873
—
—
—
—
—
50 $ — $ 13,923
$
(in thousands)
Due in one year
or less
Due in one
through two
years
Total
At December 31 2023, the Company had no gross unrealized gains and gross unrealized losses.
During the year ended December 31, 2023, gross realized gains and losses from the sale of marketable securities,
were immaterial.
There were no unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss
position for a period of less than or greater than 12 months as of December 31 2023 or 2022.
5. PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consisted of the following (in thousands):
(in thousands)
Prepaid research and development expenses
Insurance premium asset
Prepaid rent expenses
Prepaid insurance expenses
Prepaid commercial and patient advocacy
Research and development tax credit receivable
Interest receivable
Other prepaid expenses and current assets
Total prepaid expenses & other current assets
F-20
December 31, December 31,
2023
2022
$
$
2,880
566
47
72
284
262
23
100
4,234
$
$
4,272
1,131
99
71
206
252
23
617
6,671
Table of Contents
6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following (in thousands):
(in thousands)
Accrued pre-clinical and clinical expenses
Short-term insurance financing note
Deferred revenue
Accrued professional fees
Accrued compensation and benefits
Accrued commercial expenses
Accrued patent expenses
Other
Total accrued expenses & other current liabilities
December 31, December 31,
2023
10,142
310
667
1,307
2,066
19
396
379
15,286
2022
8,877
622
—
1,218
2,301
896
361
481
14,756
$
$
$
$
7. STOCK-BASED COMPENSATION
Equity Incentive Plans
In May 2019, the Company's board of directors (the "Board") adopted its 2019 Equity Incentive Plan ("2019
Plan"), which was subsequently approved by its stockholders and became effective on May 13, 2019. As a result, no
additional awards under the Company's 2016 Equity Incentive Plan, as amended (the "2016 Plan") will be granted and all
outstanding stock awards granted under the 2016 Plan that are repurchased, forfeited, expired or are cancelled will become
available for grant under the 2019 Plan in accordance with its terms. The 2016 Plan will continue to govern outstanding
equity awards granted thereunder.
The 2019 Plan provides for the issuance of incentive stock options ("ISOs") to employees, and for the grant of
nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance
stock awards, performance cash awards and other forms of stock awards to the Company's employees, officers and
directors, as well as non- employees, consultants and affiliates to the Company. Under the terms of the 2019 Plan, stock
options may not be granted at an exercise price less than fair market value of the Company's common stock on the date of
the grant. The 2019 Plan is administered by the Compensation Committee of the Company's Board.
Initially, subject to adjustments as provided in the 2019 Plan, the maximum number of the Company's common
stock that may be issued under the 2019 Plan is 4,530,000 shares, which is the sum of (i) 1,618,841 new shares, plus (ii)
the number of shares (not to exceed 2,911,159 shares) that remained available for the issuance of awards under the 2016
Plan, at the time the 2019 Plan became effective, and (iii) any shares subject to outstanding stock options or other stock
awards granted under the 2016 Plan that are forfeited, expired, or reacquired. The 2019 Plan provides that the number of
shares reserved and available for issuance under the 2019 Plan will automatically increase each January 1, beginning on
January 1, 2020, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31
or such lesser number of shares as determined by the Board. Subject to certain changes in capitalization of the Company,
the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of ISOs shall be
equal to 13,000,000 shares of common stock. Stock options awarded under the 2019 Plan expire 10 years after grant and
typically vest over four years.
On August 2, 2022, the Board took action in accordance with its authority under the terms of the 2019 Plan to
reset the per-share exercise price of all stock options previously granted under the 2019 Plan to $1.05 per share (the
"Options Repricing"), which is equal to the closing price of a share of the Company’s common stock on August 1, 2022.
The Options Repricing was deemed to be a Type I modification event under ASC 718, Compensation-Stock Compensation.
No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according
to their original vesting schedules and will retain their original expiration dates. As a result of the Options Repricing,
1,797,517 vested and 1,380,917 unvested stock options outstanding as of August 2, 2022, with
F-21
Table of Contents
original exercise prices ranging from $1.22 to $49.60, were repriced. The Options Repricing resulted in incremental stock-
based compensation expense of $1.4 million, of which $0.9 million related to vested stock option awards and was expensed
on the repricing date, and $0.5 million of which related to unvested stock option awards and is being amortized on a ratable
basis over the remaining weighted-average vesting period of those awards being approximately 2.4 years.
As of December 31, 2023, there were no shares of common stock available for issuance under the 2019 Plan. On
January 1, 2024, there were 4,243,292, shares that became issuable for future grants subject to the adjustments provided in
the 2019 Plan.
Stock-Based Compensation Expense
Total stock-based compensation expense recorded for employees, directors and non-employees (in thousands):
(in thousands)
Research and development
General and administrative
Total stock-based compensation expense
Stock Option Activity
Year Ended
December 31,
2023
3,005
4,355
7,360
$
$
2022
3,839
5,764
9,603
$
$
During the year ended December 31, 2023, the Company did not grant any stock options. For the years ended
December 31, 2023 and 2022, amortization of stock compensation of options amounted to $5.0 million and $7.8 million,
respectively. As of December 31, 2023, the total unrecognized stock-based compensation balance for unvested options was
$2.6 million, which is expected to be recognized over 1.7 years. The weighted-average fair value of options granted during
the year ended December 31, 2022 was $1.79 per share.
The following table summarizes the information about options outstanding at December 31, 2023:
Weighted-
Average
Exercise Price
$
Weighted-Average
Remaining
Contractual
Term (in years)
6.9
Aggregate
Intrinsic
Value
$ —
(in thousands, except for share data)
Outstanding at December 31, 2022
Options granted
Options exercised
Forfeited
Expired
Outstanding at December 31, 2023
Options
Outstanding
4,874,047
—
(85,619)
(84,639)
(8,170)
4,695,619
Exercisable at December 31, 2023
Nonvested at December 31, 2023
4,334,312
361,307
1.97
—
1.05
1.05
1.05
2.01
2.09
1.05
$
$
$
5.9
$ 7,875
5.7
7.7
$ 7,044
831
$
The aggregate intrinsic value is calculated as the difference between the exercise price of all outstanding and exercisable
stock options and the fair value of the Company’s common stock at December 31, 2023. The intrinsic value of stock
options exercised during the year ended December 31, 2023 was $0.1 million. There was no intrinsic value on stock
options exercised during the year ended December 31, 2022. The total grant-date fair value of stock options vested during
the years ended December 31, 2023 and December 31, 2022 was $0.4 million and $1.4 million, respectively.
F-22
Table of Contents
Valuation of Stock Options Granted to Employees that Contain Service Conditions Only
The fair value of each option award granted with service-based vesting is estimated on the date of the grant using
the Black-Scholes option valuation model based on the weighted average assumptions noted in the table below for those
options granted in the years ended December 31, 2023 and 2022.
Expected term (in years)
Volatility
Risk-free interest rate
Dividend yield
Restricted Stock Unit Activity
Year Ended
December 31,
2023
2022
—
— %
— %
— %
5.7
75.83 %
2.13 %
— %
During the year ended December 31, 2023, the Company granted 6,814,362 restricted stock units (“RSUs”). For
the years ended December 31, 2023 and 2022 amortization of stock compensation of RSUs amounted to $2.4 million and
$1.3 million, respectively. As of December 31, 2023, the unamortized compensation costs associated with non-vested
restricted stock awards was $5.5 million with a weighted-average remaining amortization period of 3.3 years.
The following table summarizes the information about restricted stock units outstanding at December 31, 2023:
(in thousands, except for share data)
Outstanding at December 31, 2022
Awarded
Released
Forfeited
Outstanding at December 31, 2023
Nonvested at December 31, 2023
Weighted-Average
Shares
815,509
6,814,362
(527,182)
(185,267)
6,917,422
6,917,422
$
$
$
Grant Date
Fair Value
5.96
2.09
4.40
2.81
2.35
2.35
Weighted Average Remaining Recognition Period (in years)
3.3
2019 Employee Stock Purchase Plan
In May 2019, the Company’s Board and its stockholders approved the 2019 Employee Stock Purchase Plan (the
“ESPP”), which became effective as of May 13, 2019. The ESPP is intended to qualify as an “employee stock purchase
plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of
common stock initially reserved for issuance under the ESPP was 180,000 shares. The ESPP provides for an annual
increase on the first day of each year beginning in 2020 and ending in 2029, in each case subject to the approval of the
Board, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the calendar month before
the date of the automatic increase and (ii) 360,000 shares; provided that prior to the date of any such increase, the Board
may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of December 31, 2023, no
shares of common stock had been issued under the ESPP. The first offering period has not yet been decided by the Board.
8. STOCKHOLDERS’ EQUITY
As of December 31, 2023 and 2022, the authorized capital stock of the Company consists of 200,000,000 shares
of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share.
F-23
Table of Contents
Common Stock
Voting
The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of
the stockholders. There is no cumulative voting.
June 2022 Offering
On June 27, 2022, the Company completed the June 2022 Offering, an underwritten public offering of 20,000,000
shares of common stock, 10,000,000 Pre-Funded Warrants, and accompanying Common Warrants to purchase up to
30,000,000 shares of common stock. The shares and accompanying Common Warrants were offered at a price to the public
of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price
to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting
discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately
exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or
Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to
exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded
Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned
more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants
or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s
outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the
event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events
affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders.
In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be
entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have
received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The
Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights
or privileges to which the Company’s stockholders are entitled.
April 2023 Offering
On April 26, 2023, the Company completed its sale of a total of 9,735,731 shares of the Company’s common
stock, at a purchase price of $0.946 per share, and 22,000,000 Pre-Funded Warrants to purchase common stock, at a
purchase price of $0.945 per Pre-Funded Warrant, in a private placement (the “April 2023 Private Placement”) to a select
group of accredited investors, pursuant to the Securities Purchase Agreement, dated as of April 23, 2023, by and between
the Company and the 2023 Purchasers. The April 2023 Private Placement resulted in net proceeds to the Company of
approximately $27.5 million, after deducting underwriting discounts, commissions and offering expenses. The Pre-Funded
Warrants are immediately exercisable from the date of issuance and do not have an expiration date. They have an exercise
price of $0.001. Holders may not exercise any Pre-Funded Warrants that would cause the aggregate number of shares of
common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock
immediately after exercise. The Pre-Funded Warrants are subject to adjustment in the event of certain stock dividends and
distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon
any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate
transactions, the holders of the Pre-Funded Warrants will be entitled to receive, upon exercise of the Pre-Funded Warrants,
the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-
Funded Warrants immediately prior to such transaction. The Pre-Funded Warrants do not entitle the holders thereof to any
voting rights or any of the other rights or privileges to which holders of common stock are entitled.
F-24
Table of Contents
ATM Offering
On August 11, 2023, the Company entered into (the “Leerink ATM Agreement”) with Leerink Partners LLC,
pursuant to which the Company may offer and sell, from time to time, shares of common stock having an aggregate
offering price of up to $75.0 million through Leerink Partners LLC as sales agent. Under the Leerink ATM Agreement, the
sales agents may sell shares of common stock by any method permitted by law deemed to be an “at the market offering” as
defined in Rule 415(a)(4) of the Securities Act of 1933, as amended. The Company will pay the sales agent a commission
rate of up to 3% of the gross offering proceeds of any shares sold and has agreed to provide the sales agent with
indemnification and contribution against certain liabilities. The Leerink ATM Agreement contains customary
representations and warranties.
As of December 31, 2023, the Company has sold an aggregate of 17,615,976 shares of the company’s common
stock, pursuant to the Leerink ATM Agreement with an average sale price of $2.04 per share, resulting in net proceeds of
$36.9 million, after deducting underwriting discounts, commissions and offering expenses. The Company intends to use the
net proceeds from the Leerink ATM to fund research and development and registration of its pipeline candidates, and for
working capital and general corporate purposes.
Venrock Warrant Exchange
On October 12, 2023, the Company entered into an exchange agreement (the “Exchange Agreement”) with
entities affiliated with Venrock Healthcare Capital Partners (the “Exchanging Stockholders”), pursuant to which the
Company exchanged an aggregate of 5,658,034 shares of common stock, owned by the Exchanging Stockholders for pre-
funded warrants to purchase an aggregate of 5,658,034 shares of common stock (subject to adjustment in the event of stock
splits, recapitalizations and other similar events affecting common stock), with an exercise price of $0.001 per share. The
common stock exchanged, and the pre-funded warrants issued were recorded at fair market value of $12.9 million. As of
December 31, 2023, our treasury stock consisted of no common stock.
9. WARRANTS
Warrants Issued with Series A Preferred Stock
On January 26, 2017, in connection with the sale and issuance of the Series A Preferred Stock, the Company
issued equity-classified warrants to purchase 309,389 shares of common stock (the “2017 Warrants”), valued at
$0.2 million, and included in the issuance costs of the Series A Preferred Stock. The warrants vested immediately and have
an exercise price of $2.49 per share and expire on March 13, 2027.
On December 5, 2019, an optionholder exercised 20,000 options in a cashless exercise at net, and the Company
issued 17,026 shares of common stock.
On February 21, 2020, two warrantholders exercised 185,634 options in a cashless exercise at net, and the
Company issued 176,092 shares of common stock. On February 24, 2020, a warrantholder exercised 72,818 options in a
cashless exercise at net, and the Company issued 69,094 shares of common stock.
On February 5, 2021, a warrantholder exercised 27,855 warrants on a cash basis and received 27,855 shares of
common stock. The Company received $69,000 in cash proceeds for the exercise of these warrants.
Warrants Issued with the 2018 Notes
On January 18, 2018, the Company entered into a placement agent agreement through which it became obligated
to issue common stock warrants in connection with the issuance of the Company’s convertible promissory notes issued on
February 5, 2018 (the “2018 Notes”). The obligation to issue the 2018 Notes Warrants was recorded as a liability at its fair
value (see Note 3), which was initially $0.1 million, and was included in the issuance costs of the 2018
F-25
Table of Contents
Notes. On November 5, 2018, in connection with the extinguishment of the 2018 Notes into shares of Series B Preferred
Stock, the Company issued the 2018 Notes Warrants, which were equity-classified warrants upon issuance, to purchase
76,847 shares of common stock, valued at $0.3 million. The 2018 Notes Warrants vested immediately upon issuance and
expire on November 4, 2028. The exercise price of the 2018 Notes Warrants was $3.99 and $6.59 per share as of December
31, 2023 and 2022, respectively.
On February 24, 2020, a warrantholder exercised 386 options in a cashless exercise at net, and the Company
issued 333 shares of common stock. On June 24, 2020, a warrantholder exercised 20,331 options in a cashless exercise at
net, and the Company issued 17,369 shares of common stock.
Warrants Issued with Series B Preferred Stock
In November and December 2018, in connection with the sale and issuance of the Series B Preferred Stock, the
Company was obligated to issue equity-classified warrants to purchase 72,261 shares of common stock (collectively the
“2018 Warrants”), valued in the aggregate at $0.2 million, which was included in the issuance costs for the Series B
Preferred Stock. The warrants vested immediately upon issuance and expire 10 years from the date of issuance. The
exercise price of the warrants was $4.86 and $8.24 per share as of December 31, 2023 and 2022, respectively.
In February 2019, in connection with the sale and issuance of the Series B Preferred Stock, the Company was
obligated to issue warrants to purchase 23,867 shares of common stock (collectively the “2019 Warrants”), valued in the
aggregate at $0.1 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vested
immediately upon issuance and expire 10 years from the date of issuance. The exercise price of the warrants was $4.86 and
$8.24 per share as of December 31, 2023 and 2022, respectively.
The inputs utilized by management to value the warrants are highly subjective. The assumptions used in
calculating the fair value of the warrants represent the Company’s best estimates, but these estimates involve inherent
uncertainties and the application of management judgment. As a result, if factors change and the Company uses different
assumptions, the fair value of the warrants may be materially different in the future.
Warrants Issued with June 2022 Offering
On June 27, 2022, in connection with the sale and issuance common stock as part of the June 2022 Offering, the
Company issued 10,000,000 Pre-Funded Warrants at an exercise price of $0.0001 per share, and 30,000,000 accompanying
Common Warrants at an exercise price of $1.00 per share. Each share of common stock and accompanying Common
Warrant was sold at a public offering price of $1.00, less underwriting discounts and commissions, and each Pre-Funded
Warrant and accompanying Common Warrant was sold at a public offering price of $0.9999, less underwriting discounts
and commissions, as described in the prospectus supplement, dated June22, 2022, filed with the Securities and Exchange
Commission on June 24, 2022 (See Note 1 and Note 8).
The June 2022 Pre-Funded Warrants were initially recorded at fair value as a liability as the Company could be
required to settle the Pre-Funded Warrants in cash in the event of an acquisition of the Company under certain
circumstances. In December 2022, the Company amended the Pre-Funded Warrants to remove the potential requirement
that they could be settled in cash under certain circumstances. Beginning December 31, 2022, the Pre-funded Warrants are
recorded as equity, using their fair value as of the amendment date.
On June 28, 2022, a warrant holder exercised 1,750,000 Pre-Funded Warrants on a cash basis and received
1,750,000 shares of common stock. The Company received $175 in cash proceeds for the exercise of these Pre-Funded
Warrants.
On April 26, 2023, in connection with the sale and issuance common of stock as part of the April Offering, the
Company issued 22,000,000 Pre-Funded Warrants at an exercise price of $0.0001 per share. Each share of common stock
was sold at a public offering price of $0.946 and each accompanying Pre-Funded Warrant was sold at a public offering
price of $0.945, pursuant to the Securities Purchase Agreement, dated as of April 23, 2023, by and between the
F-26
Table of Contents
Company and the 2023 Purchasers (See Note 1 and Note 8). The Pre-Funded Warrants are recorded as equity, using fair
value at issuance date, which was equivalent to the fair value of the common stock.
On June 8, 2023, a warrant holder exercised 4,250,000 Pre-Funded Warrants on a cash basis and received
4,250,000 shares of common stock. The Company received $425 in cash proceeds for the exercise of these Pre-Funded
Warrants.
As of December 31, 2023, the Company had 4,000,000 Pre-Funded Warrants from the June 2022 offering
outstanding with a weighted average exercise price of $0.0001 per share and an average contractual life of 5 years.
The Common Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a
settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These warrant
liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the
statement of operations.
On August 1, 2023, a warrant holder exercised 1,000,000 Common Warrants on a cash basis and received
1,000,000 shares of common stock. The Company received $1.0 million in cash proceeds for the exercise of these
Common Warrants.
On September 11, 2023, a warrant holder exercised 2,500,000 Common Warrants on a cash basis and received
2,500,000 shares of common stock. The Company received $2.5 million in cash proceeds for the exercise of these
Common Warrants.
On September 14, 2023, a warrant holder exercised 750,000 Common Warrants on a cash basis and received
750,000 shares of common stock. The Company received $0.8 million in cash proceeds for the exercise of these Common
Warrants.
On September 19, 2023, a warrant holder exercised 6,000,000 Common Warrants on a cash basis and received
6,000,000 shares of common stock. The Company received $6.0 million in cash proceeds for the exercise of these
Common Warrants.
As of December 31, 2023, the Company had 19,750,000 Common Warrants outstanding with a weighted average
exercise price of $1.00 per share and an average contractual life of 5 years.
On October 12, 2023, the Company entered into an exchange agreement with entities affiliated with Venrock
Healthcare Capital Partners pursuant to which the Company exchanged an aggregate of 5,658,034 shares of common stock,
owned by the Exchanging Stockholders for pre-funded warrants to purchase an aggregate of 5,658,034 shares of common
stock (subject to adjustment in the event of stock splits, recapitalizations and other similar events affecting common stock),
with an exercise price of $0.001 per share. The common stock exchanged, and the pre-funded warrants issued were
recorded at fair market value of $12.9 million. As of December 31, 2023, our treasury stock consisted of no common stock.
F-27
Table of Contents
A summary of the Company’s outstanding common stock warrants as of December 31, 2023 is as follows:
Equity Classified Liability Classified
Total
Outstanding as of January 1, 2023
Warrants granted and issued
Warrants exercised
Common stock exchanged for prefunded warrants
Outstanding as of December 31, 2023
Warrants
8,375,618
22,000,000
(4,250,000)
5,658,034
31,783,652
Warrants
Warrants
30,000,000
(10,250,000)
38,375,618
— 22,000,000
(14,500,000)
— 5,658,034
51,533,652
19,750,000
10. LEASES
The following table summarizes our lease related costs for the years ended December 31, 2023 and 2022:
(in thousands)
Lease Cost
Operating Lease Cost
Total lease cost
Statement of Operations Location
General and administrative
Year Ended
December 31,
2023
2022
$
$
505 $
505 $
489
489
Average lease terms and discount rates for the Company’s operating leases were as follows:
Other Information
Weighted-average remaining lease term
Operating leases
Weighted-average discount rate
Operating leases
Year Ended
December 31, December 31,
2023
2022
1.1 years
1.8 years
6.86%
5.69%
The following table summarizes the maturities of lease liabilities as of December 31, 2023:
Year
2024
2025
Thereafter
Total lease payments
Less: interest
Total lease liabilities
F-28
Operating
(in thousands)
446
23
20
489
22
467
$
Table of Contents
11. INCOME TAXES
The Company has not recorded a current or deferred tax provision for the years ended December 31, 2023 and
2022 due to net losses incurred.
A reconciliation of the Company's deferred taxes is as follows (in thousands):
Year ended
December 31,
2023
2022
Deferred Tax Assets
Operating lease liability
Stock-based compensation
License fee
Net operating loss carryforwards
Research and development tax credits
Capitalized research and development expense
Other
Total deferred tax assets
Valuation allowance
Net deferred tax assets
Deferred tax liabilities
Right of use asset
Net deferred tax liabilities
Net deferred tax asset (liability)
$
$
146
282
4,060
8,131
501
554
94,119
88,090
25,145
21,397
26,945
14,910
445
1,085
$ 134,449
$ 151,361
$ (151,222) $ (134,177)
272
$
139
$
(139)
(139) $
— $
(272)
(272)
—
$
$
Deferred tax assets result primarily from unutilized net operating losses, research tax credits, stock-based
compensation, operating lease liability, and timing differences as a result of the Company reporting its income tax returns.
As of December 31, 2023, the Company had approximately $299.8 million of federal operating loss (“NOLs”) carry
forwards. Of this amount, approximately $3.3 million will begin to expire in 2037 and approximately $296.5 million are
carried forward indefinitely. The Company had approximately $612.0 million in state and city net operating loss
carryforwards available to offset future taxable income.
As of December 31, 2023, the Company had federal research tax credits (R&D) of approximately $6.1 million
which may be used to offset future tax liabilities. Additionally, the Company had a federal orphan drug credit (“ODC”)
related to qualifying research of $19.1 million. These tax credit carryforwards will begin to expire at various times
beginning in 2037 for federal purposes.
The NOL, R&D and ODC credits carry forwards are subject to review and possible adjustment by the U.S. and
state tax authorities. NOL carry forwards and credit carry forwards may become subject to an annual limitation in the event
of certain cumulative changes in the ownership interest of significant shareholders, as defined under Sections 382 and 383
Internal Revenue Code. This could limit the amount of NOLs and credits that the Company can utilize annually to offset
future taxable income or tax liabilities. As of December 31, 2023, the Company has not performed such an analysis.
Subsequent ownership changes and proposed future changes to tax rules in respect of the utilization of losses carried
forward may further affect the limitation in future years.
In assessing the realizability of the Company’s deferred tax assets, management considers whether or not it is
more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of
deferred tax assets is dependent upon the generation of future taxable income. The Company’s assessment is based on the
weight of available evidence, including cumulative losses since inception and expected future losses and, as such, the
Company does not believe it is more likely than not that the deferred tax assets will be realized. Accordingly, a full
valuation allowance has been established and no deferred tax assets and related tax benefit have been recognized in the
accompanying financial statements. At December 31, 2023 and 2022, the Company recorded valuation allowances of
F-29
Table of Contents
$151.2 million and $134.2 million, respectively. The increase in valuation allowance is primarily driven by additional net
operating losses.
The Company files its income tax returns in the United States, California, Iowa, Massachusetts, Michigan, New
Jersey, New York State, New York City, Pennsylvania, and Texas. All years remain subject to examination for federal and
state purpose.
The U.S. federal statutory corporate tax rate reconciles to the Company’s effective tax rate for the years ended
December 31, 2023 and 2022:
Federal statutory rate
State and local taxes net of federal tax benefit
Credits
Permanent differences
Change in fair value of warrant liabilities
Change in valuation allowance
Stock-based compensation
Other
Total
12. BENEFIT PLANS
Year Ended
December 31,
2023
21.0 %
3.4
3.1
(0.1)
(9.9)
(14.2)
(3.3)
—
0.0 %
2022
21.0 %
10.2
7.8
(0.1)
—
(37.9)
(1.1)
0.1
0.0%
The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code
in 2018. This plan covers substantially all employees who meet minimum age and service requirements and allows
participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be
made at the discretion of the Company’s Board. The Company made approximately $0.4 million in matching contributions
to the plan during each of the years ended December 31, 2023 and 2022.
13. NET LOSS PER COMMON SHARE
Basic net loss per common share is computed by dividing the net loss available to common stockholders by the
weighted-average number of shares of common stock outstanding during the period which includes shares issuable under
pre-funded warrants agreements for little consideration.
Diluted net loss per common share is computed by giving the effect of all potential shares of common stock,
including stock options, preferred shares, warrants and instruments convertible into common stock, to the extent dilutive.
Basic and diluted net loss per common share was the same for the years ended December 2023 and 2022, as the inclusion
of all potential common shares outstanding would have been anti-dilutive.
F-30
Table of Contents
The following table sets forth the computation of basic and diluted net loss per common share (in thousands,
except share and per share data):
(in thousands, except for share data)
Numerator:
Net loss
Denominator:
Year Ended
December 31,
2023
2022
$
(119,763) $
(82,508)
Weighted-average common stock outstanding
84,244,494
37,825,431
Net loss per share attributable to common stockholders - basic
and diluted
$
(1.42) $
(2.18)
The Company’s potentially dilutive securities, which include restricted stock units, stock options and common
warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net
loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and
diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential
common shares, presented based on amounts outstanding at December 31, 2023 and 2022, from the computation of diluted
net loss per share attributable to common stockholders.
Options to purchase common stock
Restricted stock units
Warrants to purchase common stock
14. RELATED PARTIES
As of
December 31,
2023
4,695,619
3,867,422
19,875,618
2022
4,874,047
815,509
30,125,618
In December 2018, the Company entered into an agreement (the “LaunchLabs Agreement”) with ARE-
LaunchLabs NYC LLC (“Alexandria LaunchLabs”), a subsidiary of Alexandria Real Estate Equities, Inc. for use of
specified premises within the Alexandria LaunchLabs space on a month-to-month basis. A member of the Company’s
board of directors is the founder and executive chairman of Alexandria Real Estate Equities, Inc. During the years ended
December 31, 2023 and 2022, the Company made payments to Alexandria LaunchLabs of approximately $0.1 million
under the LaunchLabs Agreement, which was recognized in research and development expenses. As of December 31, 2023
and 2022, there was $8,000 and $0 due to Alexandria LaunchLabs under the LaunchLabs Agreement, respectively,
recorded in accounts payable.
15. REVENUE
On January 3, 2023, the Company entered into an Exclusive License and Supply Agreement (the “Advanz
Agreement”) with Mercury Pharma Group Limited (trading as Advanz Pharma Holdings) (“Advanz Pharma”). Pursuant to
the Advanz Agreement, the Company granted Advanz Pharma the exclusive right and license to commercialize drug
products containing AT-007 (also known as govorestat), our proprietary Aldose Reductase Inhibitor (ARI) (the “Licensed
Product”), for use in treatment of Sorbitol Dehydrogenase Deficiency (“SORD”) and Galactosemia (each a “Licensed
Indication”) in the European Economic Area, Switzerland and the United Kingdom (the “Territory”). The Agreement
provides that Applied will perform research and development services prior to and subsequent to marketing authorization
and manufacture and supply product for Advanz Pharma. The Company also granted Advanz Pharma a right of negotiation
and “most-favored nation” rights with respect to acquiring the European commercialization rights for any additional
indications for which the Licensed Product may be developed in the future (or any other products we may develop solely to
the extent used for the Licensed Indications).
Advanz Pharma is required to use commercially reasonable efforts to launch and commercialize the Licensed
Products in the major markets in the Territory in each Licensed Indication following, and subject to, receipt of marketing
F-31
Table of Contents
authorization therein. Under the Advanz Agreement, Advanz Pharma agreed to pay the Company (i) an upfront payment of
EUR 10.0 million (approximately USD $10.7 million), and certain development milestone payments upon clinical trial
completion and receipt of marketing authorization in the territory, as well as certain commercial milestone payments,
totaling EUR 134 million (approximately USD $142.2 million) in the aggregate, and (ii) royalties of 20% of net sales of the
Licensed Product. Such royalty rate will be payable on a country-by-country basis until the later of (i) the expiration of the
licensed patents covering the composition of matter of AT-007, or (ii) 10 years after the European Medicines Agency’s
grant of marketing authorization for the Licensed Product. The royalties are subject to certain deductions, including certain
secondary finishing costs, certain step-in establishment costs and a portion of fees for any potential third-party patent
licenses if applicable in the future. Following the initial term of the license, as described above, the royalty rate will be
reduced to 10% and shall continue in perpetuity unless the Advanz Agreement is terminated in various circumstances in
accordance with its terms. In addition, the Company is entitled to receive cost sharing consideration for post-marketing
authorization studies, if applicable.
In accordance with the Company's ASC 606 assessment, Advanz Pharma is considered to be a customer. The
Company identified three performance obligations, the exclusive license to commercialize the Licensed Product, the
obligations to provide research and development for pre and post-marketing authorization and the obligation to
manufacture and supply Advanz Pharma with the Product, at cost (a material right). The Company determined that the
upfront payment of EUR 10 million (approximately USD $10.7 million) is the estimated transaction price at contract
inception. The performance-based milestone payments, sales-based milestone payments, sales-based royalties, and post-
marketing authorization study cost sharing are each determined to be variable consideration that are fully constrained due
to the uncertainty of achievement.
At inception of the Advanz Agreement, the Company determined the estimate of standalone selling price for the
license performance obligation by using the adjusted market assessment approach. Under this method, the Company
forecasted and analyzed Galactosemia and SORD in the European market, the probability of marketing authorization
approval as well as considered recent similar license arrangements within the same phase of clinical development,
therapeutic area, type of agreement, forecasted sales for the contract period, probability of success and a market discount
rate. To estimate the standalone selling price of the research and development services, the Company forecasted its
expected costs of satisfying that performance obligation and added an appropriate margin for that service. To estimate the
standalone selling price for the manufacturing supply agreement material right, the Company utilized an adjusted market
assessment approach. The Company analyzed the discount Advance Pharma is expected to obtain by estimating the
material right the customer is receiving for the future purchase of manufacturing and supply services. This estimation
utilized the estimated number of patients to be treated per year in the Territory; the estimated volume of bottles per patient
required per year; typical margin; probability of success; and discounted at market rate.
The Company allocated the total transaction price to each performance obligation on a relative standalone selling price
basis and determined whether revenue should be recognized at a point in time or over time. The Company allocated $9.3
million to the license performance obligation; $1.3 million to the research and development performance obligation; and
$0.1 million to the manufacturing and supply material right.
Revenue should be recognized when, or as, an entity satisfies a performance obligation by transferring a promised
good or service to a customer, i.e., when the customer obtains control of the good or service. The license granted to Advanz
Pharma is being accounted for as a distinct performance obligation. The Advanz Pharma license relates to functional IP for
which revenue is recognized at a point in time – in the case of this license agreement, the point in time is at inception of the
contract because the customer obtained control of the license and was able to use and benefit from its right to use the
intellectual property at that point. The Company recognized the transaction price allocated to the license obligation of $9.3
million as license revenue on its statements of operations for the year ended December 31, 2023.
The research and development services performance obligation under the Advanz Agreement represents a separate
performance obligation. The research and development services were provided to Advanz Pharma by the Company from
inception of the agreement in January 2023 and will continue through completion of post marketing authorization approval
studies. Revenue related to the research and development services performance obligation was recognized as services were
performed based on the costs incurred through December 31, 2023, as a percentage of the estimated total costs to be
incurred for this performance obligation. The Company recognized $0.7 million of revenue
F-32
Table of Contents
during year ended December 31, 2023, and had deferred revenue of $0.5 million related to the research and development
performance obligation at December 31, 2023. The Company expects to recognize this deferred revenue over the next
three years. Operating expenses for costs incurred pursuant to this arrangement are reported in their respective expense
line items in the Statements of Operations, net of any payments due to or reimbursements due from Advanz, with such
reimbursements being recognized at the time the party becomes obligated to pay.
The manufacturing supply agreement material right performance obligation provided to Advanz Pharma by the
Company resulted in an allocation of the transaction price and resulting deferred revenue as of contract inception and
December 31, 2023, of approximately $0.1 million. Revenue associated with this performance obligation will be
recognized when Advanz Pharma buys supply from the Company after regulatory approval or upon expiration of the
material right.
16. SUBSEQUENT EVENTS
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of
the financial statements to provide additional evidence for certain estimates or to identify matters that require additional
disclosure. The Company has evaluated all subsequent events and determined that there are no material recognized or
unrecognized subsequent events requiring disclosure, other than as disclosed within the above notes to financial statements,
and except as described below.
ATM Offering
On January 31, 2024, the Company sold an additional 1,000,000 shares of the company’s common stock pursuant
to the Leerink ATM Agreement with an average sale price of $3.13 per share, resulting in net proceeds of $3.0 million,
after deducting underwriting discounts, commissions and offering expenses.
On February 16, 2024, the Company sold an additional 2,000,000 shares of the company’s common stock
pursuant to the Leerink ATM Agreement with an average sale price of $4.90 per share, resulting in net proceeds of $9.5
million, after deducting underwriting discounts, commissions and offering expenses.
Warrant Exercises
In February 2024, warrant holders exercised 4,025,000 Common Warrants on a cash basis and received 4,025,000
shares of common stock. The Company received $4.0 million in cash proceeds for the exercise of these Common Warrants.
In January 2024, warrant holders exercised 1,706,976 Pre-Funded Warrants on a cashless basis and received
1,706,285 shares of common stock.
March 2024 Private Placement
On March 1, 2024, the Company completed its sale of a total of 12,285,714 shares of the Company’s common stock,
at a purchase price of $7.00 per share, and 2,000,000 Pre-Funded Warrants to purchase common stock, at a purchase price
of $6.999 per Pre-Funded Warrant, in a private placement to a select group of accredited investors, pursuant to a Securities
Purchase Agreement, dated as of February 27, 2024, by and between the Company and the purchasers named therein (the
“2024 Purchasers”). The Private Placement resulted in gross proceeds to the Company of approximately $100 million,
before deducting placement agent commissions and other offering expenses.
The Pre-Funded Warrants are immediately exercisable from the date of issuance and do not have an expiration date.
They have an exercise price of $0.001. Holders may not exercise any Pre-Funded Warrants that would cause the aggregate
number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding
common stock immediately after exercise. The Pre-Funded Warrants are subject to adjustment in the event of certain stock
dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock
and also upon any distributions for no consideration of assets to the Company’s stockholders. In the
F-33
Table of Contents
event of certain corporate transactions, the holders of the Pre-Funded Warrants will be entitled to receive, upon exercise of
the Pre-Funded Warrants, the kind and amount of securities, cash or other property that the holders would have received
had they exercised the Pre-Funded Warrants immediately prior to such transaction. The Pre-Funded Warrants do not entitle
the holders thereof to any voting rights or any of the other rights or privileges to which holders of common stock are
entitled.
The Securities have the benefit of the Registration Rights Agreement (the “Registration Rights Agreement”), dated
as of February 27, 2024, by and among the Company and the 2024 Purchasers, requiring the Company to prepare and file a
registration statement with the SEC as soon as reasonably practicable, but in no event later than March 28, 2024. the Filing
Deadline, and to use commercially reasonable efforts to have the registration statement declared effective within 30 days of
the Filing Deadline, subject to extension under the terms of the Registration Rights Agreement. The Company intends to
use the net proceeds to fund research and development and registration of its pipeline candidates, and for working capital
and general corporate purposes.
F-34
Table of Contents
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
ITEM 9A. CONTROLS AND PROCEDURES.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed
in the reports we file or submit pursuant to the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), is
recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that
such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief
Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the
effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-
15(e) of the Exchange Act as of the end of the period covered by this Annual Report. Based on that evaluation, our Chief
Executive Officer and Chief Financial Officer have concluded that, as of December 31,2023, our disclosure controls and
procedures were not effective to provide reasonable assurance that information required to be disclosed by the Company in
reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the SEC's rules and forms, due to the material weakness in our internal control over financial reporting
described below.
After giving full consideration to the material weakness, and the additional analyses and other procedures that we
performed to ensure that preparation and fair presentation of our financial statements included in this Annual Report, our
management and the board of directors have concluded that such financial statements present fairly, in all material respects,
our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting
as defined in Rules 13a-15(f) under the Exchange Act. Our internal control was designed to provide reasonable assurance
to our management and board of directors regarding the preparation and fair presentation of published financial statements.
All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems
determined to be effective can provide only reasonable assurance with respect to financial statement preparation and
presentation.
Management maintains a comprehensive system of controls intended to ensure that transactions are executed in
accordance with management's authorization, assets are safeguarded, and financial records are reliable. Management also
takes steps to ensure that information and communication flows are effective, and to monitor performance, including
performance of internal control procedures.
Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023,
based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal
Control-Integrated Framework (2013 Framework). Based on this assessment, management believes that our internal
control over financial reporting was not effective as of December 31, 2023, due to the material weakness described below.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting,
such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not
be prevented or detected on a timely basis.
94
Table of Contents
As described below and in Part II, Item 1A. of this Annual Report on Form 10-K, in connection with the audit of
our financial statements for the year ended December 31, 2023, we and our independent registered public accounting firm
identified a material weakness in our internal control over financial reporting related to deficiencies in our controls over the
financial statement close process. Specifically, there were deficiencies in the design and operation of internal controls over
the review of complex accounting issues involving significant judgment or estimates with respect to certain transactions.
Plan for Remediation of Material Weakness
Management is implementing enhanced internal controls to remediate the material weakness. The remediation plan
includes engaging additional technical resources, enhancement of our review of new agreements to confirm appropriate
understanding of the terms, as well as implementation of a control designed to evaluate and monitor and where necessary,
document, at inception, the appropriate accounting treatment.
Changes in Internal Control over Financial Reporting
Other than the ongoing remediation efforts related to the material weakness discussed above, there were no changes
in our internal control over financial reporting (as such term is defined by Rules 13a-15(f) and 15d-15(f) of the Exchange
Act) during the most recent fiscal quarter ended December 31, 2023 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.
The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these
initiatives will ultimately have the intended effects.
ITEM 9B. OTHER INFORMATION.
None.
ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.
Not Applicable.
95
Table of Contents
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
The information required by Item 10 is incorporated by reference to the information that will be contained in our
2024 Proxy Statement under the captions “Proposal 1 - Election of Directors,” “Principal Stockholders,” “Proposal 2 –
Ratification of Independent Registered Public Accounting Firm” and “Audit Committee Report.”
ITEM 11. EXECUTIVE AND DIRECTOR COMPENSATION.
The information required by Item 11 is incorporated by reference to the information that will be contained in our
2024 Proxy Statement under the captions “Executive and Director Compensation,” “Compensation Discussion and
Analysis,” “Compensation Committee Report,” “Compensation Committee Interlocks and Insider Participation,”
“Compensation of Named Executives,” “Summary Compensation Table,” “Equity Incentive Plans,” “Non-Employee
Director Compensation,” “Stock Option Grants,” “Outstanding Equity Awards at Fiscal Year-End,” “Health and Welfare
Retirement Benefits,” and “Potential Payments and Benefits Upon Termination or Change-in-Control.”
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.
The information required by Item 12 is incorporated by reference to the information that will be contained in our
2024 Proxy Statement under the caption “Principal Stockholders.”
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.
The information required by Item 13 is incorporated by reference to the information that will be contained in our
2024 Proxy Statement under the caption “Certain Relationships and Transactions.”
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.
The information required by Item 14 is incorporated by reference to the information that will be contained in our
2024 Proxy Statement under the caption “Independent Registered Public Accounting Firm”.
96
Table of Contents
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.
(a) The following documents are filed as part of this Annual Report
PART IV
1. Financial Statements:
The following financial statements and schedules of the Registrant are contained in Part II, Item 8, “Financial
Statements and Supplementary Data” of this Annual Report:
Item
Report of Independent Registered Public Accounting Firm PCAOB Firm ID: 00042
Balance Sheets as of December 31, 2023 and 2022
Statements of Operations for the years ended December 31, 2023 and 2022
Statements of Comprehensive Loss for the years ended December 31, 2023 and 2022
Statement of Changes in Shareholders’ Equity (Deficit) for the years ended December 31, 2023 and 2022
Statements of Cash Flows for the years ended December 31, 2023 and 2022
Notes to Financial Statements
Page
F-1
F-2
F-3
F-4
F-5
F-6
F-7
2. Financial Statement Schedules:
There are no Financial Statement Schedules included with this filing for the reason that they are not applicable or
are not required or the information is included in the financial statements or notes thereto.
(b) Exhibits required by Item 601 of Regulation S-K
The information required by this Item is set forth on the exhibit index that follows the signature page of this
Annual Report.
97
Table of Contents
Exhibit Number
3.1+
3.2
3.3+
4.1+
4.2+
4.3+
4.4+
4.5+
4.6+
4.7+
4.8+
EXHIBIT INDEX
Description
Amended and Restated Certificate of
Incorporation of the Registrant, as
amended.
Certificate of Amendment to
Amended and Restated Certificate of
Incorporation of the Registrant.
Amended and Restated Bylaws of the
Registrant.
Registration Rights Agreement, dated
November 7, 2019, by and among the
Registrant and the Purchasers.
Form of Common Stock Certificate of
the Registrant.
Amended and Restated Investors’
Rights Agreement, by and among the
Registrant and certain of its
stockholders, dated November 5,
2018.
Form of Warrant, issued to affiliates of
Brookline Capital Markets, a division
of CIM Securities, LLC on March 13,
2017.
Form of Warrant, issued to affiliates of
Brookline Capital Markets, a division
of CIM Securities, LLC on November
5, 2018.
Form of Warrant, issued to affiliates of
Brookline Capital Markets, a division
of CIM Securities, LLC on April 9,
2019.
Form of Pre-Funded Warrant to
Purchase Common Stock
Form of Common Warrant to Purchase
Common Stock
98
Form
10-
K
File No.
001-
38898
Exhibit
3.1
Filing Date
March 23,
2023
8-K
10-
K
8-K
10-
Q
S-
1/A
S-
1/A
S-
1/A
S-
1/A
8-K
8-K
001-
38898
001-
38898
001-
38898
001-
38898
333-
230838
333-
230838
333-
230838
333-
230838
001-
38898
001-
38898
3.1
3.3
10.2
4.1
4.2
4.3
4.4
4.5
4.1
4.2
October
28, 2022
March 23,
2023
November
12, 2019
August
12, 2019
April 29,
2019
April 29,
2019
April 29,
2019
April 29,
2019
June 27,
2022
June 27,
2022
Table of Contents
4.9+
4.10+
10.1*+
10.2*+
10.3*+
10.4*+
10.5*+
10.6*+
10.7*+
10.8†+
10.9†
10.10*+
Form of Pre-Funded Common Stock
Purchase Warrant.
Description of securities registered
under Section 12 of the Exchange Act.
Forms of Indemnity Agreement by and
between the Registrant and its directors
and executive officers.
2019 Equity Incentive Plan, as
amended.
Forms of Option Grant Notice and
Option Agreement under 2019 Equity
Incentive Plan.
Form of Restricted Stock Unit Grant
Notice and Unit Award Agreement
under 2019 Equity Incentive Plan.
2016 Equity Incentive Plan, as
amended.
Forms of Stock Option Agreement
under the 2016 Equity Incentive Plan,
as amended.
2019 Employee Stock Purchase Plan
Exclusive License Agreement by and
between the Registrant and The
Trustees of Columbia University in the
City of New York, dated October 26,
2016.
Exclusive License Agreement by and
between the Registrant and Mercury
Pharma Group Limited, dated January
3, 2023.
Employment Agreement, by and
between the Registrant and Riccardo
Perfetti, dated August 28, 2019.
99
8-K
10-
K
S-
1/A
S-
1/A
S-
1/A
S-
1/A
S-
1/A
S-
1/A
S-
1/A
S-1
10-
K
10-
Q
001-
38898
001-
38898
333-
230838
333-
230838
333-
230838
333-
230838
333-
230838
333-
230838
333-
230838
333-
230838
4.1
4.7
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.11
April 24,
2023
March 13,
2020
April 29,
2019
April 29,
2019
April 29,
2019
April 29,
2019
April 29,
2019
April 29,
2019
April 29,
2019
April 12,
2019
001-
38898-
10.9
March 23,
2023
001-
38898
10.1
November
13, 2019
Table of Contents
10.11*
10.12*
10.13*
10.14*+
10.15+
10.16+
10.17+
10.18+
10.19+
23.1
Employment Agreement, by and
between the Registrant and Shoshana
Shendelman, dated March 9, 2020.
Amendment to Employment
Agreement, by and between the
Registrant and Riccardo Perfetti, dated
March 9, 2020.
Employment Agreement, by and
between Applied Therapeutics, Inc.
and Les Funtleyder, dated November
17, 2023.
Employment letter, by and between
Applied Therapeutics, Inc. and
Constantine Chinoporos, dated
December 28, 2023.
Securities Purchase Agreement, dated
April 23, 2023, by and among the
Company and the 2023 Purchasers.
Registration Rights Agreement, dated
April 23, 2023, by and among the
Company and the 2023 Purchasers.
Exchange Agreement, dated as of
October 12, 2023, between Applied
Therapeutics, Inc. and Venrock
Healthcare Capital Partners EG, L.P.,
Venrock Healthcare Capital Partners
III, L.P. and VHCP Co-Investment
Holdings III, LLC.
Securities Purchase Agreement, dated
February 27, 2024, by and among the
Company and the 2024 Purchasers
Registration Rights Agreement, dated
February 27, 2024, by and among the
Company and the 2024 Purchasers
Consent of Ernst & Young LLP,
Independent Registered Public
Accounting Firm.
100
10-
K
10-
K
001-
38898
001-
38898
10.13
March 13,
2020
10.14
March 13,
2020
8-K
001-
38898
10.1
November
17, 2023
8-K
001-
38898
10.1
December
29, 2023
8-K
8-K
8-K
8-K
8-K
001-
38898
001-
38898
001-
38898
001-
38898
001-
38898
10.1
10.2
10.1
10.1
10.2
April 24,
2023
April 24,
2023
October
13, 2023
February
29, 2024
February
29, 2024
Table of Contents
31.1
31.2
32.1
32.2
Rule 13a-14(a)/15d-14(a) Certification
under the Exchange Act by Shoshana
Shendelman, President and Chief
Executive Officer (Principal Executive
Officer).
Rule 13a-14(a)/15d-14(a) Certification
under the Exchange Act by Leslie
Funtleyder, Chief Financial Officer
(Principal Financial Officer).
Certification of Chief Executive
Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
Section 1350 Certifications.
Certification of Principal Financial
Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
Section 1350 Certifications.
97.1*
Applied Therapeutics, Inc. Clawback
Policy
101.INS
Inline XBRL Instance Document.
101.SCH
101.CAL
101.DEF
101.LAB
101.PRE
104
XBRL Taxonomy Extension Schema
Document.
XBRL Taxonomy Extension
Calculation Linkbase Document.
XBRL Taxonomy Extensions
Definition Linkbase Document.
XBRL Taxonomy Extension Label
Linkbase Document.
XBRL Taxonomy Extension
Presentation Linkbase Document.
Cover Page Interactive Data File
(formatted as Inline XBRL with
applicable taxonomy extension
information contained in Exhibits 101).
101
Table of Contents
* Indicates a management contract or compensatory plan.
† Portions of this exhibit have been omitted.
+ Previously filed.
ITEM 16.
FORM 10-K SUMMARY
None.
102
Table of Contents
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Dated: March 6, 2024
Applied Therapeutics, Inc.
/s/ Shoshana Shendelman
Name: Shoshana Shendelman, Ph.D.
Title: President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the Company and in the capacities indicated on the 6th of March 2024.
Name
Title
/s/ Shoshana Shendelman
Shoshana Shendelman, Ph.D.
Chair of the Board
President and Chief Executive Officer
(Principal Executive Officer)
Date
March 6, 2024
/s/ Les Funtleyder
Les Funtleyder
/s/ Les Funtleyder
Les Funtleyder
/s/ Teena Lerner
Teena Lerner, Ph.D.
/s/ Stacy Kanter
Stacy Kanter
/s/ Joel S. Marcus
Joel S. Marcus
/s/ Jay S. Skyler
Jay S. Skyler, M.D., MACP
Chief Financial Officer
(Principal Accounting Officer and Principal
Financial Officer)
March 6, 2024
Director
Director
Director
Director
Director
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
March 6, 2024
103
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
● Registration Statement (Form S-8 No. 333-231618) of Applied Therapeutics, Inc., pertaining to the
2016 Equity Incentive Plan, as Amended, the 2019 Equity Incentive Plan, and the 2019 Employee
Stock Purchase Plan;
● Registration Statement (Form S-8 No. 333-255018) of Applied Therapeutics, Inc., pertaining to the
2019 Equity Incentive Plan;
● Registration Statement (Form S-8 No. 333-270767) of Applied Therapeutics, Inc., pertaining to the
2019 Equity Incentive Plan; and
● Registration Statement (Form S-3 No. 333-271887) of Applied Therapeutics, Inc.
of our report dated March 6, 2024, with respect to the financial statements of Applied Therapeutics, Inc.
included in this Annual Report (Form 10-K) of Applied Therapeutics for the year ended December 31,
2023.
/s/ Ernst & Young LLP
New York, New York
March 6, 2024
Exhibit 31.1
CERTIFICATIONS
The undersigned certifies that:
1. I have reviewed this Form 10-K of Applied Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred
during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process,
summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant’s internal control over financial reporting.
Date: March 6, 2024
/s/ Shoshana Shendelman
By:
Name: Shoshana Shendelman,
Title:
Ph.D.
Chief Executive Officer
(Principal Executive
Officer)
Exhibit 31.2
CERTIFICATIONS
The undersigned certifies that:
1. I have reviewed this Form 10-K of Applied Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period
in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report
our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred
during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control
over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or
persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process,
summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant’s internal control over financial reporting.
Date: March 6, 2024
/s/ Les Funtleyder
By:
Name: Les Funtleyder
Title:
Chief Financial Officer
(Principal Financial
Officer)
CERTIFICATION
Exhibit 32.1
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the
“Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), the
undersigned hereby certifies that, to the best of their knowledge:
1.
2.
The Annual Report on Form 10-K of Applied Therapeutics, Inc. (the “Company”) for the fiscal year ended
December 31, 2023, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully
complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
The information contained in the Annual Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
Dated: March 6, 2024
By:
/s/ Shoshana
Shendelman
Name: Shoshana Shendelman,
Title:
Ph.D.
Chief Executive Officer
(Principal Executive
Officer)
CERTIFICATION
Exhibit 32.2
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the
“Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), the
undersigned hereby certifies that, to the best of their knowledge:
1.
2.
The Annual Report on Form 10-K of Applied Therapeutics, Inc. (the “Company”) for the fiscal year ended
December 31, 2023, to which this Certification is attached as Exhibit 32.2 (the “Annual Report”), fully
complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
The information contained in the Annual Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.
Dated: March 6, 2024
/s/ Les Funtleyder
By:
Name: Les Funtleyder
Title:
Chief Financial Officer
(Principal Financial
Officer)
Exhibit 97.1
APPLIED THERAPEUTICS, INC.
CLAWBACK POLICY
The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Applied
Therapeutics, Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback
Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be
effective as of the Effective Date.
1. Definitions
For purposes of this Policy, the following definitions shall apply:
a) “Company Group” means the Company and each of its Subsidiaries, as applicable.
b) “Covered Compensation” means any Incentive-Based Compensation granted, vested or paid to
a person who served as an Executive Officer at any time during the performance period for the
Incentive-Based Compensation and that was Received (i) on or after the effective date of the
Nasdaq listing standard, (ii) after the person became an Executive Officer and (iii) at a time
that the Company had a class of securities listed on a national securities exchange or a national
securities association.
c) “Effective Date” means November 6, 2023.
d) “Erroneously Awarded Compensation” means the amount of Covered Compensation granted,
vested or paid to a person during the fiscal period when the applicable Financial Reporting
Measure relating to such Covered Compensation was attained that exceeds the amount of
Covered Compensation that otherwise would have been granted, vested or paid to the person
had such amount been determined based on the applicable Restatement, computed without
regard to any taxes paid (i.e., on a pre-tax basis). For Covered Compensation based on stock
price or total shareholder return, where the amount of Erroneously Awarded Compensation is
not subject to mathematical recalculation directly from the information in a Restatement, the
Committee will determine the amount of such Covered Compensation that constitutes
Erroneously Awarded Compensation, if any, based on a reasonable estimate of the effect of the
Restatement on the stock price or total shareholder return upon which the Covered
Compensation was granted, vested or paid and the Committee shall maintain documentation of
such determination and provide such documentation to the Nasdaq.
e) “Exchange Act” means the U.S. Securities Exchange Act of 1934.
f) “Executive Officer” means each “officer” of the Company as defined under Rule 16a-1(f)
under Section 16 of the Exchange Act, which shall be deemed to include any individuals
identified by the Company as executive officers pursuant to Item 401(b) of Regulation S-K
under the Exchange Act. Both current and former Executive Officers are subject to the Policy
in accordance with its terms.
1
g) “Financial Reporting Measure” means (i) any measure that is determined and presented in
accordance with the accounting principles used in preparing the Company’s financial
statements, and any measures derived wholly or in part from such measures and may consist of
GAAP or non-GAAP financial measures (as defined under Regulation G of the Exchange Act
and Item 10 of Regulation S-K under the Exchange Act), (ii) stock price or (iii) total
shareholder return. Financial Reporting Measures may or may not be filed with the SEC and
may be presented outside the Company’s financial statements, such as in Managements’
Discussion and Analysis of Financial Conditions and Result of Operations or in the
performance graph required under Item 201(e) of Regulation S-K under the Exchange Act.
h) “Home Country” means the Company’s jurisdiction of incorporation.
i)
j)
“Incentive-Based Compensation” means any compensation that is granted, earned or vested
based wholly or in part upon the attainment of a Financial Reporting Measure.
“Lookback Period” means the three completed fiscal years (plus any transition period of less
than nine months that is within or immediately following the three completed fiscal years and
that results from a change in the Company’s fiscal year) immediately preceding the date on
which the Company is required to prepare a Restatement for a given reporting period, with
such date being the earlier of: (i) the date the Board, a committee of the Board, or the officer or
officers of the Company authorized to take such action if Board action is not required,
concludes, or reasonably should have concluded, that the Company is required to prepare a
Restatement, or (ii) the date a court, regulator or other legally authorized body directs the
Company to prepare a Restatement. Recovery of any Erroneously Awarded Compensation
under the Policy is not dependent on if or when the Restatement is actually filed.
k) “Nasdaq” means the Nasdaq Stock Market.
l)
“Received”: Incentive-Based Compensation is deemed “Received” in the Company’s fiscal
period during which the Financial Reporting Measure specified in or otherwise relating to the
Incentive-Based Compensation award is attained, even if the grant, vesting or payment of the
Incentive-Based Compensation occurs after the end of that period.
m) “Restatement” means a required accounting restatement of any Company financial statement
due to the material noncompliance of the Company with any financial reporting requirement
under the securities laws, including (i) to correct an error in previously issued financial
statements that is material to the previously issued financial statements (commonly referred to
as a “Big R” restatement) or (ii) to correct an error in previously issued financial statements
that is not material to the previously issued financial statements but that would result in a
material misstatement if the error were corrected in the current period or left uncorrected in the
current period (commonly referred to as a “little r” restatement). Changes to the Company’s
financial statements that do not represent error corrections under the then-current relevant
accounting standards will not constitute Restatements. Recovery of any Erroneously Awarded
Compensation under the Policy is not dependent on fraud or misconduct by any person in
connection with the Restatement.
2
n) “SEC” means the U.S. Securities and Exchange Commission.
o) “Subsidiary” means any domestic or foreign corporation, partnership, association, joint stock
company, joint venture, trust or unincorporated organization “affiliated” with the Company,
that is, directly or indirectly, through one or more intermediaries, “controlling”, “controlled by”
or “under common control with”, the Company. “Control” for this purpose means the
possession, direct or indirect, of the power to direct or cause the direction of the management
and policies of such person, whether through the ownership of voting securities, contract or
otherwise.
2. Recoupment of Erroneously Awarded Compensation
In the event of a Restatement, any Erroneously Awarded Compensation Received during the Lookback
Period prior to the Restatement (a) that is then-outstanding but has not yet been paid shall be automatically
and immediately forfeited and (b) that has been paid to any person shall be subject to reasonably prompt
repayment to the Company Group in accordance with Section 3 of this Policy. The Committee must
pursue (and shall not have the discretion to waive) the forfeiture and/or repayment of such Erroneously
Awarded Compensation in accordance with Section 3 of this Policy, except as provided below.
Notwithstanding the foregoing, the Committee (or, if the Committee is not a committee of the Board
responsible for the Company’s executive compensation decisions and composed entirely of independent
directors, a majority of the independent directors serving on the Board) may determine not to pursue the
forfeiture and/or recovery of Erroneously Awarded Compensation from any person if the Committee
determines that such forfeiture and/or recovery would be impracticable due to any of the following
circumstances: (i) the direct expense paid to a third party (for example, reasonable legal expenses and
consulting fees) to assist in enforcing the Policy would exceed the amount to be recovered (following
reasonable attempts by the Company Group to recover such Erroneously Awarded Compensation, the
documentation of such attempts, and the provision of such documentation to the Nasdaq), (ii) pursuing
such recovery would violate the Company’s Home Country laws adopted prior to November 28, 2022
(provided that the Company obtains an opinion of Home Country counsel acceptable to the Nasdaq that
recovery would result in such a violation and provides such opinion to the Nasdaq), or (iii) recovery would
likely cause any otherwise tax-qualified retirement plan, under which benefits are broadly available to
employees of Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C.
411(a) and regulations thereunder.
3. Means of Repayment
In the event that the Committee determines that any person shall repay any Erroneously Awarded
Compensation, the Committee shall provide written notice to such person by email or certified mail to the
physical address on file with the Company Group for such person, and the person shall satisfy such
repayment in a manner and on such terms as required by the Committee, and the Company Group shall be
entitled to set off the repayment amount against any amount owed to the person by the Company Group, to
require the forfeiture of any award granted by the Company Group to the person, or to take any and all
necessary actions to reasonably promptly recoup the repayment amount from the person, in each case, to
the fullest extent permitted under applicable law, including without limitation, Section
3
409A of the U.S. Internal Revenue Code and the regulations and guidance thereunder. If the Committee
does not specify a repayment timing in the written notice described above, the applicable person shall be
required to repay the Erroneously Awarded Compensation to the Company Group by wire, cash or
cashier’s check no later than thirty (30) days after receipt of such notice.
4. No Indemnification
No person shall be indemnified, insured or reimbursed by the Company Group in respect of any loss of
compensation by such person in accordance with this Policy, nor shall any person receive any
advancement of expenses for disputes related to any loss of compensation by such person in accordance
with this Policy, and no person shall be paid or reimbursed by the Company Group for any premiums paid
by such person for any third-party insurance policy covering potential recovery obligations under this
Policy. For this purpose, “indemnification” includes any modification to current compensation
arrangements or other means that would amount to de facto indemnification (for example, providing the
person a new cash award which would be cancelled to effect the recovery of any Erroneously Awarded
Compensation). In no event shall the Company Group be required to award any person an additional
payment if any Restatement would result in a higher incentive compensation payment.
5. Miscellaneous
This Policy generally will be administered and interpreted by the Committee, provided that the Board
may, from time to time, exercise discretion to administer and interpret this Policy, in which case, all
references herein to “Committee” shall be deemed to refer to the Board. Any determination by the
Committee with respect to this Policy shall be final, conclusive and binding on all interested parties. Any
discretionary determinations of the Committee under this Policy, if any, need not be uniform with respect
to all persons, and may be made selectively amongst persons, whether or not such persons are similarly
situated.
This Policy is intended to satisfy the requirements of Section 954 of the Dodd-Frank Wall Street
Reform and Consumer Protection Act, as it may be amended from time to time, and any related rules or
regulations promulgated by the SEC or the Nasdaq, including any additional or new requirements that
become effective after the Effective Date which upon effectiveness shall be deemed to automatically
amend this Policy to the extent necessary to comply with such additional or new requirements.
The provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent
that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such
provision will be applied to the maximum extent permitted and shall automatically be deemed amended in
a manner consistent with its objectives to the extent necessary to conform to applicable law. The
invalidity or unenforceability of any provision of this Policy shall not affect the validity or enforceability
of any other provision of this Policy. Recoupment of Erroneously Awarded Compensation under this
Policy is not dependent upon the Company Group satisfying any conditions in this Policy, including any
requirements to provide applicable documentation to the Nasdaq.
The rights of the Company Group under this Policy to seek forfeiture or reimbursement are in addition
to, and not in lieu of, any rights of recoupment, or remedies or rights other than recoupment, that may be
available to the Company Group pursuant to the terms of any law, government regulation or
4
stock exchange listing requirement or any other policy, code of conduct, employee handbook, employment
agreement, equity award agreement, or other plan or agreement of the Company Group.
6. Amendment and Termination
To the extent permitted by, and in a manner consistent with applicable law, including SEC and Nasdaq
rules, the Committee may terminate, suspend or amend this Policy at any time in its discretion.
7. Successors
This Policy shall be binding and enforceable against all persons and their respective beneficiaries,
heirs, executors, administrators or other legal representatives with respect to any Covered Compensation
granted, vested or paid to or administered by such persons or entities.
5
APPLIED THERAPEUTICS, INC.
CLAWBACK POLICY
ACKNOWLEDGMENT, CONSENT AND AGREEMENT
I acknowledge that I have received and reviewed a copy of the Applied Therapeutics, Inc. Clawback
Policy (as may be amended from time to time, the “Policy”) and I have been given an opportunity to ask
questions about the Policy and review it with my counsel. I knowingly, voluntarily and irrevocably
consent to and agree to be bound by and subject to the Policy’s terms and conditions, including that I will
return any Erroneously Awarded Compensation that is required to be repaid in accordance with the Policy.
I further acknowledge, understand and agree that (i) the compensation that I receive, have received or may
become entitled to receive from the Company Group is subject to the Policy, and the Policy may affect
such compensation and (ii) I have no right to indemnification, insurance payments or other reimbursement
by or from the Company Group for any compensation that is subject to recoupment and/or forfeiture under
the Policy. Capitalized terms used but not defined herein have the meanings set forth in the Policy.
Signed:
_________________________________________
Print Name: _________________________________________
Date:
_________________________________________